# EDGAR Filing Document

**Accession Number:** 0000310764
**File Stem:** 0000310764-26-000010
**Filing Date:** 2026-2
**Character Count:** 391990
**Document Hash:** ce26821250e69340764e3cb2f5cb8b42
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000310764-26-000010.hdr.sgml**: 20260211

**ACCESSION NUMBER**: 0000310764-26-000010

**CONFORMED SUBMISSION TYPE**: 10-K

**PUBLIC DOCUMENT COUNT**: 136

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260211

**DATE AS OF CHANGE**: 20260211

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** STRYKER CORP
- **CENTRAL INDEX KEY:** 0000310764
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 381239739
- **STATE OF INCORPORATION:** MI
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-13149
- **FILM NUMBER:** 26619240

**BUSINESS ADDRESS:**
- **STREET 1:** 1941 STRYKER WAY
- **CITY:** PORTAGE
- **STATE:** MI
- **ZIP:** 49002
- **BUSINESS PHONE:** 2693852600

**MAIL ADDRESS:**
- **STREET 1:** 1941 STRYKER WAY
- **CITY:** PORTAGE
- **STATE:** MI
- **ZIP:** 49002

?xml version='1.0' encoding='ASCII'? syk-20251231

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-K**

☒ **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the fiscal year ended December 31, 2025

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Commission file number: 001-13149

![strykerlogoa72.jpg](syk-20251231_g1.jpg)

**STRYKER CORPORATION**

(Exact name of registrant as specified in its charter)

---

| | | | |
|:---|:---|:---|:---|
| **Michigan** |  |  | **38-1239739** |
| (State of incorporation) |  |  | (I.R.S. Employer Identification No.) |
| **1941 Stryker Way,** | **Portage,** | **Michigan** | **49002** |
| (Address of principal executive offices) | (Address of principal executive offices) | (Address of principal executive offices) | (Zip Code) |
|  | **(269)** | **385-2600** |  |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |

---

---

| | | |
|:---|:---|:---|
| **Securities registered pursuant to Section 12(b) of the Act:** | **Securities registered pursuant to Section 12(b) of the Act:** | **Securities registered pursuant to Section 12(b) of the Act:** |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Common Stock, $.10 Par Value** | **SYK** | **New York Stock Exchange** |
| **2.125% Notes due 2027** | **SYK27** | **New York Stock Exchange** |
| **3.375% Notes due 2028** | **SYK28** | **New York Stock Exchange** |
| **0.750% Notes due 2029** | **SYK29** | **New York Stock Exchange** |
| **2.625% Notes due 2030** | **SYK30** | **New York Stock Exchange** |
| **1.000% Notes due 2031** | **SYK31** | **New York Stock Exchange** |
| **3.375% Notes due 2032** | **SYK32** | **New York Stock Exchange** |
| **3.625% Notes due 2036** | **SYK36** | **New York Stock Exchange** |

---

**Securities registered pursuant to Section 12(g) of the Act: None**

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes ☒No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.Yes ☐ No☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during

the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for

the past 90 days.Yes☒No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation

S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging

growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the

Exchange Act.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ | Emerging growth company | ☐ |
| Non-accelerated filer | ☐ | Small reporting company | ☐ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised

financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over

financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit

report.☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing

reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any

of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐No ☒

The aggregate market value of the voting stock held by non-affiliates of the registrant was approximately $144,306,436,547 at June 30, 2025. There were

382,688,675 shares outstanding of the registrant's common stock, $0.10 par value, on January 31, 2026.

**DOCUMENTS INCORPORATED BY REFERENCE**

Portions of the proxy statement to be filed with the U.S. Securities and Exchange Commission relating to the 2026 Annual Meeting of Shareholders (the 2026

proxy statement) are incorporated by reference into Part III.

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| **PART I** | **PART I** |  |
| Item 1. | Business | <u>[1](#i59ca9e85af6d416eb58f77ff50c4c1c5_13)</u> |
| Item 1A. | Risk Factors | <u>[5](#i59ca9e85af6d416eb58f77ff50c4c1c5_16)</u> |
| Item 1B. | Unresolved Staff Comments | <u>[12](#i59ca9e85af6d416eb58f77ff50c4c1c5_19)</u> |
| Item 1C. | Cybersecurity | <u>[12](#i59ca9e85af6d416eb58f77ff50c4c1c5_22)</u> |
| Item 2. | Properties | <u>[12](#i59ca9e85af6d416eb58f77ff50c4c1c5_25)</u> |
| Item 3. | Legal Proceedings | <u>[12](#i59ca9e85af6d416eb58f77ff50c4c1c5_28)</u> |
| Item 4. | Mine Safety Disclosures | <u>[12](#i59ca9e85af6d416eb58f77ff50c4c1c5_31)</u> |
| **PART II** | **PART II** |  |
| Item 5. | Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | <u>[13](#i59ca9e85af6d416eb58f77ff50c4c1c5_37)</u> |
| Item 6. | Selected Financial Data | <u>[14](#i59ca9e85af6d416eb58f77ff50c4c1c5_40)</u> |
| Item 7. | Management's Discussion and Analysis of Financial Condition and Results of Operations | <u>[15](#i59ca9e85af6d416eb58f77ff50c4c1c5_43)</u> |
| Item 7A. | Quantitative and Qualitative Disclosures About Market Risk | <u>[24](#i59ca9e85af6d416eb58f77ff50c4c1c5_76)</u> |
| Item 8. | Financial Statements and Supplementary Data | <u>[25](#i59ca9e85af6d416eb58f77ff50c4c1c5_79)</u> |
|  | Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | <u>[25](#i59ca9e85af6d416eb58f77ff50c4c1c5_79)</u> |
|  | Consolidated Statements of Earnings | <u>[27](#i59ca9e85af6d416eb58f77ff50c4c1c5_82)</u> |
|  | Consolidated Statements of Comprehensive Income | <u>[27](#i59ca9e85af6d416eb58f77ff50c4c1c5_88)</u> |
|  | Consolidated Balance Sheets | <u>[28](#i59ca9e85af6d416eb58f77ff50c4c1c5_91)</u> |
|  | Consolidated Statements of Shareholders' Equity | <u>[29](#i59ca9e85af6d416eb58f77ff50c4c1c5_94)</u> |
|  | Consolidated Statements of Cash Flows | <u>[30](#i59ca9e85af6d416eb58f77ff50c4c1c5_97)</u> |
|  | Notes to Consolidated Financial Statements | <u>[31](#i59ca9e85af6d416eb58f77ff50c4c1c5_100)</u> |
| Item 9. | Changes in and Disagreements With Accountants on Accounting and Financial Disclosure | <u>[45](#i59ca9e85af6d416eb58f77ff50c4c1c5_157)</u> |
| Item 9A. | Controls and Procedures | <u>[45](#i59ca9e85af6d416eb58f77ff50c4c1c5_160)</u> |
| Item 9B. | Other Information | <u>[46](#i59ca9e85af6d416eb58f77ff50c4c1c5_163)</u> |
| Item 9C. | Disclosure Regarding Foreign Jurisdictions That Prevent Inspections | <u>[46](#i59ca9e85af6d416eb58f77ff50c4c1c5_166)</u> |
| **PART III** | **PART III** |  |
| Item 10. | Directors, Executive Officers and Corporate Governance | <u>[46](#i59ca9e85af6d416eb58f77ff50c4c1c5_172)</u> |
| Item 11. | Executive Compensation | <u>[46](#i59ca9e85af6d416eb58f77ff50c4c1c5_175)</u> |
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | <u>[46](#i59ca9e85af6d416eb58f77ff50c4c1c5_178)</u> |
| Item 13. | Certain Relationships and Related Transactions, and Director Independence | <u>[46](#i59ca9e85af6d416eb58f77ff50c4c1c5_181)</u> |
| Item 14. | Principal Accountant Fees and Services | <u>[47](#i59ca9e85af6d416eb58f77ff50c4c1c5_184)</u> |
| **PART IV** | **PART IV** |  |
| Item 15. | Exhibits, Financial Statement Schedules | <u>[48](#i59ca9e85af6d416eb58f77ff50c4c1c5_190)</u> |
| Item 16. | Form 10-K Summary | <u>[51](#i59ca9e85af6d416eb58f77ff50c4c1c5_196)</u> |

---

**Dollar amounts in millions except per share amounts or as otherwise specified.**<sub>1</sub>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

**PART I**<br>

---

| | |
|:---|:---|
| **ITEM 1.** | **BUSINESS.** |

---

Stryker Corporation (Stryker or the Company) is a global leader

in medical technologies and, together with our customers, we are

driven to make healthcare better. We offer innovative products

and services in MedSurg, Neurotechnology and Orthopaedics

that help improve patient and healthcare outcomes. Alongside

our customers around the world, we impact more than 150 million

patients annually.

Our core values guide our behaviors and actions and are

fundamental to how we execute our mission.

![missionvaluesa10.jpg](syk-20251231_g2.jpg)

Stryker was incorporated in Michigan in 1946 as the successor

company to a business founded in 1941 by Dr. Homer H. Stryker,

a prominent orthopaedic surgeon and inventor of several medical

products. Our products are sold in approximately 61 countries

through company-owned subsidiaries and branches as well as

third-party dealers and distributors, and include surgical

equipment and surgical navigation systems; endoscopic and

communications systems; patient handling, emergency medical

equipment and intensive care disposable products; clinical

communication and artificial intelligence-assisted virtual care

platform technology; products for traditional brain and open skull-

based surgical procedures; minimally invasive products for the

treatment of acute ischemic and hemorrhagic stroke and venous

thromboembolism; implants used in joint replacement and trauma

surgeries; Mako robotic-arm assisted technology; as well as other

products used in a variety of medical specialties. Most of our

products are marketed directly to doctors, hospitals and other

healthcare facilities.

As used herein, and except where the context otherwise requires,

"Stryker," "we," "us," and "our" refer to Stryker Corporation and its

consolidated subsidiaries.

**Business Segments and Geographic Information**

We segregate our operations into two reportable business

segments: (i) MedSurg and Neurotechnology and (ii)

Orthopaedics. Financial information regarding our reportable

business segments and certain geographic information is

included under "Consolidated Results of Operations" in Item 7 of

this report and Note 14 to our Consolidated Financial Statements.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| ***Net Sales by Reportable Segment*** | ***Net Sales by Reportable Segment*** | ***Net Sales by Reportable Segment*** | ***Net Sales by Reportable Segment*** | ***Net Sales by Reportable Segment*** | ***Net Sales by Reportable Segment*** | ***Net Sales by Reportable Segment*** |
|  | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| MedSurg and <br>Neurotechnology<br>| $15647 | 62% | $13518 | 60% | $12163 | 59% |
| Orthopaedics | 9469 | 38 | 9077 | 40 | 8335 | 41 |
| **Total** | **$25116** | **100%** | **$22595** | **100%** | **$20498** | **100%** |

---

**MedSurg and Neurotechnology**

MedSurg and Neurotechnology products include surgical

equipment, patient and caregiver safety technologies, and

navigation systems (Instruments), endoscopic and

communications systems (Endoscopy), and patient handling,

emergency medical equipment, intensive care disposable

products, clinical communication and artificial intelligence-

assisted virtual care platform technology (Medical), minimally

invasive products for the treatment of acute ischemic and

hemorrhagic stroke and venous thromboembolism (Vascular) and

a comprehensive line of products for traditional brain and open

skull-based surgical procedures, orthobiologic and biosurgery

products, including synthetic bone grafts and vertebral

augmentation products (Neuro Cranial).

We are one of five leading global competitors in Instruments; the

other four being Zimmer Biomet Holdings, Inc. (Zimmer),

Medtronic plc (Medtronic), Johnson & Johnson MedTech (a

subsidiary of Johnson & Johnson) and ConMed Linvatec, Inc. (a

subsidiary of CONMED Corporation). We are one of seven

leading global competitors in Endoscopy; the other six being Karl

Storz GmbH & Co., Olympus Optical Co. Ltd., Smith & Nephew

plc (Smith & Nephew), ConMed Linvatec, Arthrex, Inc. and

STERIS plc. We are one of five leading global competitors in

Medical; the other four being Baxter International Inc., Zoll

Medical Corporation, Medline Industries and Ferno-Washington,

Inc. We are one of five leading global competitors in Vascular and

Neuro Cranial; the other four being Medtronic, Johnson &

Johnson MedTech, Terumo Corporation and Penumbra, Inc.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| ***Composition of MedSurg and Neurotechnology Net Sales*** | ***Composition of MedSurg and Neurotechnology Net Sales*** | ***Composition of MedSurg and Neurotechnology Net Sales*** | ***Composition of MedSurg and Neurotechnology Net Sales*** | ***Composition of MedSurg and Neurotechnology Net Sales*** | ***Composition of MedSurg and Neurotechnology Net Sales*** | ***Composition of MedSurg and Neurotechnology Net Sales*** |
|  | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| Instruments | $3183 | 20% | $2834 | 21% | $2534 | 21% |
| Endoscopy | 3807 | 24 | 3389 | 25 | 3068 | 25 |
| Medical | 4204 | 27 | 3852 | 28 | 3459 | 28 |
| Vascular | 1968 | 13 | 1307 | 10 | 1226 | 11 |
| Neuro Cranial | 2485 | 16 | 2136 | 16 | 1876 | 15 |
| **Total** | **$15647** | **100%** | **$13518** | **100%** | **$12163** | **100%** |

---

In 2025 Instruments launched Steri-Shield 8 which is a lighter,

more comfortable, and more customizable operating room

personal protection system, with improved visibility, cooling, and

battery performance versus prior generations. In addition, we

completed the acquisition of Guard Medical Inc., whose primary

focus is on Negative Pressure Wound Therapy for surgical

patients. The acquisition of Guard Medical, Inc. is

complementary to our Orthopaedic Instruments business as we

continue to focus on the surgical wound care market.

Endoscopy continued to deliver its 4K 1788 Camera platform to

the market in addition to the launch of the Connected OR IP

BRAVoE integration portfolio. Our 1788 Camera platform features

several enhancements for a broader range of clinical applications

and specialties, including urology, neurology, ear, nose, throat

and arthroscopy and can be used to visualize indocyanine green

and CYTALUX. The Connected OR IP BRAVoE launch expands

the connected capabilities of iSuite.

Medical continued the global launch of the LIFEPAK 35 monitor/

defibrillator, our next generation platform designed to optimize

care with new clinical features such as the new Glasgow 30.4

algorithm, cprINSIGHT, 15-lead monitoring capabilities, and STJ

insight and mapping. LIFEPAK 35 combines a modern intuitive

touch screen display and increased processing power with

Bluetooth and WiFi data connectivity. We also launched the

Vocera Sync Badge this year, a trusted clinician handsfree

communication endpoint that provides real-time communication

and alerts while extending Smart Hospital workflows directly into

**Dollar amounts in millions except per share amounts or as otherwise specified.**<sub>2</sub>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

daily clinical practice. Medical also completed the acquisition of

Advanced Medical Balloons (AMB), an indwelling fecal

management system that specializes in solutions that help

enhance care delivery by combining intelligent design with the

exceptional properties of ultra-thin polyurethane. AMB Medical

adds complementary technology to the Stryker Sage

incontinence portfolio and will help address problems in the

market that include hospital-acquired infections, pressure injuries,

staff satisfaction and retention.

In 2025 we changed the name of our Neurovascular business to

Vascular with the acquisition of Inari Medical, Inc. (Inari) whose

product portfolio includes minimally invasive products for the

treatment of venous thromboembolism. Neurovascular and Inari

are jointly now Vascular. Vascular launched the Broadway

System in the United States, a fully integrated stroke solution that

provides a new level of access and support in large- and super-

bore catheter procedures. Additionally, Vascular accelerated the

launch of the Surpass Elite Flow Diverting Stent (FDS) in the

United States, Europe, and parts of Asia-Pacific. Surpass Elite

FDS is designed to reduce thrombin generation when compared

to unmodified stents.

Neuro Cranial launched OptaBlate BVN in 2025 which is a

radiofrequency nerve ablation system used to access and ablate

the basivertebral nerve to treat vertebrogenic pain.

**Orthopaedics**

Orthopaedics products primarily include implants used in total

joint replacements, such as hip, knee and shoulder, ankle, and

trauma and extremities surgeries. We bring patients and

physicians advanced implant designs and specialized

instrumentation that make orthopaedic surgery and recovery

simpler, faster and more effective. We support surgeons with the

technologies, products and services they need to support each

patient's clinical challenge.

We are one of four leading global competitors for joint

replacement and trauma and extremities products and robotics;

the other three being Zimmer, Johnson & Johnson MedTech and

Smith & Nephew.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| ***Composition of Orthopaedics Net Sales*** | ***Composition of Orthopaedics Net Sales*** | ***Composition of Orthopaedics Net Sales*** | ***Composition of Orthopaedics Net Sales*** | ***Composition of Orthopaedics Net Sales*** | ***Composition of Orthopaedics Net Sales*** | ***Composition of Orthopaedics Net Sales*** |
|  | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| Knees | $2656 | 28% | $2447 | 27% | $2273 | 27% |
| Hips | 1865 | 20 | 1704 | 19 | 1544 | 18 |
| Trauma and Extremities | 3948 | 42 | 3507 | 39 | 3147 | 38 |
| Spinal Implants | 185 | 2 | 707 | 8 | 713 | 9 |
| Other | 815 | 9 | 712 | 8 | 658 | 8 |
| **Total** | **$9469** | **100%** | **$9077** | **100%** | **$8335** | **100%** |

---

In 2025 we continued to expand the global footprint of Mako

SmartRobotics, which is now available in more than 45 countries.

To date, over one million robotic Mako Total Knee procedures

and more than two million robotic procedures across Mako Total

Knee, Mako Total Hip, and Mako Partial Knee have been

performed worldwide.

2025 also marked a significant period of product launches and

new application development. Most notably, we introduced the

Mako 4 platform, a meaningful advancement for both newly

established and existing Mako sites. This platform is built around

our Q-Guidance system—an advanced guidance technology

designed to enable new hardware and software capabilities

across a broad range of subspecialties.

The first application released on the Mako 4 platform is the Total

Hip Advanced Primary and Revision application. We received

510(k) clearance for Mako Total Hip with Advanced Primary and

Revision with full market release in the third quarter of 2025.

Complex primary and revision total hip arthroplasty procedures

often present challenges such as bone loss and absent

anatomical landmarks. With our advanced Mako Total Hip

solution, we aim to extend the benefits of Mako SmartRobotics™

to simplify these demanding cases. Mako Total Hip with

Advanced Primary and Revision represents Stryker's first-to-

market, robotically enabled revision hip arthroplasty procedure.

We also introduced Mako Shoulder, which expands the

SmartRobotics suite of applications. Mako Shoulder integrates

three market-leading technologies: Tornier implants, Blueprint

planning software, and Mako SmartRobotics. The application

offers haptically guided preparation for Tornier Perform Reversed

Glenoid and Tornier Reversed Augmented Glenoid implants for

primary shoulder arthroplasty. We completed the first Mako

Shoulder cases in 2024, and the application remained in limited

market release throughout 2025. Full commercial launch in the

United States is planned for the first quarter of 2026.

**Raw Materials and Inventory**

Raw materials essential to our business are generally readily

available from multiple sources; however, certain of our raw

materials are currently sourced from single suppliers.

Substantially all products we manufacture are stocked in

inventory, while certain MedSurg products are assembled to

order.

**Patents and Trademarks**

Patents and trademarks are significant to our business to the

extent that a product or an attribute of a product represents a

unique design or process. Patent protection of such products

restricts competitors from duplicating these unique designs and

features. We seek to obtain patent protection on our products

whenever appropriate for protecting our competitive advantage.

On December 31, 2025 we owned approximately 5,600 United

States patents and approximately 9,000 patents in other

countries.

**Seasonality**

Our business is generally not seasonal in nature; however, the

number of orthopaedic implant surgeries is typically lower in the

summer months, and sales of capital equipment are generally

higher in the fourth quarter.

**Competition**

In each of our product lines we compete with local and global

companies. The development of innovative products is important

to our success in all areas of our business. Competition in

research involving the development and improvement of new and

existing products and processes is particularly significant. The

competitive environment requires substantial investments in

continuing research and maintaining sales forces.

We believe our commitment to innovation, quality and service

and our reputation differentiates us in the highly competitive

product categories in which we operate and enables us to

compete effectively. We believe that our competitive position in

the future will depend largely on our ability to develop new

products and make improvements to existing products.

**Regulation**

Our businesses are subject to varying degrees of governmental

regulation in the countries in which we operate, and the general

trend is toward increasingly stringent regulation. We are required

to comply with the unique regulatory requirements of each

country in which we market and sell our products.

In the United States the Medical Device Amendments of 1976 to

the Federal Food, Drug and Cosmetic Act and its subsequent

**Dollar amounts in millions except per share amounts or as otherwise specified.**<sub>3</sub>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

amendments and the regulations issued and proposed

thereunder provide for federal regulation by the United States

Food and Drug Administration (FDA) of the design, manufacture

and marketing of medical devices, including most of our products.

In addition, state licensing requirements often apply to certain of

our business operations and products. On the federal level, many

of our new products fall into FDA classifications that require

notification submitted as a 510(k) and review by the FDA before

we begin marketing them. Certain of our products require

extensive clinical testing, consisting of safety and efficacy

studies, followed by pre-market approval applications for specific

surgical indications. Certain of our products also fall under other

FDA classifications, such as drugs and Human Cells, Tissues,

and Cellular and Tissue-Based Products.

The FDA's Quality System regulations set forth standards for our

product design and manufacturing processes, require the

maintenance of certain records and provide for inspections of our

facilities by the FDA. There are also certain requirements of

state, local and foreign governments that must be complied with

in the manufacture and marketing of our products.

The European Union enacted the European Union Medical

Device Regulation in May 2017 with an original effective date of

May 2022, which imposes stricter requirements for the marketing

and sale of medical devices, including in the areas of clinical

evaluation requirements, quality systems, labeling and post-

market surveillance. Extended transition timelines were published

in 2023 which range from May 2026 through December 2028

depending on the type of device and we are on track to meet

these timelines.

Initiatives to limit the growth of general healthcare expenses and

hospital costs are ongoing. These initiatives are sponsored by

government agencies, legislative bodies and the private sector

and include price regulation and competitive pricing. It is not

possible to predict the long-term impact of such cost containment

measures on our future business. In addition, business practices

in the healthcare industry are scrutinized, particularly in the

United States, by federal and state government agencies. Any

resulting investigations and prosecutions potentially carry the risk

of significant civil and criminal penalties.

**Environment**

We are subject to various rules and regulation in the United

States and internationally related to the protection of human

health and the environment. Our operations involve the use of

substances regulated under environmental laws, primarily in

manufacturing and sterilization processes. We believe our

policies, practices and procedures are properly designed to

comply, in all material respects, with applicable environmental

laws and regulations. We do not expect compliance with these

requirements to have a material effect on purchases of property,

plant and equipment, cash flows, net earnings or competitive

position.

**Employees**

On December 31, 2025 we had approximately 56,000 employees

globally, with approximately 28,000 employees in the United

States. Our talented employees are an integral reason for our

standing as a global leader in medical technologies where,

together with our customers, we are driven to make healthcare

better. Our company values of integrity, accountability, people

and performance are a key component of that mission. Our

people, as one of our core values, continue to be a key focus.

Our success depends on our ability to attract the best talent. To

do so, we continue to focus on establishing and maintaining a

great workplace. We believe in attracting the right people,

maintaining and building employee engagement and developing

our employees. We believe when people are able to do what they

do best, they will look forward to coming to work and, in turn, will

deliver great business results.

Our leadership team and Board of Directors receive regular

updates on our people and culture strategy and provide feedback

on our strategy and goals, including alignment to our mission and

values, peer benchmarking and stakeholder feedback.

**Employee Development**

Our employee development is extensive and exists at all levels of

the organization, including company-wide training on our Code of

Conduct, job-related technical training and management and

leadership training. Our development programs include on-the-

job learning, coaching and mentoring, management and

leadership development courses, team building and collaboration

training and immersive experiences with expert partners.

We encourage all employees to establish development

objectives, in partnership with their manager, to help employees

gain the needed development experience to grow their careers.

**Employee Engagement**

An engaged workplace culture that drives performance and

business outcomes is central to our mission. Listening to and

learning from our employees forms the foundation of an engaging

culture. More than 90% of our employees participate in our

annual engagement survey, which provides a valued platform for

listening and allows us to act on the feedback collected.

We supplement our annual engagement survey with targeted

pulse surveys to gather feedback on topics relevant to the current

climate.

We also provide tools and resources that enable managers and

teams to act on the insights we gain from our surveys and to

drive employee engagement and strong business outcomes.

**Inclusion**

We believe our individual strengths, experiences, and

perspectives are essential for delivering on our mission. By

caring for each other, we foster a culture where everyone feels

heard and valued. How we work together is critical to our

success, and we believe it takes everyone. Every voice. Every

person. Every connection.

**Attracting and Hiring**

We understand that every employee drives our success. We

focus on attracting, identifying and selecting strong candidates

who will be successful at Stryker and ensuring that each person

we hire brings the talent, expertise and passion we need to

continue to be successful.

**Health and Safety**

Ensuring our employees' safety is a top priority. It is a

responsibility that we share throughout the company and one that

has evolved to meet the needs of our workforce. Employees'

safety risks vary depending on the roles they perform, so we

tailor our safety efforts accordingly.

**Competitive Pay and Benefits**

Our compensation and benefits programs are designed to attract

and retain top talent and to incentivize performance and

alignment to our mission and values.

We offer market-competitive base pay and benefits to our

employees in countries around the world. We regularly evaluate

**Dollar amounts in millions except per share amounts or as otherwise specified.**<sub>4</sub>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

our compensation and benefit offerings and levels, using

recognized outside consulting firms to ensure internal fairness

and competitiveness in our offerings.

Most of our employees also have variable compensation

components that reward employees based on individual,

business unit and/or company-wide performance.

Our proxy statement provides more detail on the competitive

compensation programs we offer to our executive officers.

**Information about our Executive Officers**

---

| | | | |
|:---|:---|:---|:---|
| ***As of January 31, 2026*** | ***As of January 31, 2026*** | ***As of January 31, 2026*** | ***As of January 31, 2026*** |
| **Name** | **Age** | **Title** | **First Became** <br>**an Executive** <br>**Officer**<br>|
| Kevin A. Lobo | 60 | Chair and Chief Executive Officer | 2011 |
| William E. Berry Jr. | 60 | Vice President, Chief Accounting <br>Officer<br>| 2014 |
| Dylan B. Crotty | 49 | Group President, Orthopaedics | 2026 |
| M. Kathryn Fink | 56 | Vice President, Chief Human <br>Resources Officer<br>| 2016 |
| Robert S. Fletcher | 55 | Vice President, Chief Legal <br>Officer<br>| 2019 |
| Debra King | 54 | Vice President, Chief Digital and <br>Information Officer<br>| 2025 |
| Viju S. Menon | 58 | Group President, Global Quality <br>and Operations<br>| 2018 |
| Kimberly A. Montagnino | 38 | Vice President, Chief <br>Communications Officer<br>| 2025 |
| J. Andrew Pierce | 52 | Group President, MedSurg and <br>Neurotechnology<br>| 2021 |
| Spencer S. Stiles | 49 | President and Chief Operating <br>Officer<br>| 2021 |
| Preston W. Wells | 49 | Vice President, Chief Financial <br>Officer<br>| 2025 |

---

Each of our executive officers held the position above or served

Stryker in various executive or administrative capacities for at

least five years, except for Ms. King and Ms. Montagnino. Prior to

joining Stryker in May 2025, Ms. King served as the Chief

Technology Officer at Bunge for two years and as the Chief

Information Officer at Corteva, Inc. from 2017 to 2021. Prior to

joining Stryker in June 2024, Ms. Montagnino held multiple

corporate affairs leadership roles with Johnson & Johnson during

the previous eight years, most recently as Senior Director,

Communications Johnson & Johnson MedTech. While at Stryker,

Ms. Montagnino previously served as Vice President, Global

Communications.

**Available Information**

Our main corporate website address is *www.stryker.com.* The

information on our website is not incorporated by reference into

this report. Copies of our filings with the United States Securities

and Exchange Commission (SEC) are available free of charge on

our website within the "Investors Relations" section as soon as

reasonably practicable after having been electronically filed or

furnished to the SEC. All SEC filings are also available at the

SEC's website at www.sec.gov.

**Forward-Looking Statements**

This report contains statements that are not historical facts and

are considered "forward-looking statements" within the meaning

of the Private Securities Litigation Reform Act of 1995. These

statements are based on current projections about operations,

industry conditions, financial condition and liquidity. Words that

identify forward-looking statements include, without limitation,

words such as "may," "could," "will," "should," "possible," "plan,"

"predict," "forecast," "potential," "anticipate," "estimate," "expect,"

"project," "intend," "believe," "may impact," "on track," "goal,"

"strategy" and words and terms of similar substance used in

connection with any discussion of future operating or financial

performance, an acquisition or our businesses. In addition, any

statements that refer to expectations, projections or other

characterizations of future events or circumstances, including any

underlying assumptions, are forward-looking statements. Those

statements are not guarantees and are subject to risks,

uncertainties and assumptions that are difficult to predict.

Therefore, actual results could differ materially and adversely

from these forward-looking statements, historical experience or

our present expectations. Some important factors that could

cause our actual results to differ from our expectations in any

forward-looking statements include:

• weakening of economic conditions, or the anticipation thereof,

that could adversely affect the level of demand for our

products;

• geopolitical risks, including from international conflicts and

tariffs, which could, among other things, lead to increased

market volatility;

• pricing pressures generally, including cost-containment

measures that have adversely affected and could in the future

adversely affect the price of or demand for our products;

• changes in foreign currency exchange markets;

• legislative and regulatory actions;

• unanticipated issues arising in connection with clinical studies

and otherwise that affect approval of new products by the

FDA and foreign regulatory agencies;

• inflationary pressures;

• increased interest rates or interest rate volatility;

• supply chain disruptions;

• changes in labor markets;

• changes in coverage and reimbursement levels from third-

party payors;

• changes in the competitive environment;

• breaches, failures or other disruptions of our or our vendors'

or customers' information technology systems or products,

including by cyber-attack, data leakage, unauthorized access

or theft;

• a significant increase in product liability claims;

• the ultimate total cost with respect to recall-related and other

regulatory and quality matters;

• the impact of investigative and legal proceedings and

compliance risks;

• resolution of tax audits;

• changes in tax laws and regulations;

• the impact of legislation to reform the healthcare system in the

United States or other countries;

• costs to comply with medical device regulations;

• changes in financial markets;

• changes in our credit ratings;

• our ability to integrate and realize the anticipated benefits of

acquisitions in full or at all or within the expected timeframes,

including our acquisition of Inari Medical, Inc. ("Inari");

• our ability to realize any anticipated cost savings;

• potential negative impacts resulting from climate change or

other environmental, social and governance and sustainability

related matters;

• the impact on our operations and financial results of any

public health emergency and any related policies and actions

by governments or other third parties; and

• other risks detailed in our filings with the SEC.

While we believe that the assumptions underlying such forward-

looking statements are reasonable, there can be no assurance

that future events or developments will not cause such

statements to be inaccurate. All forward-looking statements

**Dollar amounts in millions except per share amounts or as otherwise specified.**<sub>5</sub>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

contained in this report are qualified in their entirety by this

cautionary statement. We expressly disclaim any intention or

obligation to publicly update or revise any forward-looking

statement to reflect any change in our expectations or in events,

conditions or circumstances on which those expectations may be

based, or that affect the likelihood that actual results will differ

from those contained in the forward-looking statements

**Trademarks**

All trademarks or trade names referred to in this report are the

property of the Company, or, to the extent trademarks or trade

names belonging to other companies are referenced in this

report, the property of their respective owners. Solely for

convenience, the trademarks and trade names in this report are

referred to without the® and™ symbols, but such references

should not be construed as any indicator that the Company or, to

the extent applicable, their respective owners will not assert, to

the fullest extent under applicable law, the Company's or their

rights thereto. We do not intend the use or display of other

companies' trademarks and trade names to imply a relationship

with, or endorsement or sponsorship of us by, any other

companies.

---

| | |
|:---|:---|
| **ITEM 1A.** | **RISK FACTORS.** |

---

Our operations and financial results are subject to various risks

and uncertainties discussed below that could materially and

adversely affect our business, cash flows, financial condition and

results of operations. Additional risks and uncertainties not

currently known to us or that we currently deem not to be material

or that could apply to any company may also materially and

adversely affect our business, cash flows, financial condition or

results of operations. If any of the risks discussed below or other

risks actually occur or continue to occur, our business, financial

condition, operating results or cash flows could be materially

adversely affected. Accordingly, you should carefully consider the

following risk factors, as well as other information contained in or

incorporated by reference in this report.

**BUSINESS AND OPERATIONAL RISKS**

**We use a variety of raw materials, components, devices and**

**third-party services in our global supply chains, production**

**and distribution processes; significant shortages, price**

**increases or unavailability of third-party services have in the**

**past increased, and could in the future increase, our**

**operating costs and could require significant capital**

**expenditures or adversely impact the competitive position of**

**our products:** Our reliance on certain suppliers to secure raw

materials, components and finished devices, and on certain third-

party service providers, such as sterilization service providers,

exposes us to the risk of product shortages and unanticipated

increases in prices, whether due to inflationary pressure,

regulatory changes, litigation exposure, tariffs, geopolitical

tensions or otherwise. For example, in the past we have

experienced limited product availability due to an electronic

component shortage in certain product lines. If a similar shortage

occurs in the future with respect to any raw materials or

components, we may not be able to obtain them from our

suppliers on a timely basis, or at all, or identify alternative

suppliers. In addition, several raw materials, components,

finished devices and services are procured from a sole source

due to, among other things, the quality considerations, unique

intellectual property considerations or constraints associated with

regulatory requirements. If sole-source suppliers or service

providers are unable or unwilling to deliver these materials or

services as a result of financial difficulties, business disruptions,

acquisition by a third party, natural disasters, embargoes, tariffs

or otherwise, we may not be able to manufacture or have

available one or more products during such period of

unavailability and our business could suffer, possibly materially.

In certain cases, we may not be able to establish additional or

replacement suppliers for such materials or service providers for

such services in a timely or cost-effective manner, often as a

result of FDA and other regulations that require, among other

things, validation of materials, components and services prior to

their use in or with our products. In certain instances we have

been unable to meet demand due to supply chain challenges,

which has led to loss of sales. Although the impacts have not

been material to date, an inability to meet demand due to supply

chain challenges in the future could materially adversely impact

our reputation, the competitive position of our products and our

business. In addition, recently enacted tariffs by the United States

government and retaliatory measures by other governments

could adversely impact our supply chain or the availability of

certain components. Any of the foregoing risks could have a

material adverse impact on our profitability and results of

operations.

In addition, in recent years, the market has experienced

inflationary pressures in part due to global supply chain

disruptions, labor shortages and other impacts following the

COVID-19 pandemic. Inflation in the United States and in many

of the countries where we conduct business has resulted in, and

may in the future result in, high interest rates and increased

capital, energy, shipping and labor costs, weakening or

strengthening exchange rates against the United States Dollar

and other similar effects. We have continued to experience, and

may in the future experience, inflationary increases in

manufacturing costs and operating expenses, as well as negative

impacts from weakening or strengthening exchange rates against

the United States Dollar. Although we have been able to pass

certain cost increases on to our customers, we have not been

able to pass along all cost increases and we cannot guarantee

that we will be able to do so in the future, including in connection

with proposed or enacted tariffs. Inflation, high interest rates,

interest rate volatility or proposed or enacted tariffs may also

cause our customers to reduce or delay orders for our products

and services. Any of the foregoing could have a material adverse

impact on our sales, profitability and results of operations.

**We are subject to pricing pressures as a result of cost**

**containment measures in the United States and other**

**countries and other factors, including changes in**

**reimbursement practices and coverage policies and third-**

**party payor cost containment measures:** Initiatives to limit the

growth of general healthcare expenses and hospital costs are

ongoing and gaining increased attention in the markets in which

we do business. These initiatives are sponsored by government

agencies, legislative bodies and the private sector and include

price regulation and competitive pricing. For example, China has

implemented a volume-based procurement process designed to

decrease prices for medical devices and other products. Pricing

pressure has also increased due to pressures on healthcare

budgets, continued consolidation among healthcare providers,

trends toward managed care, the shift toward governments

becoming the primary payers of healthcare expenses, reduction

in coverage or reimbursement levels and medical procedure

volumes and government laws and regulations relating to sales

and promotion, reimbursement and pricing generally. Coverage

policies and reimbursement levels can vary across the payer

community globally, regionally, and locally, and may affect which

products customers purchase, the market acceptance rate for

new technologies and the prices customers are willing to pay for

**Dollar amounts in millions except per share amounts or as otherwise specified.**<sub>6</sub>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

those products in a particular jurisdiction. Furthermore, any

changes to the coverage or reimbursement landscape, or

adverse decisions relating to our products by administrators of

these systems could significantly reduce reimbursement for

procedures using our products or result in denial of

reimbursement for those products, which could adversely affect

customer demand, or the price customers are willing to pay for

such products. Public and private payers have challenged, and

are expected to continue to challenge, prices charged for medical

products and services. Such downward pricing pressures from

any or all of these payers may result in an adverse effect on our

business, results of operations, financial condition and cash

flows. We have also reduced prices for certain products due to

increased competition and if we further reduce prices, we could

become less profitable. In addition, due to healthcare industry

consolidation in recent years, competition to provide goods and

services to industry participants has become, and may continue

to become, more intense, and this consolidation has produced,

and may continue to produce, larger enterprises with more

bargaining power. Pricing pressures related to any of the

foregoing or other factors have impacted and could in the future

impact our results of operations and profitability.

**We operate in a highly competitive industry in which**

**competition and the regulatory burden in the development**

**and improvement of new and existing products is**

**significant:** The markets in which we compete are highly

competitive, and a significant element of our strategy is to

increase revenue growth by focusing on innovation, new product

development and improvement of existing products, including

connectivity solutions. New business models, products and

surgical procedures, as well as improvements to existing

products, are introduced on an ongoing basis and our present or

future products could be rendered obsolete or uneconomical by

internal or external technological advances, including by our

existing competitors and new market entrants, which could

adversely impact demand for certain of our existing products. The

success of our products and services depends on, among other

things, our ability to properly identify customer needs and predict

future needs, including connectivity solutions; innovate and

develop new technologies, services and applications at an

accelerated pace; and appropriately allocate our research and

development spending to products and services with higher

growth. Our existing competitors and new market entrants may

respond more quickly to or integrate new or emerging

technologies such as robotics, artificial intelligence (AI) and

machine learning in their product offerings, undertake more

extensive marketing campaigns, have greater access to clinical

information to support ongoing product position in the market,

have greater financial, marketing and other resources or be more

successful in attracting potential customers, employees and

strategic partners. There can be no assurance that any products

now in development, or that we may seek to develop in the

future, will achieve technological feasibility, obtain regulatory

approval or gain market acceptance. If we are unable to develop

and launch new products, our ability to maintain or expand our

market position in the markets in which we participate may be

negatively impacted.

**We may be unable to maintain adequate working**

**relationships with healthcare professionals:** We work with

healthcare professionals in a transparent and responsible

manner and seek to maintain these relationships with respected

physicians and medical personnel in healthcare organizations,

such as hospitals and universities, who assist in product research

and development. We rely on these professionals to assist us in

the development and improvement of proprietary products. If we

are unable to maintain these relationships due to regulatory

restrictions, hospital access restrictions for non-patients or for

other reasons, our ability to develop, market and sell new and

improved products could be adversely affected.

**We rely on indirect distribution channels and major**

**distributors that are independent of Stryker:** In many markets

we rely on indirect distribution channels to market, distribute and

sell our products. These indirect channels often are the main

point of contact for the healthcare professionals and healthcare

organization customers who buy and use our products. Our

ability to continue to market, distribute and sell our products may

be at risk if the indirect channels become insolvent, choose to sell

competitive products, choose to stop selling medical technology,

fail to adhere to Stryker requirements or are subject to new or

additional government regulation.

We are subject to risks associated with our extensive global

operations: We develop, manufacture and distribute our products

globally. Our global operations are subject to risks and costs

related to, among other things, changes in coverage or

reimbursement levels from third-party payors in the United States

and other countries; changes in regulatory requirements (such as

the staggered phase-in period for manufacturers to comply with

the European Union Medical Device Regulation (MDR) through

December 2028); differing local product preferences and product

requirements; diminished protection of intellectual property in

some countries; tariffs and other trade protection measures, as

well as increasing localization and protectionism policies in

certain jurisdictions; international trade disputes and import or

export requirements; difficulty in staffing and managing foreign

operations; introduction of new internal business structures and

programs; political and economic instability and uncertainty;

current or potential geopolitical conflicts, such as the tensions

between China and Taiwan and the wars in Ukraine and the

Middle East, and related sanctions and other developments;

disruptions of transportation, including port closures, increased

border controls or border closures or reduced transportation

availability, due to military conflicts, a global pandemic of

contagious diseases; increased energy or transportation costs;

fluctuations in currency exchange rates and financial markets;

and increased security threats to our supply chain. For example,

the United States has recently enacted and proposed to enact

new tariffs. These developments, the perception they could

occur, or changes to the existing exemption framework may have

a material adverse effect on global economic conditions and may

significantly reduce global trade. Many of these risks are rapidly

evolving and subject to an accelerating pace of change. Our

business could be adversely impacted if we are unable to

successfully manage these and other risks of global operations in

an increasingly volatile environment. In addition, in many

countries, the laws and regulations applicable to us or our

industry are evolving, and we have in certain cases become

subject to divergent and conflicting laws and regulations across

our operations, which has increased the risks we are subject to.

**We may be unable to capitalize on previous or future**

**acquisitions:** In addition to internally developed products, we

invest in new products and technologies through acquisitions,

including our acquisition of Inari in 2025. Such investments are

inherently risky, and we cannot guarantee that any acquisition will

be successful or will not have a material unfavorable impact on

us. The risks include the activities required and resources

allocated to integrate new businesses, a slower pace of

integration than initially projected, diversion of management time

that could adversely affect management's ability to focus on other

**Dollar amounts in millions except per share amounts or as otherwise specified.**<sub>7</sub>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

projects, the inability to realize the expected benefits, savings or

synergies from the acquisition, the loss of key personnel,

litigation resulting from the acquisition and exposure to

unexpected liabilities of acquired companies. Certain acquisitions

are subject to antitrust and competition laws, and antitrust

scrutiny by regulatory agencies and changes to the regulatory

approval process in the United States and foreign jurisdictions

may cause approvals to take longer than anticipated to obtain,

not be obtained at all, or contain burdensome conditions, which

may jeopardize, delay or reduce the anticipated benefits of

acquisitions to us and could impede the execution of our

business strategy. In addition, we cannot be certain that the

businesses we acquire will become or remain profitable.

**We, our business partners or our third-party vendors could**

**experience a material failure or breach of a key information**

**technology system, network, process or site:** We rely

extensively on information technology (IT) systems to conduct

business. In addition, we rely on networks and services, including

internet sites, cloud and software-as-a-service solutions, data

hosting and processing facilities and tools and other hardware,

software (including open-source software) and technical

applications and platforms, some of which are managed, hosted,

provided and/or used by third parties or their vendors, to assist in

conducting our business. Furthermore, numerous and evolving

cybersecurity threats have posed, and will continue to pose, risks

to the security of our IT systems, networks and product offerings,

as well as the confidentiality, availability and integrity of our data.

Emerging technologies such as generative AI may be used by

malicious actors to create more targeted phishing narratives,

spread disinformation about us or our products or otherwise

strengthen social engineering capabilities. An increasing risk of

civil unrest, political tensions, wars or other military conflicts may

also impact the cybersecurity threat risk landscape. Some of our

products, services, and information technology systems contain

or use open-source software which poses particular risks,

including potential security vulnerabilities, licensing compliance

issues and quality issues. We, our customers and third-party

hosting services have experienced, and expect to continue to

experience, security breaches of, unauthorized access to, and

disruptions of, products or systems. While such breaches,

unauthorized access and disruptions have not had a material

effect on us to date, we cannot guarantee that any future breach

or unauthorized access will not be material and any breach or

unauthorized access could impact the use of such products and

systems and the security of information stored therein. Although

we have made investments and expect to continue to make

investments seeking to address these threats, including

monitoring of networks and systems, use of AI, hiring of experts,

employee training, security policies for employees and third-party

providers and designing, developing and maintaining processes

and procedures to come into compliance with regulatory and

legal enactments such as Section 524B of the Federal Food,

Drug, and Cosmetic Act in the United States, the techniques used

in these attacks change frequently and may be difficult to detect

for periods of time and we may face difficulties in anticipating and

implementing adequate preventative measures.

When cybersecurity or other technology related incidents occur,

we follow our incident response protocols and address them in

accordance with applicable governmental regulations and other

legal requirements. Our response to these incidents and our

investments to protect our product offerings and information

technology infrastructure and data may not shield us from

significant losses and potential liability or prevent any future

interruption or breach of our systems. Moreover, given the

increasing complexity and sophistication of the techniques used

by threat actors to obtain unauthorized access or disable or

degrade systems, a cyberattack could occur and persist for an

extended period of time before being detected, and we may not

anticipate these acts or mitigate them adequately or timely, which

may compound damages before the incident is discovered or

remediated. The extent of a particular cyber incident and the

steps that we may need to take to investigate the incident may

not be immediately clear, and it may take a significant amount of

time before such investigation can be completed and full and

reliable information about the incident is known. New regulations

may require us to disclose information about a material

cybersecurity incident before it has been resolved or fully

investigated. Additionally, as threats continue to evolve and

increase, and as the regulatory environment and customer

requirements related to information security, data collection and

use, and privacy become increasingly rigorous, we may be

required to devote significant additional resources to modify and

enhance our security controls and to identify and remediate any

security vulnerabilities, which could adversely impact our net

income. In addition, a significant number of our employees

working remotely has exposed us, and may continue to expose

us, to greater risks related to cybersecurity and cyber-liability.

Hardware and software failures or delays in our key information

technology systems, networks, processes or sites could disrupt

our operations, cause the loss of confidential information or

otherwise adversely impact our business. Our systems, networks,

processes and sites may be vulnerable to damage, disruptions

and shutdown from a variety of sources, including malfunctions in

maintenance updates or security patches, design defects, the

age of the technology, network failures, modernization or other

initiatives, human acts and natural disasters. For example, some

of our information technology systems contain legacy third-party

software components for which we depend on a layered security

approach to protect against exploitation, which may not be

effective. Any such damage or disruptions could also compromise

the security of our information systems and networks. These

issues can also arise as a result of failures by, or in the software

or hardware of, third parties, including networks or service

providers, with whom we do business and over whom we have

limited or no control. Any disruption or failure of our systems,

networks, processes or sites could have a material impact on our

business and operations.

If our IT systems, networks or processes are damaged or cease

to function properly for any reason, the networks, service

providers, hardware or software we rely upon fail to function

properly, or we or one of our third-party providers suffer a loss or

disclosure of our business or stakeholder information due to any

number of causes ranging from catastrophic events or power

outages to improper data handling or security breaches or

unauthorized access and our business continuity plans do not

effectively address these failures on a timely basis, we may be

exposed to reputational, competitive and business harm as well

as litigation and regulatory action and fines, penalties and

expenses related thereto.

**An inability to successfully manage the implementation of**

**our new commercial global enterprise resource planning**

**(ERP) system could adversely affect our operations and**

**operating results:** We are in the process of implementing a new

commercial ERP system. This system will replace many of our

existing operating and financial systems. The implementation is a

major undertaking, both financially and from a management and

personnel perspective. Any material disruptions, delays or

deficiencies in the design and implementation of our new ERP

**Dollar amounts in millions except per share amounts or as otherwise specified.**<sub>8</sub>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

system could adversely affect our ability to process orders, ship

products, provide services and customer support, send invoices

and track payments, fulfill contractual obligations or otherwise

operate our business.

**We may be unable to attract, develop and retain executives**

**and key employees:** Our sales, technical and other key

personnel play an integral role in the development, marketing and

selling of new and existing products. Our future performance also

depends in large part on the continued services of our senior

management. If we are unable to recruit, hire, develop and retain

a talented, competitive workforce in our highly competitive

industry, or if we are unable to plan effective succession for the

future, we may not be able to meet our strategic business

objectives. Inflationary pressures, labor demand and shortages

and other macroeconomic factors have increased and could

further increase the cost of labor and could harm our ability to

recruit, hire and retain talented employees. In addition, increased

unionization could negatively impact our labor costs and ability to

create an engaging, connected culture, which could adversely

affect our ability to recruit, hire, develop and retain a talented,

competitive workforce. Further, if we are unable to maintain

competitive and equitable compensation and benefit programs,

including incentive programs which reward financial and

operational performance, our ability to recruit, hire, engage,

motivate and retain talent could be negatively affected.

Additionally, if we are unable to maintain an inclusive culture that

aligns our workforce with our mission and values, it could

adversely impact our ability to recruit, hire, develop and retain

key talent. Further, our remote and hybrid work practices, and

ability to provide flexible and alternative work arrangements may

not meet the needs or expectations of our employees, including

senior management or other key employees, which could

negatively impact our ability to attract and retain highly skilled

employees, or may harm our culture and/or decrease employee

engagement, which could adversely impact our ability to recruit,

hire, develop and retain a talented, competitive workforce.

Effective succession planning is also important to our long-term

success. Failure to ensure effective transfer of knowledge and

smooth transitions involving executives and other key employees

could hinder our strategic planning and execution. Changes in

our management team may be disruptive to our business, and

any failure to successfully integrate key new hires or promoted

employees could adversely affect our business and results of

operations. The loss of the services of any of our senior

management or other key personnel, or our inability to attract

highly qualified senior management and other key personnel,

could harm our business. Our ability to execute our business

strategy could be impaired if we are unable to replace such

persons timely. In addition, recent legal and regulatory changes

affect our ability to enforce post-termination obligations from

certain employees with respect to non-competition, non-

solicitation and protection of confidential information. This may

negatively impact our ability to retain employees and protect our

information and relationships with customers and other third

parties.

**Interruption of manufacturing operations could adversely**

**affect our business:** We and our suppliers have manufacturing

and supply sites all over the world. However, the manufacturing

of certain of our product lines is concentrated in one or more

plants or geographic regions. We have principal manufacturing

and distribution facilities in the United States in Arizona,

California, Florida, Illinois, Indiana, Michigan, Minnesota, New

Jersey, Puerto Rico, Tennessee, Texas, Utah and Washington,

and outside the United States in China, France, Germany,

Ireland, Mexico, the Netherlands, Poland, Switzerland and

Turkey. Damage to our facilities, to our suppliers' or service

providers' facilities, or to our central distribution centers as a

result of natural disasters, fires, explosions or otherwise, as well

as issues in our manufacturing arising from a failure to follow

specific internal protocols and procedures, compliance concerns

relating to the quality systems regulation, equipment breakdown

or malfunction, IT system failures or cybersecurity incidents,

environmental hazard incidents or changes to environmental

regulations or other factors, could adversely affect the availability

of our products. In the event of an interruption in manufacturing,

we may be unable to move quickly to alternate means of

producing and distributing affected products to meet customer

demand. In the event of a significant interruption, we may

experience lengthy delays in resuming production or distribution

of affected products due to the need for regulatory approvals, and

we may experience loss of market share, additional expense and

harm to our reputation.

**Our insurance program may not be adequate to cover future**

**losses:** We maintain third-party insurance to cover our exposure

to certain property and casualty losses and are self-insured for

claims and expenses related to other property and casualty

losses, including product liability, intellectual property

infringement and enforcement, environmental, and cybersecurity

and data privacy losses. We manage a portion of our exposure to

self-insured losses through a wholly-owned captive insurance

company. Insurance coverage limits provided by third-party

insurers and/or our captive insurance company may not be

sufficient to fully cover certain losses we may experience.

**We have experienced, and may continue to experience, a**

**significant and unpredictable need to adjust our operations**

**as market demand for certain of our products has shifted**

**and continues to shift or as may be mandated by**

**governmental authorities:** Some of our products are particularly

sensitive to reductions in elective medical procedures. It is not

possible to predict whether elective medical procedures will be

suspended or reduced in the future and, to the extent individuals

and customers are required to delay or cancel elective

procedures, our business, cash flows, financial condition and

results of operations could be negatively affected. Further, our

customers have experienced, and may continue to experience,

staffing shortages that may result in decreased demand for our

products, which could negatively affect our business and financial

results.

Unpredictable increases in demand for certain of our products

have exceeded in the past, and could exceed in the future, our

capacity to meet such demand timely, which could adversely

affect our customer relationships and result in negative publicity.

In this regard, the accelerated development and production of

products and services to address medical and other requirements

could increase the risk of regulatory enforcement actions, product

defects or related claims or reputational harm, among other

things.

**Our use of AI and other emerging technologies could**

**adversely impact our business and financial results:** We

have begun to deploy AI and other emerging technologies in

various facets of our operations and products and we continue to

explore further use cases. The rapid advancement of these

technologies presents opportunities for us in research,

manufacturing, commercialization, and other business

endeavors, but also entails risks, including that AI-generated

content, analyses, or recommendations we utilize could be

deficient, that our competitors may more quickly or effectively

adopt AI capabilities, or that our use of AI or other emerging

**Dollar amounts in millions except per share amounts or as otherwise specified.**<sub>9</sub>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

technologies increases regulatory, cybersecurity and other

significant risks. In addition, any disruption or failure in the AI

functionality we incorporate into our business activities, products

or services could adversely impact our business or result in

delays or errors in our product offerings. The legal and regulatory

landscape surrounding AI technologies is rapidly evolving and

uncertain, including in the areas of intellectual property,

cybersecurity and privacy and data protection. Compliance with

new or changing laws, regulations or industry standards relating

to AI may impose significant costs on us and limit our ability to

effectively develop, deploy or use AI technologies. Furthermore, if

we are unable to effectively manage the use of AI technologies

by our employees and service providers, our confidential

information, intellectual property and reputation could be put at

risk. Failure to appropriately respond to this evolving landscape

may result in reputational, competitive and business harm as well

as litigation and regulatory action and fines, penalties and

expenses related thereto.

**Pandemics and public health emergencies, and the fear**

**thereof, have in the past materially adversely affected and**

**could in the future materially adversely affect, our**

**operations, supply chain, manufacturing, product**

**distribution, customers and other business activities:**

Pandemics and public health emergencies, and the fear thereof,

have in the past materially adversely affected and could in the

future materially adversely affect, our operations, supply chain,

manufacturing, product distribution, customers and other

business activities:

In connection with prior pandemics, governmental authorities and

private enterprises implemented, and may in the future

implement in connection with another pandemic or public health

emergency (or in response to the fear thereof), measures, such

as travel bans and restrictions, quarantines, shelter-in-place

orders and shutdowns. Our customers, global suppliers,

distributors and manufacturing facilities have in the past been,

and could in the future be, materially affected by restrictive

measures implemented in response to a pandemic or public

health emergency, which has in the past caused and could in the

future cause them to be unable to hire and retain employees,

distribute or use our products or provide required services. We

have as a result experienced, and could in the future experience,

delays in, or the suspension of, our manufacturing operations,

sales activities, research and product development activities,

regulatory work streams, clinical development programs and

other important commercial functions, which may result in our

inability to satisfy consumer demand for our products in a timely

manner or at all and which could harm our reputation, future

sales and profitability. The extent of any future pandemic or

public health emergency's effect on our business and industry will

depend on, among other things, the severity of the disease, the

successful development, distribution and acceptance of vaccines

for diseases, future resurgences and/or the spread of disease

variants, all of which are uncertain and difficult to predict. The

COVID-19 pandemic materially impacted us, and any future

pandemic or public health emergency could materially impact us

and would heighten many of the other risks described in this

report.

**LEGAL AND REGULATORY RISKS**

**Current economic and political conditions make tax rules in**

**jurisdictions subject to significant change:** Our future results

of operations could be affected by changes in the effective tax

rate as a result of changes in tax laws, regulations and judicial

rulings. We are continuing to evaluate the impact of tax reform in

the countries in which we operate as new guidance is published

and new regulations are adopted. In addition, further changes in

the tax laws could arise, including as a result of the base erosion

and profit shifting project undertaken by the Organisation for

Economic Cooperation and Development (OECD). The OECD,

which represents a coalition of member countries, has put forth

two proposed frameworks that revise the existing profit allocation

and nexus rules (Pillar 1) and ensure a minimal level of taxation

(Pillar 2), respectively, and several countries enacted tax

legislation based on these frameworks. In January 2026 the

OECD released Administrative Guidance containing the Side-by-

Side system (SbS System) and introduced two new Pillar 2 safe

harbors for multinationals headquartered in jurisdictions including

the United States with eligible tax systems. The safe harbors

must now be legislated domestically by each country with

enacted Pillar 2 legislation impacted by the new OECD

Administrative Guidance. These tax law changes and any

additional contemplated tax law changes could impact tax

expense in future periods.

**We could be negatively impacted by future changes in the**

**allocation of income to each of the income tax jurisdictions**

**in which we operate:** We operate in multiple income tax

jurisdictions both in the United States and internationally.

Accordingly, our management must determine the appropriate

allocation of income to each jurisdiction based on current

interpretations of complex income tax regulations. Income tax

authorities regularly perform audits of our income tax filings.

Income tax audits associated with the allocation of income and

other complex issues, including inventory transfer pricing and

cost sharing, product royalty and foreign branch arrangements,

may require an extended period to resolve and may result in

significant income tax adjustments including the assessment of

additional income taxes, interest and penalties. For example, we

received a final audit report and assessments from the German

Federal Central Tax Office ("FCTO") related to audits of tax years

2010 through 2017. Although we intend to defend our filing

positions through the FCTO independent appeals process and, if

necessary, litigation, there can be no assurance that we will be

successful. If the resolution of this matter results in additional

German income taxes, we intend to seek associated foreign tax

credits, but such credits may not be available on a timely basis or

at all, or may not fully offset any additional liability. Any such

outcome could materially adversely affect our business, financial

condition and results of operations. See Note 11 to our

Consolidated Financial Statements for more information.

**The impact of healthcare reform legislation on our business**

**remains uncertain:** Several markets where we sell our products

are making efforts to expand access to healthcare or health

insurance coverage while decreasing costs. These efforts may

have a direct or unintended negative impact on access to medical

technology and could have a significant effect on our business.

Both in the United States and internationally, governmental

authorities may make legislative or administrative reforms to

existing reimbursement programs, make adverse decisions

relating to our products' coverage or reimbursement, or make

changes to patient access to healthcare, all of which could

adversely impact the demand for and usage of our products or

the prices that our customers are willing to pay for them. We

cannot predict what healthcare programs and regulations could

ultimately be implemented at the federal or state level or the

effect that any future legislation or regulation in the United States

may have on our business. Similarly, we cannot predict the

impact that healthcare reform legislation in other countries where

we sell our products may have on our business.

**Dollar amounts in millions except per share amounts or as otherwise specified.**<sub>10</sub>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

**We are subject to extensive governmental regulation relating**

**to the classification, manufacturing, sterilization, licensing, labeling, marketing and sale of our products:** The

classification, manufacturing, sterilization, licensing, labeling,

marketing and sale of our products are subject to extensive and

evolving regulations and rigorous regulatory enforcement by the

FDA, state governments, European Union and other

governmental authorities in the United States and internationally.

These governmental authorities may impose additional

requirements or limits on the methods, procedures or agents we

use to manufacture and sterilize our products, which could have

a negative impact on our business. For example, governmental

authorities in the United States and internationally have or are

considering adopting regulations on the use of per- and

polyfluoroalkyl substances. In addition, the process of obtaining

licenses, regulatory clearances and/or approvals to market and

sell our products can be costly and time consuming and the

clearances and/or approvals might not be granted timely. We

have ongoing responsibilities under the laws and regulations

applicable to the manufacturing of products within our facilities

and those contracted by third parties that are subject to periodic

inspections by the FDA, state Boards of Pharmacy and other

governmental authorities to determine compliance with the quality

system, medical device reporting regulations and other

requirements. We may also be subject to legal obligations in

some countries that require disclosure or sharing of proprietary

information. We incur significant costs to comply with regulations,

including the MDR. If we fail to comply with applicable regulatory

requirements, we may be subject to a range of sanctions,

including substantial fines, warning letters that require corrective

action, product seizures, recalls, import restrictions, the

suspension of product manufacturing or sales, revocation of

approvals, exclusion from future participation in government

healthcare programs, substantial fines and criminal prosecution.

**We are subject to federal, state and foreign healthcare**

**regulations, including anti-bribery, anti-corruption, anti-**

**kickback and false claims laws, globally and could face**

**substantial penalties if we fail to comply with such**

**regulations and laws:** The relationships that we, and third

parties that market and/or sell our products, have with healthcare

professionals, such as physicians, hospitals, healthcare

organizations and others, are subject to scrutiny under various

state and federal laws often referred to collectively as healthcare

fraud and abuse laws. In addition, the United States and foreign

government regulators have increased the enforcement of the

Foreign Corrupt Practices Act (FCPA) and other anti-bribery and

anti-kickback laws. We also must comply with a variety of other

laws that impose extensive tracking and reporting related to all

transfers of value provided to certain healthcare professionals

and others. These laws and regulations are broad in scope and

are subject to evolving interpretation and we have in the past

been, and in the future could be, required to incur substantial

costs to investigate, audit and monitor compliance or to alter our

practices. Violations or alleged violations of these laws have in

the past resulted and could in the future result in investigations,

litigation or government proceedings, and we have been and may

in the future be subject to criminal or civil penalties and

sanctions, including substantial fines, imprisonment of current or

former employees and exclusion from participation in

governmental healthcare programs. For example, in 2013 and

2018 we settled claims brought by the SEC related to the FCPA.

Pursuant to these settlements, we paid fines and penalties and

retained an independent compliance consultant. We continue to

implement recommendations that resulted from the independent

compliance consultant's review of our commercial practices to

enhance our commercial business practices. In addition, as

disclosed in our prior filings, we were previously contacted by the

SEC, the United States Department of Justice, and other

regulatory authorities involving whether certain business activities

in certain foreign countries violated provisions of the FCPA and

analogous local laws. We have completed our investigation into

these matters. On April 1, 2025, and December 16, 2025, we

were informed by the DOJ and SEC, respectively, that each

agency had closed its inquiry. We are currently responding to

inquiries by certain foreign authorities arising in the normal

course of business, however, we do not expect these matters to

have a material effect, if any, on our financial statements.

**We are subject to privacy, data protection and data security**

**regulations and laws globally, and could face substantial**

**penalties if we fail to comply with such regulations and laws:**

We are subject to a variety of laws and regulations globally

regarding privacy, data protection and data security, including

those related to the collection, storage, handling, use, disclosure,

transfer and security of personally identifiable healthcare

information and the development and use of AI in sharing certain

data. For example, in the United States, privacy and security

regulations under the Health Insurance Portability and

Accountability Act of 1996, including the expanded requirements

under the Health Information Technology for Economic and

Clinical Health Act of 2009, establish comprehensive standards

with respect to the use and disclosure of protected health

information (PHI), by covered entities, in addition to setting

standards to protect the confidentiality, integrity and security of

PHI. Regulators are also imposing new data privacy and security

requirements, including new and greater monetary fines for

privacy violations. For example, the European Union's General

Data Protection Regulation (GDPR) established rules regarding

the handling of personal data. Non-compliance with the GDPR

may result in monetary penalties of up to 4% of total company

revenue. Various government authorities within the United States

and around the world have imposed or are considering similar

types of laws and regulations, data breach reporting and

penalties for non-compliance or unauthorized disclosure and

increasing security requirements. These laws and regulations are

broad in scope and are subject to evolving interpretation and

enforcement and we have in the past been, and in the future

could be, required to incur substantial costs to monitor

compliance or to alter our practices. As new privacy-related laws

and AI-related regulations are implemented, the time and

resources needed for us to comply with such laws and

regulations, as well as our potential liability for non-compliance

and reporting obligations in the case of data breaches, have

increased and may further increase.

**We may be adversely affected by product liability claims, unfavorable court decisions or legal settlements:** We are

exposed to potential product liability risks inherent in the design,

manufacture and marketing of medical devices, many of which

are implanted in the human body for long periods of time or

indefinitely. We are currently defendants in a number of product

liability matters, including those relating to our Rejuvenate and

ABGII Modular-Neck hip stems, LFIT Anatomic CoCr V40

Femoral Heads and the product liability lawsuits and claims

relating to Wright Medical Group N.V. (Wright) legacy hip

products discussed in Note 7 to our Consolidated Financial

Statements. These matters are subject to uncertainties and

outcomes are not predictable. Further, the European

Representative Actions Directive (the Collective Redress

Directive) mandates a class action regime in each EU member

**Dollar amounts in millions except per share amounts or as otherwise specified.**<sub>11</sub>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

state to facilitate domestic and cross-border class actions in a

wide range of areas, including product liability claims with

medical devices. The European Product Liability Directive was

revised in 2024 and will become fully adopted into each member

state's national laws by December 9, 2026. The revised Product

Liability Directive and Collective Redress Directive exposes us to

additional litigation risks and could result in significant legal

expenses. In addition, we may incur significant legal expenses or

reputational damage for product liability claims regardless of

whether we are found to be liable.

**Intellectual property litigation and infringement claims could**

**cause us to incur significant expenses or prevent us from**

**selling certain of our products:** The medical device industry is

characterized by extensive intellectual property litigation and,

from time to time, we are the subject of claims of infringement or

misappropriation. Regardless of the outcome, such claims are

expensive to defend and divert management and operating

personnel from other business issues. A successful claim or

claims of patent or other intellectual property infringement against

us could result in payment of significant monetary damages and/

or royalty payments or negatively impact our ability to sell current

or future products in the affected category.

**Dependence on intellectual proprietary rights and failing to**

**protect such rights or to be successful in litigation related to**

**such rights may impact offerings in our product portfolios:**

Our long-term success largely depends on our ability to market

technologically competitive products. If we fail to obtain or

maintain adequate intellectual property protection, it could allow

others to sell products that directly compete with proprietary

features in our product portfolio. Also, our issued patents may be

subject to claims challenging their validity and scope and raising

other issues. In addition, currently pending or future patent

applications may not result in issued patents and the expiration of

patents may lead to a loss of exclusive rights and/or increased

competition.

**MARKET RISKS**

We have exposure to exchange rate fluctuations on cross border

transactions and translation of local currency results into United

States Dollars: We report our financial results in United States

Dollars and approximately 24% of our net sales are denominated

in foreign currencies, including the Australian Dollar, British

Pound, Canadian Dollar, Euro and Japanese Yen. Cross border

transactions with external parties, financing transactions in

currencies other than the United States Dollar and intercompany

relationships result in increased exposure to foreign currency

exchange effects. While we use derivative instruments to

manage the impact of currency exchange, our hedging strategies

may not be successful, and our unhedged exposures continue to

be subject to currency fluctuations. In addition, the weakening or

strengthening of the United States Dollar results in favorable or

unfavorable translation effects when the results of our foreign

locations are translated into United States Dollars. Currency

exchange rates continue to be volatile, and these currency

fluctuations have affected, and may continue to affect, our results

of operations.

**Additional capital that we may require in the future may not**

**be available to us or may only be available to us on**

**unfavorable terms, which could negatively affect our**

**liquidity:** Our future capital requirements will depend on many

factors, including operating requirements, current and future

acquisitions and the need to refinance existing debt. Our ability to

issue additional debt or enter into other financing arrangements

on acceptable terms could be adversely affected by our debt

levels, unfavorable changes in economic conditions or

uncertainties that affect the capital markets. Changes in credit

ratings issued by nationally recognized credit rating agencies

could also adversely affect our access to and cost of financing.

Higher borrowing costs or the inability to access capital markets

could adversely affect our ability to support future growth and

operating requirements. In addition, we have experienced, and

could in the future experience, loss of sales and profits due to

delayed payments or insolvency of healthcare professionals,

hospitals and other customers and suppliers facing liquidity

issues due to the current macroeconomic environment, type and

number of conditions being treated or for other reasons. As a

result, we may be compelled to take additional measures to

preserve our cash flow, including through the reduction of

operating expenses or suspension of dividend payments.

**ENVIRONMENTAL, SOCIAL AND GOVERNANCE RISKS**

**We could be negatively impacted by evolving requirements**

**and expectations related to corporate responsibility and**

**sustainability-related matters, including those related to**

**climate:** Governments, investors, customers, employees and

other stakeholders have been focused on corporate responsibility

practices and disclosures, and expectations in this area continue

to rapidly evolve, including in diverging directions. On occasion,

we announce new initiatives and make disclosures, including

goals, relating to various corporate responsibility matters.

Implementation of these initiatives involves risks and

uncertainties, requires investments and depends in part on third-

party performance or data that is outside our control. We cannot

guarantee that we will achieve our announced corporate

responsibility initiatives. If we fail or are perceived to have failed

to achieve previously announced initiatives or goals, comply with

corporate responsibility laws and regulations, meet evolving

expectations or accurately disclose our progress, we could face

legal and regulatory proceedings and our reputation, business,

financial condition and results of operations could be adversely

impacted. Furthermore, there is no guarantee that we will satisfy

the evolving and diverging expectations of our various

stakeholders on corporate responsibility matters, and a failure to

satisfy the expectations of any key stakeholder group could result

in, among other things, reduced demand for our products,

reduced profits, increased investigations and litigation and an

increased risk of reputational damage. If we are unable to satisfy

evolving and diverging expectations on these matters, certain

investors and other stakeholders may conclude that our policies

and/or actions with respect to corporate responsibility matters are

inadequate or undesirable.

**Physical weather events, as well as legal, regulatory or**

**market measures related to environmental, climate and other**

**sustainability matters, could adversely affect our operations**

**and operating results:** Weather-related events and evolving

environmental conditions may result in operational, supply chain

and infrastructure disruptions. Such events, including hurricanes,

tornadoes, wildfires, droughts, extreme temperatures, flooding,

and other natural disasters, could damage our facilities and

products, or those of our suppliers, disrupt manufacturing and

distribution, reduce workforce availability, increase raw material

and component costs, increase liabilities, or adversely affect the

operations of hospitals, medical care facilities and other

customers, any of which could negatively impact our results of

operations. In addition, sustainability-related matters continue to

be the subject of regulatory, legal and market attention.

Regulatory requirements and enforcement approaches may

evolve, differ by jurisdiction, or change over time, including

through the adoption, modification, interpretation, or enforcement

**Dollar amounts in millions except per share amounts or as otherwise specified.**<sub>12</sub>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

of environmental laws and regulations. Such developments may

increase compliance costs, create uncertainty, affect raw material

availability and sourcing, require operational changes, or

otherwise adversely affect our manufacturing, supply chain,

distribution activities or operating results.

---

| | |
|:---|:---|
| **ITEM 1B.** | **UNRESOLVED STAFF COMMENTS.** |

---

None.

---

| | |
|:---|:---|
| **ITEM 1C.** | **CYBERSECURITY.** |

---

**RISK MANAGEMENT AND STRATEGY**

We review cybersecurity risk as part of our overall enterprise risk

management program. This ensures that cybersecurity risk

management remains a top priority in our business strategy and

operations.

**MANAGEMENT'S ROLE IN MANAGING RISK**

Primary management responsibility for assessing, monitoring and

managing our cybersecurity risks rests with our chief information

security officer ("CISO"). Our current CISO has over 30 years of

experience in information technology and cybersecurity in the

United States military, retail and healthcare sectors and oversees

our team of cybersecurity professionals. The CISO is regularly

informed about recent developments in cybersecurity, including

potential threats and innovative risk management techniques.

The CISO implements and oversees processes for the regular

monitoring of our information systems. We use various tools and

methodologies to manage cybersecurity risk that are tested

regularly. We also monitor and evaluate our cybersecurity

posture and performance on an ongoing basis through regular

vulnerability scans, penetration tests and threat intelligence

feeds. In addition, we engage third-party consultants to conduct

annual cybersecurity assessments and to conduct audits for

compliance with regulatory, Sarbanes-Oxley Act, Service

Organization Control Type 2 and International Organization for

Standardization standards. We also engage third parties to

assess our cybersecurity maturity and risk management

programs.

We use a cross-departmental approach to addressing

cybersecurity risk, with our cybersecurity, product security and

legal teams presenting quarterly on key topics to a committee of

leaders in technology, legal, finance, regulatory and corporate

affairs functions. This leadership committee meets quarterly to

ensure that we have input and oversight from critical

stakeholders into our cybersecurity program and evolving issues.

The CISO oversees a training and awareness program for

employees to take part in protecting the Company against

cybersecurity risks. We have implemented annual mandatory

security education to help employees understand cybersecurity

risks and comply with our cybersecurity policies. Additionally, we

provide frequent communications around pertinent cybersecurity

topics and policies to all employees. We also provide additional

cybersecurity and data protection training to employees in certain

roles.

As part of our cybersecurity risk management program, we also

conduct cybersecurity, data protection, and privacy assessments

on all third parties who integrate with Stryker's data, network,

systems and products. We use a combination of internal and

external tools to confirm that these third parties meet our security

requirements. We leverage standard industry threat model and

privacy impact assessment concepts to confirm that data

minimization and adequate data protections are in place. We

perform supplemental reviews as necessary, commensurate with

the risk associated with each vendor.

In the event of a cybersecurity incident, we have an incident

response plan that includes immediate actions to mitigate the

impact and long-term strategies for remediation and prevention of

future incidents. The cybersecurity and product security teams

routinely practice this plan with functions across the organization.

We conduct tabletop exercises with senior management, during

which we practice the procedures in place to ensure that

potentially material cybersecurity risks and incidents are

escalated to management and the Board of Directors where

applicable.

**GOVERNANCE**

Cybersecurity risks are overseen by the full Board of Directors

and the Audit Committee. The Audit Committee is central to the

Board of Directors' oversight of cybersecurity risks and bears the

primary responsibility for overseeing cybersecurity risk. The Audit

Committee actively participates in strategic decisions related to

cybersecurity, offering guidance and approval for major

cybersecurity initiatives. This involvement ensures that

cybersecurity considerations are integrated into our broader

strategic objectives.

Our CISO provides comprehensive updates to the Audit

Committee at least three times a year and the full Board of

Directors periodically. These briefings include a range of topics,

including:

• Current cybersecurity landscape and emerging threats;

• Status of ongoing cybersecurity initiatives and strategies;

• Incident reports and learnings from any cybersecurity events;

• Metrics demonstrating company and industry-standard

prevention of common threats; and

• Regulatory changes impacting cybersecurity requirements

and strategy.

The Board of Directors is aware of the critical nature of managing

risks associated with cybersecurity threats and is actively

engaged in our cybersecurity risk management strategy.

**RISKS FROM CYBERSECURITY THREATS**

Although cybersecurity risks have not materially affected us,

including our business strategy, results of operations or financial

condition, to date, we face numerous and evolving cybersecurity

threats in our business. For more information about the

cybersecurity risks we face, see the risk factor entitled "We, our

business partners or our third-party vendors could experience a

material failure or breach of a key information technology system,

network, process or site" in Item 1A. Risk Factors.

---

| | |
|:---|:---|
| **ITEM 2.** | **PROPERTIES.** |

---

We have approximately 27 company-owned and 306 leased

locations worldwide including 55 manufacturing locations. We

believe that our properties are in good operating condition and

adequate for the manufacture and distribution of our products.

We do not anticipate difficulty in renewing existing leases as they

expire or in finding alternative facilities.

---

| | |
|:---|:---|
| **ITEM 3.** | **LEGAL PROCEEDINGS.** |

---

We are involved in various ongoing proceedings, legal actions

and claims arising in the normal course of our business, including

proceedings related to product, labor, tax, intellectual property

and other matters. Refer to Notes 7 and 11 to our Consolidated

Financial Statements for further information.

---

| | |
|:---|:---|
| **ITEM 4.** | **MINE SAFETY DISCLOSURES.** |

---

Not applicable.

**Dollar amounts in millions except per share amounts or as otherwise specified.**<sub>13</sub>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

**PART II**<br>

---

| | |
|:---|:---|
| **ITEM 5.** | **MARKET FOR THE REGISTRANT'S COMMON** <br>**EQUITY, RELATED STOCKHOLDER** <br>**MATTERS AND ISSUER PURCHASES OF** <br>**EQUITY SECURITIES.**<br>|

---

Our common stock is traded on the New York Stock Exchange

under the symbol SYK.

Our Board of Directors considers payment of cash dividends at

its quarterly meetings. On January 31, 2026 there were 2,323

shareholders of record of our common stock.

We did not repurchase any shares in the three months ended

December 31, 2025 and the total dollar value of shares that could

be acquired under our authorized repurchase program at

December 31, 2025 was $1,033.

In the fourth quarter 2025 we did not issue shares of our common

stock as performance incentive awards to employees. When

issued, these shares are not registered under the Securities Act

of 1933 based on the conclusion that the awards are not events

of sale within the meaning of Section 2(a)(3) of the Act.

The following graph compares our total returns (including

reinvestment of dividends) against the Standard & Poor's (S&P)

500 Index and the S&P 500 Health Care Index. The graph

assumes $100 (not in millions) invested on December 31, 2020 in

our common stock and each of the indices.

![997](syk-20251231_g3.gif)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Company / Index** | **2020** | **2021** | **2022** | **2023** | **2024** | **2025** |
| **Stryker Corporation** | **$100.00** | **$110.22** | **$102.05** | **$126.33** | **$153.30** | **$151.03** |
| S&P 500 Index | $100.00 | $128.71 | $105.40 | $133.10 | $166.40 | $196.16 |
| S&P 500 Health Care <br>Index<br>| $100.00 | $126.13 | $123.67 | $126.21 | $129.46 | $148.36 |

---

**Dollar amounts in millions except per share amounts or as otherwise specified.**<sub>14</sub>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

---

| | |
|:---|:---|
| **ITEM 6.** | **SELECTED FINANCIAL DATA.** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Statement of Earnings Data** | **2025** | **2024** | **2023** | **2022** | **2021** |
| **Net sales** | **$25116** | **$22595** | **$20498** | **$18449** | **$17108** |
| Cost of sales | 9051 | 8155 | 7440 | 6871 | 6140 |
| **Gross profit** | **$16065** | **$14440** | **$13058** | **$11578** | **$10968** |
| Research, development and engineering expenses | 1623 | 1466 | 1388 | 1454 | 1235 |
| Selling, general and administrative expenses | 8651 | 7685 | 7111 | 6386 | 6266 |
| Amortization of intangible assets | 732 | 623 | 635 | 627 | 619 |
| Goodwill and other impairments | 170 | 977 | 36 | 270 | 264 |
| Total operating expenses | $11176 | $10751 | $9170 | $8737 | $8384 |
| **Operating income** | **$4889** | **$3689** | **$3888** | **$2841** | **$2584** |
| Interest expense | (607) | (409) | (363) | (341) | (354) |
| Other income | 232 | 212 | 148 | 183 | 51 |
| **Earnings before income taxes** | **$4514** | **$3492** | **$3673** | **$2683** | **$2281** |
| Income taxes | 1268 | 499 | 508 | 325 | 287 |
| **Net earnings** | **$3246** | **$2993** | **$3165** | **$2358** | **$1994** |
| **Net earnings per share of common stock:** |  |  |  |  |  |
| Basic | $8.49 | $7.86 | $8.34 | $6.23 | $5.29 |
| Diluted | $8.40 | $7.76 | $8.25 | $6.17 | $5.21 |
| **Dividends declared per share of common stock** | **$3.400** | **$3.240** | **$3.050** | **$2.835** | **$2.585** |
| **Balance Sheet Data** |  |  |  |  |  |
| Cash, cash equivalents and current marketable securities | $4100 | $3743 | $3053 | $1928 | $3019 |
| Accounts receivable, net | 4039 | 3987 | 3765 | 3565 | 3022 |
| Inventories | 5310 | 4774 | 4843 | 3995 | 3314 |
| Property, plant and equipment, net | 3876 | 3448 | 3215 | 2970 | 2833 |
| **Total assets** | **$47844** | **$42971** | **$39912** | **$36884** | **$34631** |
| Accounts payable | 1799 | 1679 | 1517 | 1413 | 1129 |
| Total debt | 15859 | 13597 | 12995 | 13048 | 12479 |
| **Shareholders' equity** | **$22420** | **$20634** | **$18593** | **$16616** | **$14877** |
| **Cash Flow Data**  |  |  |  |  |  |
| **Net cash provided by operating activities** | **$5044** | **$4242** | **$3711** | **$2624** | **$3263** |
| Purchases of property, plant and equipment | 761 | 755 | 575 | 588 | 525 |
| Depreciation | 461 | 427 | 393 | 371 | 371 |
| Acquisitions, net of cash acquired | 4960 | 1628 | 390 | 2563 | 339 |
| Amortization of intangible assets | 732 | 623 | 635 | 627 | 619 |
| Payments of dividends | 1284 | 1219 | 1139 | 1051 | 950 |
| **Other Data** |  |  |  |  |  |
| Number of shareholders of record | 2334 | 2520 | 2518 | 2533 | 2551 |
| Approximate number of employees | 56000 | 53000 | 52000 | 51000 | 46000 |

---

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **15** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

---

| | |
|:---|:---|
| **ITEM 7.** | **MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.** |

---

**About Stryker**

Stryker is a global leader in medical technologies and, together

with our customers, we are driven to make healthcare better. We

offer innovative products and services in MedSurg,

Neurotechnology, and Orthopaedics that help improve patient

and healthcare outcomes. Alongside our customers around the

world, we impact more than 150 million patients annually. Our

goal is to achieve sales growth at the high-end of the medical

technology (MedTech) industry and maintain our long-term capital

allocation strategy that prioritizes: (1) Acquisitions, (2) Dividends

and (3) Share repurchases.

We segregate our operations into two reportable business

segments: (i) MedSurg and Neurotechnology and (ii)

Orthopaedics. MedSurg and Neurotechnology products include

surgical equipment and navigation systems (Instruments),

endoscopic and communications systems (Endoscopy), patient

handling, emergency medical equipment and intensive care

disposable products (Medical), minimally invasive products for

the treatment of acute ischemic and hemorrhagic stroke and

venous thromboembolism (Vascular), a comprehensive line of

products for traditional brain and open skull-based surgical

procedures; orthobiologic and biosurgery products, including

synthetic bone grafts and vertebral augmentation products

(Neuro Cranial). Orthopaedics products consist primarily of

implants used in hip and knee joint replacements and trauma and

extremity surgeries.

**Macroeconomic Environment**

In 2025 the United States government has announced new tariffs

on goods imported into the United States from dozens of

countries, including China and the European Union member

states. In response, governments have threatened or imposed

reciprocal tariffs or taken other measures, and the United States

is in the process of negotiating with certain governments. We

continue to monitor and evaluate the situation. Tariffs are

expected to continue to result in an increase in certain product

costs or have adverse impacts on, among other things, demand

for our products and supply chains. The overall macroeconomic

and geopolitical environment, including tariffs or changes in trade

policies, slower economic growth or recession, market volatility

and inflation, and uncertainty regarding all of the foregoing, pose

risks that could impact our business and results of operations.

For more information about these risks, see Item 1A. "Risk

Factors."

**Overview of 2025**

In 2025 we achieved reported net sales growth of 11.2%.

Excluding the impact of acquisitions and divestitures, sales grew

10.3% in constant currency. We reported net earnings of $3,246

and net earnings per diluted shareof$8.40. Excluding the impact

of certain items, we achieved adjusted net earnings<sup>(1)</sup> of $5,267

and adjusted net earnings per diluted share<sup>(1)</sup>of $13.63

representing growth of 11.8%.

We continued our capital allocation strategy by investing $4,960

in acquisitions and paying $1,284 in dividends to our

shareholders.

In 2025 we completed various acquisitions for total consideration

of $4,960, net of cash acquired. Refer to Note 6 to our

Consolidated Financial Statements for further information.

In February 2025 we entered into a new revolving credit

agreement that replaces our previous agreement dated October

2021. The primary changes included increasing the aggregate

principal amount of the facility by $750 to $3,000 and extending

the maturity date to February 25, 2030. On December 31, 2025

there were no borrowings outstanding under our revolving credit

facility or our commercial paper program which allows for

maturities up to 397 days from the date of issuance. The

maximum amount of our commercial paper that can be

outstanding at any time is $3,000.

In February 2025 we issued $500 of 4.550% senior unsecured

notes due February 10, 2027, $700 of 4.700% senior unsecured

notes due February 10, 2028, $800 of 4.850% senior unsecured

notes due February 10, 2030 and $1,000 of 5.200% senior

unsecured notes due February 10, 2035. In the second quarter

2025 we repaid $650 of 1.150% senior unsecured notes and in

the fourth quarter 2025 we repaid $750 of 3.375% senior

unsecured notes.

<sup>(1)</sup> Refer to "Non-GAAP Financial Measures" for a discussion of non-GAAP financial measures used in this report and a reconciliation to the most directly

comparable GAAP financial measure.

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **16** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

**CONSOLIDATED RESULTS OF OPERATIONS**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| |  |  |  | **Percent Net Sales** | **Percent Net Sales** | **Percent Net Sales** | **Percentage Change** | **Percentage Change** |
| | **2025** | **2024** | **2023** | **2025** | **2024** | **2023** | **2025 vs. 2024** | **2024 vs. 2023** |
| **Net sales** | **$25116** | **$22595** | **$20498** | **100.0%** | **100.0%** | **100.0%** | **11.2%** | **10.2%** |
| Gross profit | 16065 | 14440 | 13058 | 64.0 | 63.9 | 63.7 | 11.3 | 10.6 |
| Research, development and engineering expenses | 1623 | 1466 | 1388 | 6.5 | 6.5 | 6.8 | 10.7 | 5.6 |
| Selling, general and administrative expenses | 8651 | 7685 | 7111 | 34.4 | 34.0 | 34.7 | 12.6 | 8.1 |
| Amortization of intangible assets | 732 | 623 | 635 | 2.9 | 2.8 | 3.1 | 17.5 | (1.9) |
| Goodwill and other impairments | 170 | 977 | 36 | 0.7 | 4.3 | 0.2 | nm | nm |
| Interest expense | (607) | (409) | (363) | (2.4) | (1.8) | (1.8) | 48.4 | 12.7 |
| Other income | 232 | 212 | 148 | 0.9 | 0.9 | 0.8 | 9.4 | 43.2 |
| Income taxes | 1268 | 499 | 508 | nm | nm | nm | 154.1 | (1.8) |
| **Net earnings** | **$3246** | **$2993** | **$3165** | **12.9%** | **13.2%** | **15.4%** | **8.5%** | **(5.4)%** |
| **Net earnings per diluted share** | **$8.40** | **$7.76** | **$8.25** |  |  |  | **8.2%** | **(5.9)%** |
| **Adjusted net earnings per diluted share**<sup>(1)</sup> | **$13.63** | **$12.19** | **$10.60** |  |  |  | **11.8%** | **15.0%** |

---

nm - not meaningful

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| ***Geographic and Segment Net Sales*** | | | | **Percentage Change** | **Percentage Change** | **Percentage Change** | **Percentage Change** |
| ***Geographic and Segment Net Sales*** | | | | **2025 vs. 2024** | **2025 vs. 2024** | **2024 vs. 2023** | **2024 vs. 2023** |
|  | **2025** | **2024** | **2023** | **As** <br>**Reported**<br>| **Constant**<br>**Currency**<br>| **As** <br>**Reported**<br>| **Constant**<br>**Currency**<br>|
| **Geographic:** |  |  |  |  |  |  |  |
| United States | $19006 | $16943 | $15257 | 12.2% | 12.2% | 11.0% | 11.0% |
| International | 6110 | 5652 | 5241 | 8.1 | 6.4 | 7.9 | 9.8 |
| **Total** | **$25116** | **$22595** | **$20498** | **11.2%** | **10.7%** | **10.2%** | **10.7%** |
| **Segment:** |  |  |  |  |  |  |  |
| MedSurg and Neurotechnology | $15647 | $13518 | $12163 | 15.7% | 15.4% | 11.1% | 11.6% |
| Orthopaedics | 9469 | 9077 | 8335 | 4.3 | 3.8 | 8.9 | 9.4 |
| **Total** | **$25116** | **$22595** | **$20498** | **11.2%** | **10.7%** | **10.2%** | **10.7%** |

---

---

| | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| ***Supplemental Net Sales Growth Information*** | ***Supplemental Net Sales Growth Information*** | ***Supplemental Net Sales Growth Information*** | ***Supplemental Net Sales Growth Information*** | ***Supplemental Net Sales Growth Information*** | ***Supplemental Net Sales Growth Information*** | ***Supplemental Net Sales Growth Information*** | ***Supplemental Net Sales Growth Information*** | ***Supplemental Net Sales Growth Information*** | ***Supplemental Net Sales Growth Information*** | ***Supplemental Net Sales Growth Information*** | ***Supplemental Net Sales Growth Information*** | ***Supplemental Net Sales Growth Information*** | ***Supplemental Net Sales Growth Information*** |
|  |  |  |  | **Percentage Change** | **Percentage Change** | **Percentage Change** | **Percentage Change** | **Percentage Change** | **Percentage Change** | **Percentage Change** | **Percentage Change** | **Percentage Change** | **Percentage Change** |
|  |  |  |  | **2025 vs. 2024** | **2025 vs. 2024** | **2025 vs. 2024** | **2025 vs. 2024** | **2025 vs. 2024** | **2024 vs. 2023** | **2024 vs. 2023** | **2024 vs. 2023** | **2024 vs. 2023** | **2024 vs. 2023** |
|  |  |  |  |  |  | **United** <br>**States**<br>| **International** | **International** |  |  | **United** <br>**States**<br>| **International** | **International** |
|  | **2025** | **2024** | **2023** | **As** <br>**Reported**<br>| **Constant** <br>**Currency**<br>| **As** <br>**Reported**<br>| **As** <br>**Reported**<br>| **Constant** <br>**Currency**<br>| **As** <br>**Reported**<br>| **Constant** <br>**Currency**<br>| **As** <br>**Reported**<br>| **As** <br>**Reported**<br>| **Constant** <br>**Currency**<br>|
| **MedSurg and** <br>**Neurotechnology:**<br>|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Instruments | $3183 | $2834 | $2534 | 12.3% | 11.9% | 13.0% | 9.5% | 7.5% | 11.9% | 12.1% | 12.5% | 9.5% | 10.6% |
| Endoscopy | 3807 | 3389 | 3068 | 12.3 | 12.3 | 12.2 | 12.8 | 12.4 | 10.5 | 11.0 | 11.1 | 7.7 | 10.7 |
| Medical | 4204 | 3852 | 3459 | 9.1 | 8.8 | 10.0 | 4.8 | 2.8 | 11.4 | 11.7 | 14.6 | (2.0) | (0.3) |
| Vascular | 1968 | 1307 | 1226 | 50.6 | 50.0 | 107.5 | 14.8 | 13.4 | 6.6 | 8.2 | 4.7 | 7.9 | 10.5 |
| Neuro Cranial | 2485 | 2136 | 1876 | 16.3 | 15.9 | 16.5 | 15.5 | 13.1 | 13.9 | 14.1 | 15.0 | 8.7 | 10.2 |
|  | **$15647** | **$13518** | **$12163** | **15.7%** | **15.4%** | **17.0%** | **11.3%** | **9.7%** | **11.1%** | **11.6%** | **12.7%** | **5.9%** | **7.9%** |
| **Orthopaedics:** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Knees | $2656 | $2447 | $2273 | 8.5% | 8.2% | 7.6% | 11.0% | 9.7% | 7.6% | 8.2% | 6.7% | 10.4% | 12.2% |
| Hips | 1865 | 1704 | 1544 | 9.5 | 8.9 | 7.4 | 12.9 | 11.2 | 10.3 | 11.3 | 7.2 | 15.9 | 18.4 |
| Trauma and Extremities | 3948 | 3507 | 3147 | 12.6 | 11.8 | 13.1 | 11.0 | 8.2 | 11.4 | 11.6 | 12.6 | 8.3 | 9.1 |
| Other | 815 | 712 | 658 | 14.5 | 14.0 | 18.2 | 5.3 | 3.6 | 8.1 | 9.6 | 7.3 | 10.1 | 15.4 |
|  | 9284 | 8370 | 7622 | 10.9% | 10.3% | 10.9% | 11.0% | 9.0% | 9.8% | 10.4% | 9.3% | 10.9% | 12.8% |
| Spinal Implants | 185 | 707 | 713 | (73.9) | (73.9) | (76.0) | (69.3) | (69.2) | (0.7) | (0.3) | (2.1) | 2.5 | 3.8 |
|  | **$9469** | **$9077** | **$8335** | **4.3%** | **3.8%** | **4.3%** | **4.4%** | **2.6%** | **8.9%** | **9.4%** | **8.4%** | **10.2%** | **12.0%** |
| **Total** | **$25116** | **$22595** | **$20498** | **11.2%** | **10.7%** | **12.2%** | **8.1%** | **6.4%** | **10.2%** | **10.7%** | **11.0%** | **7.9%** | **9.8%** |

---

**Consolidated Net Sales**

Consolidated net sales in 2025increased11.2% as reported and

10.7% in constant currency, as foreign currency exchange rates

positively impacted net sales by 0.5%. Excluding the 0.4% impact

of acquisitions and divestitures, net sales in constant currency

increased by 9.9% from increased unit volume and0.4% due to

higher prices. The unit volume increase was primarily due to

higher shipments across all businesses.

Consolidated net sales in 2024increased10.2% as reported and

10.7% in constant currency, as foreign currency exchange rates

negatively impacted net sales by 0.5%. Excluding the 0.5%

impact of acquisitions and divestitures, net sales in constant

currency increased by 9.1% from increased unit volume and

1.1% due to higher prices. The unit volume increase was due to

higher shipments across all MedSurg and Neurotechnology

businesses and most Orthopaedics businesses.

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **17** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

**MedSurg and Neurotechnology Net Sales**

MedSurg and Neurotechnology net sales in 2025increased

15.7% as reported and 15.4% in constant currency, as foreign

currency exchange rates positively impacted net sales by 0.3%.

Excluding the 4.7% impact of acquisitions and divestitures, net

sales in constant currency increased by 10.0% from increased

unit volume and0.7% due to higher prices. The unit volume

increase was due to higher shipments across all MedSurg and

Neurotechnology businesses.

MedSurg and Neurotechnology net sales in 2024increased

11.1% as reported and 11.6% in constant currency, as foreign

currency exchange rates negatively impacted net sales by 0.5%.

Excluding the 0.4% impact of acquisitions and divestitures, net

sales in constant currency increased by 9.5% from increased unit

volume and1.7% due to higher prices. The unit volume increase

was due to higher shipments across all MedSurg and

Neurotechnology businesses.

**Orthopaedics Net Sales**

Orthopaedics net sales in 2025increased4.3% as reported and

3.8% in constant currency, as foreign currency exchange rates

positively impacted net sales by 0.5%. Excluding the 5.7% impact

of acquisitions and divestitures, net sales in constant currency

increased by 9.6% from increased unit volume partially offset by

0.1% due to lower prices. The unit volume increase was due to

higher shipments across most Orthopaedics businesses.

Orthopaedics net sales in 2024increased8.9% as reported and

9.4% in constant currency, as foreign currency exchange rates

negatively impacted net sales by 0.5%. Excluding the 0.7%

impact of acquisitions and divestitures, net sales in constant

currency increased by 8.7% from increased unit volume. The unit

volume increase was due to higher shipments across all

Orthopaedics businesses.

**Gross Profit**

Gross profit was $16,065, $14,440 and $13,058 in 2025, 2024,

and 2023. The key components of the change were:

---

| | |
|:---|:---|
|  | **Gross Profit** <br>**Percent Net Sales**<br>|
| **2023** | **63.7%** |
| Sales pricing | 40 bps |
| Volume and mix | 60 bps |
| Manufacturing and supply chain costs | (40) bps |
| Inventory stepped up to fair value | (20) bps |
| Structural optimization and other special charges | (20) bps |
| **2024** | **63.9%** |
| Sales pricing | 10 bps |
| Volume and mix | 70 bps |
| Manufacturing and supply chain costs | 0 bps |
| Inventory stepped up to fair value | (60) bps |
| Structural optimization and other special charges | (10) bps |
| **2025** | **64.0%** |

---

Gross profit as a percentage of net sales increased to 64.0% in

2025 from 63.9% in 2024 primarily due to higher sales pricing

and favorable volume partially offset by higher amortization of

inventory stepped up to fair value.

Gross profit as a percentage of net sales increased to 63.9% in

2024 from 63.7% in 2023 due to higher sales pricing and

favorable volume offset by higher manufacturing and supply

chain costs primarily due to inflationary pressures impacting fixed

and variable manufacturing costs as well as higher amortization

of inventory stepped up to fair value.

While segment mix was not a significant driver of the change in

gross profit as a percent of net sales between 2025, 2024 and

2023, we generally expect segment mix to have an unfavorable

impact for the foreseeable future as we anticipate more rapid

sales growth in our lower gross margin MedSurg and

Neurotechnology segment than our Orthopaedics segment.

**Research, Development and Engineering Expenses**

Research, development and engineering expenses as a

percentage of net sales in 2025 of 6.5% remained flat with 2024.

Research, development and engineering expenses as a

percentage of net sales in 2024decreased to 6.5% from 6.8% in

2023 primarily due to lower spend on medical device regulations

in the European Union.

**Selling, General and Administrative Expenses**

Selling, general and administrative expenses as a percentage of

net sales in 2025increased to 34.4% from 34.0% in 2024

primarily due to higher acquisition-related costs and continued

investments to support our growth. A charge of $139 for share-

based awards for Inari employees that vested upon our

acquisition is included in 2025.

Selling, general and administrative expenses as a percentage of

net sales in 2024decreased to 34.0% from 34.7% in 2023

primarily due to continued spend discipline and lower charges for

structural optimization and certain legal matters partially offset by

higher acquisition-related costs.

**Amortization of Intangible Assets**

Amortization of intangible assets was $732, $623 and $635 in

2025, 2024 and 2023. These amounts include amortization

related to intangible assets acquired in 2025 from Inari, 2024

from various acquisitions and 2023 from Cerus Endovascular

Limited (Cerus). Refer to Notes 6 and 8 to our Consolidated

Financial Statements for further information.

**Goodwill and Other Impairments**

Goodwill and other impairments of $170, $977 and $36 were

recorded in 2025, 2024 and 2023.

In 2024 we recorded goodwill impairment charges of $456 related

to our Spine business and recognized an estimated loss of $362

as a result of classifying certain assets in our Spinal Implants

business as held for sale. Refer to Notes 8 and 16 to our

Consolidated Financial Statements for further information.

In 2025, 2024 and 2023 we recorded other impairments of $109,

$159 and $36. Refer to Note 15 to our Consolidated Financial

Statements for further information.

**Operating Income**

Operating income was $4,889, $3,689 and $3,888 in 2025, 2024

and 2023. Operating income increased as a percentage of sales

to 19.5% in 2025 from 16.3% in 2024 and increased from 19.0%

in 2023. Refer to the comments above for discussion of the

primary drivers of the change.

MedSurg and Neurotechnology operating income as a

percentage of net sales increased to 29.9% in 2025 from 29.6%

in 2024. MedSurg and Neurotechnology operating income as a

percentage of net sales increased to 29.6% in 2024 from 28.5%

in 2023. Orthopaedics operating income as a percentage of net

sales increased to 29.8% in 2025 from 28.5% in 2024.

Orthopaedics operating income as a percentage of net sales

increased to 28.5% in 2024 from 27.2% in 2023. The key

components of the change were:

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **18** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

---

| | | |
|:---|:---|:---|
|  | **Operating Income**<br>**Percent Net Sales** | **Operating Income**<br>**Percent Net Sales** |
|  | **MedSurg and** <br>**Neurotechnology**<br>| **Orthopaedics** |
| **2023** | **28.5%** | **27.2%** |
| Sales pricing | 70 bps  | 0 bps |
| Volume | 40 bps  | 70 bps |
| Manufacturing and supply chain costs | (40) bps  | (20) bps |
| Research, development and <br>engineering expenses<br>| 0 bps  | 10 bps |
| Selling, general and administrative <br>expenses<br>| 40 bps  | 70 bps |
| **2024** | **29.6%** | **28.5%** |
| Sales pricing | 30 bps  | 0 bps |
| Volume | 90 bps  | 30 bps |
| Manufacturing and supply chain costs | 80 bps  | (90) bps |
| Research, development and <br>engineering expenses<br>| (30) bps  | 50 bps |
| Selling, general and administrative <br>expenses<br>| (140) bps  | 140 bps |
| **2025** | **29.9%** | **29.8%** |

---

The increase in MedSurg and Neurotechnology operating income

as a percentage of net sales in 2025 from 2024 was primarily

driven by higher unit volumes and prices, and lower

manufacturing and supply chain costs partially offset by higher

selling, general and administrative expenses due to the

acquisition of Inari.

The increase in MedSurg and Neurotechnology operating income

as a percentage of net sales in 2024 from 2023 was primarily

driven by higher unit volumes, higher prices and a decrease in

selling, general and administrative expenses as a percentage of

sales partially offset by higher manufacturing and supply chain

costs.

The increase in Orthopaedics operating income as a percentage

of net sales for 2025 from 2024 was primarily by driven lower

selling, general and administrative expenses and higher unit

volumes partially offset by higher manufacturing and supply chain

costs.

The increase in Orthopaedics operating income as a percentage

of net sales for 2024 from 2023 was primarily driven by higher

sales volumes and a decrease in selling, general and

administrative expenses as a percentage of sales partially offset

by higher manufacturing and supply chain costs.

**Interest Expense**

Interest expense was $607, $409 and $363 in 2025, 2024 and

2023. The increase in 2025 from 2024 was due to increased

interest expense from our 2025 debt issuances. The increase in

2024 from 2023was primarily due to the impact of additional

interest expense from our 2024 debt issuances.

**Other Income**

Other income was $232, $212 and $148 in 2025, 2024 and 2023.

The increase in 2025 from 2024 was primarily due to higher

interest income in 2025. The increase in 2024 from 2023 was

primarily due to higher interest income.

**Income Taxes**

Our effective tax rate was 28.1%, 14.3% and 13.8% for 2025,

2024 and 2023. The effective income tax rate for 2025 increased

from 2024 due to the 2025 tax effect of transfers of intellectual

property between tax jurisdictions and the 2024 tax effect of the

sale of the Spinal Implants business. The effective income tax

rate for 2024 increased from 2023 due to the 2023 tax effect of

transfers of intellectual property between tax jurisdictions offset

by the 2024 tax effect of the sale of the Spinal Implants business.

Our future results of operations could be affected by changes in

the effective tax rate as a result of changes in tax laws,

regulations and judicial rulings. We are continuing to evaluate the

impact of tax reform in the countries in which we operate as new

guidance is published and new regulations are adopted. In

addition, further changes in the tax laws could arise, including as

a result of the base erosion and profit shifting project undertaken

by the Organisation for Economic Cooperation and Development

(OECD). The OECD, which represents a coalition of member

countries, has put forth two proposed frameworks that revise the

existing profit allocation and nexus rules (Pillar 1) and ensure a

minimal level of taxation (Pillar 2), respectively, and several

countries enacted tax legislation based on these frameworks. In

January 2026, the OECD released Administrative Guidance

containing the SbS System and introduced two new Pillar 2 safe

harbors for multinationals headquartered in jurisdictions including

the United States with eligible tax systems. The safe harbors

must now be legislated domestically by each country with

enacted Pillar 2 legislation impacted by the new OECD

Administrative Guidance. These tax law changes and any

additional contemplated tax law changes, could impact tax

expense in future periods.

**Net Earnings**

Net earnings for 2025 increased to $3,246 or $8.40 per diluted

share from $2,993 or $7.76 per diluted share in 2024 and $3,165

or $8.25 per diluted share in 2023. Refer to the comments above

for discussion of the primary drivers of the change.

**Non-GAAP Financial Measures**

We supplement the reporting of our financial information

determined under accounting principles generally accepted in the

United States (GAAP) with certain non-GAAP financial measures,

including percentage sales growth in constant currency;

percentage organic sales growth; adjusted gross profit; adjusted

selling, general and administrative expenses; adjusted research,

development and engineering expenses; adjusted operating

income; adjusted other income (expense), net; adjusted income

taxes; adjusted effective income tax rate; adjusted net earnings;

and adjusted net earnings per diluted share (Diluted EPS). We

believe these non-GAAP financial measures provide meaningful

information to assist investors and shareholders in understanding

our financial results and assessing our prospects for future

performance. Management believes percentage sales growth in

constant currency and the other adjusted measures described

above are important indicators of our operations because they

exclude items that may not be indicative of or are unrelated to our

core operating results and provide a baseline for analyzing trends

in our underlying businesses. Management uses these non-

GAAP financial measures for reviewing the operating results of

reportable business segments and analyzing potential future

business trends in connection with our budget process and bases

certain management incentive compensation on these non-GAAP

financial measures. To measure percentage sales growth in

constant currency, we remove the impact of changes in foreign

currency exchange rates that affect the comparability and trend

of sales. Percentage sales growth in constant currency is

calculated by translating current and prior year results at the

same foreign currency exchange rate. To measure percentage

organic sales growth, we remove the impact of changes in

foreign currency exchange rates, acquisitions and divestitures,

which affect the comparability and trend of sales. Percentage

organic sales growth is calculated by translating current year and

prior year results at the same foreign currency exchange rates

excluding the impact of acquisitions and divestitures. To measure

earnings performance on a consistent and comparable basis, we

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **19** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

exclude certain items that affect the comparability of operating

results and the trend of earnings. The income tax effect of each

adjustment was determined based on the tax effect of the

jurisdiction in which the related pre-tax adjustment was recorded.

These adjustments are irregular in timing and may not be

indicative of our past and future performance. The following are

examples of the types of adjustments that may be included in a

period:

1.*Acquisition and integration-related costs*. Costs related to

integrating recently acquired businesses (e.g., costs

associated with the termination of sales relationships,

employee retention and workforce reductions, manufacturing

integration costs and other integration-related activities),

changes in the fair value of contingent consideration,

amortization of inventory stepped-up to fair value, specific

costs (e.g., deal costs and costs associated with legal entity

rationalization) related to the consummation of the

acquisition process and legal entity rationalization and

acquisition-related tax items.

2.*Amortization of purchased intangible assets*. Periodic

amortization expense related to purchased intangible assets.

3.*Structural optimization and other special charges.* Costs

associated with employee retention and workforce

reductions, the closure or transfer of manufacturing and

other facilities (e.g., site closure costs, contract termination

costs and redundant employee costs during the work

transfers), product line exits (primarily inventory, long-lived

asset and specifically-identified intangible asset write-offs),

certain long-lived and intangible asset write-offs and

impairments and other charges.

4.*Medical device regulations.* Costs specific to updating our

quality system, product labeling, asset write-offs and product

remanufacturing to comply with the new medical device

reporting regulations and other requirements of the

European Union.

5.*Recall-related matters*. Changes in our best estimate of the

probable loss, or the minimum of the range of probable

losses when a best estimate within a range is not known, to

resolve the Rejuvenate, LFIT V40, Wright legacy hip

products and other product recalls.

6.*Regulatory and legal matters*. Changes in our best estimate

of the probable loss, or the minimum of the range of

probable losses when a best estimate within a range is not

known, to resolve certain regulatory or other legal matters

and the amount of favorable awards from settlements.

7.*Tax matters*. Impact of accounting for certain significant and

discrete tax items.

Because non-GAAP financial measures are not standardized, it

may not be possible to compare these financial measures with

other companies' non-GAAP financial measures having the same

or similar names. These adjusted financial measures should not

be considered in isolation or as a substitute for reported sales

growth, gross profit, selling, general and administrative expenses,

research, development and engineering expenses, operating

income, other income (expense), net, income taxes, effective

income tax rate, net earnings and net earnings per diluted share,

the most directly comparable GAAP financial measures. These

non-GAAP financial measures are an additional way of viewing

aspects of our operations when viewed with our GAAP results

and the reconciliations to corresponding GAAP financial

measures at the end of the discussion of Consolidated Results of

Operations below. We strongly encourage investors and

shareholders to review our financial statements and publicly-filed

reports in their entirety and not to rely on any single financial

measure.

The weighted-average diluted shares outstanding used in the

calculation of adjusted net earnings per diluted share are the

same as those used in the calculation of reported net earnings

per diluted share for the respective period.

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **20** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

**Reconciliation of the Most Directly Comparable GAAP Financial Measure to Non-GAAP Financial Measure**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **2025** | **Gross** <br>**Profit**<br>| **Selling,** <br>**General &** <br>**Administrative** <br>**Expenses**<br>| **Research,** <br>**Development &** <br>**Engineering** <br>**Expenses**<br>| **Operating** <br>**Income**<br>| **Other** <br>**Income** <br>**(Expense),** <br>**Net**<br>| **Income** <br>**Taxes**<br>| **Net** <br>**Earnings**<br>| **Effective**<br>**Tax Rate**<br>| **Diluted** <br>**EPS**<br>|
| **Reported** | **$16065** | **$8651** | **$1623** | **$4889** | **$(375)** | **$1268** | **$3246** | **28.1%** | **$8.40** |
| Acquisition and integration-related costs: |  |  |  |  |  |  |  |  |  |
| Inventory stepped-up to fair value | 173 |  |  | 173 |  | 42 | 131 | 0.3 | 0.34 |
| Other acquisition and integration-related (a) | 24 | (296) | (15) | 335 |  | 36 | 299 | (0.3) | 0.78 |
| Amortization of purchased intangible assets |  |  |  | 732 |  | 151 | 581 | 0.9 | 1.49 |
| Structural optimization and other special charges (b) | 74 | (113) | (4) | 191 | (27) | 24 | 140 |  | 0.37 |
| Goodwill and other impairments (c) |  |  |  | 170 |  | 50 | 120 | 0.5 | 0.31 |
| Medical device regulations (d) | 1 |  | (37) | 38 |  | 8 | 30 | 0.1 | 0.08 |
| Recall-related matters (e) | 54 | (4) |  | 58 |  | 10 | 48 |  | 0.12 |
| Regulatory and legal matters (f) |  | (17) |  | 17 |  | 5 | 12 |  | 0.03 |
| Tax matters (g) |  |  |  |  |  | (660) | 660 | (14.5) | 1.71 |
| **Adjusted** | **$16391** | **$8221** | **$1567** | **$6603** | **$(402)** | **$934** | **$5267** | **15.1%** | **$13.63** |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **2024** | **Gross** <br>**Profit**<br>| **Selling,** <br>**General &** <br>**Administrative** <br>**Expenses**<br>| **Research,** <br>**Development &** <br>**Engineering** <br>**Expenses**<br>| **Operating** <br>**Income**<br>| **Other** <br>**Income** <br>**(Expense),** <br>**Net**<br>| **Income** <br>**Taxes**<br>| **Net** <br>**Earnings**<br>| **Effective**<br>**Tax Rate**<br>| **Diluted** <br>**EPS**<br>|
| **Reported** | **$14440** | **$7685** | **$1466** | **$3689** | **$(197)** | **$499** | **$2993** | **14.3%** | **$7.76** |
| Acquisition and integration-related costs: |  |  |  |  |  |  |  |  |  |
| Inventory stepped-up to fair value | 46 |  |  | 46 |  | 12 | 34 | 0.2 | 0.09 |
| Other acquisition and integration-related (a) |  | (107) | (1) | 108 |  | 23 | 85 | 0.2 | 0.22 |
| Amortization of purchased intangible assets |  |  |  | 623 |  | 128 | 495 | 1.0 | 1.28 |
| Structural optimization and other special charges (b) | 59 | (77) | (2) | 138 | 1 | 29 | 110 | 0.3 | 0.29 |
| Goodwill and other impairments (c) |  |  |  | 977 |  | 125 | 852 | (0.6) | 2.21 |
| Medical device regulations (d) | 9 |  | (49) | 58 |  | 14 | 44 | 0.1 | 0.11 |
| Recall-related matters (e) | 11 | (29) |  | 40 |  | 10 | 30 | 0.1 | 0.08 |
| Regulatory and legal matters (f) |  | (36) |  | 36 |  | 7 | 29 | 0.1 | 0.08 |
| Tax matters (g) |  |  |  |  |  | (28) | 28 | (0.9) | 0.07 |
| **Adjusted** | **$14565** | **$7436** | **$1414** | **$5715** | **$(196)** | **$819** | **$4700** | **14.8%** | **$12.19** |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **2023** | **Gross** <br>**Profit**<br>| **Selling,** <br>**General &** <br>**Administrative** <br>**Expenses**<br>| **Research,** <br>**Development &** <br>**Engineering** <br>**Expenses**<br>| **Operating** <br>**Income**<br>| **Other** <br>**Income** <br>**(Expense),** <br>**Net**<br>| **Income** <br>**Taxes**<br>| **Net** <br>**Earnings**<br>| **Effective**<br>**Tax Rate**<br>| **Diluted** <br>**EPS**<br>|
| **Reported** | **$13058** | **$7111** | **$1388** | **$3888** | **$(215)** | **$508** | **$3165** | **13.8%** | **$8.25** |
| Acquisition and integration-related costs: |  |  |  |  |  |  |  |  |  |
| Inventory stepped-up to fair value |  |  |  |  |  |  |  |  |  |
| Other acquisition and integration-related (a) |  | (20) |  | 20 |  | (25) | 45 | (0.8) | 0.12 |
| Amortization of purchased intangible assets |  |  |  | 635 |  | 132 | 503 | 1.2 | 1.31 |
| Structural optimization and other special charges (b) | 39 | (130) | (1) | 170 |  | 38 | 132 | 0.4 | 0.34 |
| Goodwill and other impairments (c) |  |  |  | 36 |  | 9 | 27 | 0.1 | 0.08 |
| Medical device regulations (d) | 2 |  | (94) | 96 |  | 22 | 74 | 0.2 | 0.19 |
| Recall-related matters (e) |  | (18) |  | 18 |  | 4 | 14 |  | 0.04 |
| Regulatory and legal matters (f) |  | (92) |  | 92 |  | 29 | 63 | 0.4 | 0.16 |
| Tax matters (g) |  |  |  |  | (8) | (51) | 43 | (1.2) | 0.11 |
| **Adjusted** | **$13099** | **$6851** | **$1293** | **$4955** | **$(223)** | **$666** | **$4066** | **14.1%** | **$10.60** |

---

(a) Charges represent certain acquisition and integration-related costs associated with acquisitions, including:

---

| | | | |
|:---|:---|:---|:---|
|  | **2025** | **2024** | **2023** |
| Termination of sales relationships | $— | $4 | $5 |
| Employee retention and workforce reductions | 60 | 22 | 6 |
| Changes in the fair value of contingent consideration | 21 | 8 | (1) |
| Manufacturing integration costs | 19 | 3 | 2 |
| Stock compensation payments upon a change in control | 140 | 22 |  |
| Other integration-related activities | 95 | 49 | 8 |
| **Adjustments to Operating Income**  | **$335** | **$108** | **$20** |
| Charges for acquisition-related tax provisions |  |  |  |
| Other income taxes related to acquisition and integration-related costs | 36 | 23 | (25) |
| **Adjustments to Income Taxes** | **$36** | **$23** | **$(25)** |
| **Adjustments to Net Earnings** | **$299** | **$85** | **$45** |

---

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **21** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

(b) Structural optimization and other special charges represent the costs associated with:

---

| | | | |
|:---|:---|:---|:---|
|  | **2025** | **2024** | **2023** |
| Employee retention and workforce reductions | $55 | $23 | $69 |
| Closure/transfer of manufacturing and other facilities | 31 | 31 | 50 |
| Product line exits | 13 | 37 | 22 |
| Termination of sales relationships | 7 | 8 |  |
| Other charges | 85 | 39 | 29 |
| **Adjustments to Operating Income**  | **$191** | **$138** | **$170** |
| **Adjustments to Other Income (Expense), Net** | **$(27)** | **$1** | **$—** |
| **Adjustments to Income Taxes** | **$24** | **$29** | **$38** |
| **Adjustments to Net Earnings** | **$140** | **$110** | **$132** |

---

(c) Goodwill and other impairments represent the costs associated with:

---

| | | | |
|:---|:---|:---|:---|
|  | **2025** | **2024** | **2023** |
| Goodwill impairments | $— | $456 | $— |
| Certain long-lived and intangible asset write-offs and impairments | 114 | 466 | 26 |
| Product line exits (e.g., long-lived asset and specifically-identified intangible asset write-offs) | 56 | 55 | 10 |
| **Adjustments to Operating Income**  | **$170** | **$977** | **$36** |
| **Adjustments to Income Taxes** | **$50** | **$125** | **$9** |
| **Adjustments to Net Earnings** | **$120** | **$852** | **$27** |

---

(d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device

reporting regulations and other requirements of the new medical device regulations in the European Union.

(e) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to

resolve certain recall-related matters.

(f) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to

resolve certain regulatory or other legal matters and the amount of favorable awards from settlements.

(g) Benefits / (charges) represent the accounting impact of certain significant and discrete tax items, including:

---

| | | | |
|:---|:---|:---|:---|
|  | **2025** | **2024** | **2023** |
| Adjustments related to the transfer of certain intellectual properties between tax jurisdictions | $(718) | $(185) | $(89) |
| Certain tax audit settlements |  | (1) | 24 |
| Deferred tax benefit on outside basis related to the anticipated sale of the Spinal Implants business |  | 170 |  |
| Other tax matters | 58 | (12) | 14 |
| **Adjustments to Income Taxes** | **$(660)** | **$(28)** | **$(51)** |
| Benefits for certain tax audit settlements |  |  | (9) |
| Other tax related adjustments |  |  | 1 |
| **Adjustments to Other Income (Expense), Net** | **$—** | **$—** | **$(8)** |
| **Adjustments to Net Earnings** | **$660** | **$28** | **$43** |

---

**FINANCIAL CONDITION AND LIQUIDITY**

---

| | | | |
|:---|:---|:---|:---|
| **Net cash provided by (used in):** | **2025** | **2024** | **2023** |
| Operating activities | $5044 | $4242 | $3711 |
| Investing activities | (4866) | (3000) | (962) |
| Financing activities | 113 | (525) | (1594) |
| Effect of exchange rate changes | 68 | (36) | (28) |
| **Change in cash and cash equivalents** | **$359** | **$681** | **$1127** |

---

We believe our financial condition continues to be of high quality,

as evidenced by our ability to generate substantial cash from

operations and to readily access capital markets at competitive

rates despite the current macroeconomic environment. Operating

cash flow provides the primary source of cash to fund operating

needs and capital expenditures. Excess operating cash is used

first to fund acquisitions to complement our portfolio of

businesses. Other discretionary uses include dividends and

potentially share repurchases. We supplement operating cash

flow with debt to fund our activities as necessary. Our overall

cash position reflects our business results and a global cash

management strategy that takes into account liquidity

management, economic factors and tax considerations.

**Operating Activities**

Cash provided by operating activities was $5,044, $4,242 and

$3,711 in 2025, 2024 and 2023. The increase in 2025 was

primarily due to higher cash earnings and working capital

improvements. The increase in 2024 from 2023 was primarily due

to higher cash earnings partially offset by changes in working

capital.

**Investing Activities**

Cash used in investing activities was $4,866, $3,000 and $962 in

2025, 2024 and 2023. Cash used in 2025 included cash paid for

the acquisition of Inari, purchases of property, plant and

equipment, partially offset by proceeds from the sale of short

term investments and our Spinal Implants business. Cash used in

2024 included cash paid for various acquisitions and purchases

of short-term investments partially offset by proceeds from other

investing activities.

**Financing Activities**

Cash provided by financing activities in 2025 was $113 and used

in financing activities in 2024 and 2023 was $525 and $1,594.

Cash provided by 2025 was primarily driven by dividend

payments of $1,284 and repayments of $1,400 to pay off

maturing senior unsecured notes. These repayments were offset

by net proceeds of $2,979 from the issuance of senior unsecured

notes as described in Note 10 to our Consolidated Financial

statements.Cash used in 2024 was primarily driven by dividend

payments of $1,219 and repayments of $2,039 to pay off

maturing senior unsecured notes. These repayments were offset

by net proceeds of$3,011 from issuance of senior unsecured

notes.

We maintain debt levels that we consider appropriate after

evaluating a number of factors including cash requirements for

ongoing operations, investment and financing plans (including

acquisitions and share repurchase activities) and overall cost of

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **22** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

capital. Refer to Note 10 to our Consolidated Financial

Statements for further information.

---

| | | | |
|:---|:---|:---|:---|
|  | **2025** | **2024** | **2023** |
| Dividends paid per common share | $3.36 | $3.20 | $3.00 |
| Total dividends paid to common shareholders | $1284 | $1219 | $1139 |

---

**Liquidity**

Cash, cash equivalents and marketable securities were $4,100

and $3,743, and our current assets exceeded current liabilities by

$6,961 and $7,231 on December 31, 2025 and 2024. We

anticipate being able to support our short-term liquidity and

operating needs from a variety of sources including cash from

operations, commercial paper and existing credit lines. We also

have a revolving credit agreement maturing in February 2030

with an aggregate principal amount of $3,000.

We raised funds in the capital markets in the past and may

continue to do so from time-to-time. We continue to have strong

investment-grade short-term and long-term debt ratings that we

believe should enable us to refinance our debt as needed.

Our cash, cash equivalents and marketable securities held in

locations outside the United States was approximately 20%on

December 31, 2025 and 2024.

**Guarantees and Other Off-Balance Sheet Arrangements**

We do not have guarantees or other off-balance sheet financing

arrangements, including variable interest entities, of a magnitude

that we believe could have a material impact on our financial

condition or liquidity.

**CONTRACTUAL OBLIGATIONS AND FORWARD-LOOKING**

**CASH REQUIREMENTS**

In 2025 we recorded charges for various legal matters as further

described in Note 7 to our Consolidated Financial Statements.

Recorded reserves represent the best estimate of the probable

loss, or the minimum of the range of probable losses when a best

estimate within the range is not known. The final outcome of

these matters is dependent on many variables that are difficult to

predict. The ultimate cost to entirely resolve these matters may

be materially different from the amount of the current estimates

and could have a material adverse effect on our financial

position, results of operations and cash flows. We are not able to

reasonably estimate the future periods in which payments will be

made.

As further described in Note 11 to our Consolidated Financial

Statements, on December 31, 2025 we had a reserve for

uncertain income tax positions of $403. Due to uncertainties

regarding the ultimate resolution of income tax audits, we are not

able to reasonably estimate the future periods in which any

income tax payments to settle these uncertain income tax

positions will be made.

As further described in Note 12 to our Consolidated Financial

Statements, on December 31, 2025 our defined benefit pension

plans were underfunded by $269, of which approximately $268

related to plans outside the United States. Due to the rules

affecting tax-deductible contributions in the jurisdictions in which

the plans are offered and the impact of future plan asset

performance, changes in interest rates and potential changes in

legislation in the United States and other foreign jurisdictions, we

are not able to reasonably estimate the amounts that may be

required to fund defined benefit pension plans.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| ***Contractual Obligations*** | **Total** | **2026** | **2027-**<br>**2028**<br>| **2029-**<br>**2030**<br>| **After** <br>**2030**<br>|
| Debt repayments | $15973 | $1000 | $3988 | $4256 | $6729 |
| Interest payments | 4287 | 536 | 957 | 670 | 2124 |
| Minimum lease payments | 524 | 164 | 212 | 93 | 55 |
| Other | 85 | 6 | 28 | 27 | 24 |
| **Total** | **$20869** | **$1706** | **$5185** | **$5046** | **$8932** |

---

**CRITICAL ACCOUNTING POLICIES AND ESTIMATES**

In preparing our financial statements in accordance with

generally accepted accounting principles, there are certain

accounting policies, which may require substantial judgment or

estimation in their application. We believe these accounting

policies and the others set forth in Note 1 to our Consolidated

Financial Statements are critical to understanding our results of

operations and financial condition.Actual results could differ from

our estimates and assumptions, and any such differences could

be material to our results of operations and financial condition.

**Income Taxes**

Our annual tax rate is determined based on our income, statutory

tax rates and the tax impacts of items treated differently for tax

purposes than for financial reporting purposes. Tax law requires

certain items be included in the tax return at different times than

the items are reflected in the financial statements. Some of these

differences are permanent, such as expenses that are not

deductible in our tax return, and some differences are temporary

and reverse over time, such as depreciation expense. These

temporary differences create deferred tax assets and liabilities.

Deferred tax assets generally represent the tax effect of items

that can be used as a tax deduction or credit in future years for

which we have already recorded the tax benefit in our income

statement. Deferred tax liabilities generally represent tax expense

recognized in our financial statements for which payment was

deferred, the tax effect of expenditures for which a deduction was

taken in our tax return but has not yet been recognized in our

financial statements or assets recorded at fair value in business

combinations for which there was no corresponding tax basis

adjustment.

Inherent in determining our annual tax rate are judgments

regarding business plans, tax planning opportunities and

expectations about future outcomes. Realization of certain

deferred tax assets is dependent upon generating sufficient

taxable income in the appropriate jurisdiction prior to the

expiration of the carryforward periods. Although realization is not

assured, management believes it is more likely than not that our

deferred tax assets, net of valuation allowances, will be realized.

We operate in multiple jurisdictions with complex tax policy and

regulatory environments. In certain of these jurisdictions, we may

take tax positions that management believes are supportable but

are potentially subject to successful challenge by the applicable

taxing authority. These differences of interpretation with the

respective governmental taxing authorities can be impacted by

the local economic and fiscal environment. We evaluate our tax

positions and establish liabilities in accordance with the

applicable accounting guidance on uncertainty in income taxes.

We review these tax uncertainties in light of changing facts and

circumstances, such as the progress of tax audits, and adjust

them accordingly. We have a number of audits in process in

various jurisdictions. Although the resolution of these tax

positions is uncertain, based on currently available information,

we believe that it is more likely than not that the ultimate

outcomes will not have a material adverse effect on our financial

position, results of operations or cash flows.

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **23** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

Due to the number of estimates and assumptions inherent in

calculating the various components of our tax provision, certain

changes or future events, such as changes in tax legislation,

geographic mix of earnings, completion of tax audits or earnings

repatriation plans, could have an impact on those estimates and

our effective tax rate.

We received a final audit report and assessments from the

German Federal Central Tax Office (FCTO) related to the years

2010 through 2017 of $754 and expect to receive additional

assessments of $11 based on the final audit report. We intend to

defend our filing positions through the FCTO independent

appeals process and/or litigation as necessary. If the resolution of

this matter results in additional German income taxes, we expect

to pursue a claim for associated foreign tax credits. Our

unrecognized tax benefits associated with this matter remain

unchanged from 2024. Refer to Note 11 to our Consolidated

Financial Statements for further discussion.

**Acquisitions, Goodwill and Intangibles, and Long-Lived**

**Assets**

Our financial statements include the operations of an acquired

business starting from the completion of the acquisition. In

addition, the assets acquired and liabilities assumed are recorded

on the date of acquisition at their respective estimated fair values,

with any excess of the purchase price over the estimated fair

values of the net assets acquired recorded as goodwill.

Significant judgment is required in estimating the fair value of

intangible assets and in assigning their respective useful lives.

Accordingly, we typically obtain the assistance of third-party

valuation specialists for significant items. The fair value estimates

are based on available historical information and on future

expectations and assumptions deemed reasonable by

management but are inherently uncertain. We typically use an

income method to estimate the fair value of intangible assets,

which is based on forecasts of the expected future cash flows

attributable to the respective assets. Significant estimates and

assumptions inherent in the valuations reflect a consideration of

other marketplace participants and include the amount and timing

of future cash flows (including expected growth rates and

profitability), the underlying product or technology life cycles, the

economic barriers to entry and the discount rate applied to the

cash flows. Unanticipated market or macroeconomic events and

circumstances may occur that could affect the accuracy or

validity of the estimates and assumptions.

Determining the useful life of an intangible asset also requires

judgment. With the exception of certain trade names, the majority

of our acquired intangible assets (e.g., certain trademarks or

brands, customer and distributor relationships, patents and

technologies) are expected to have determinable useful lives.

Our assessment as to the useful lives of these intangible assets

is based on a number of factors including competitive

environment, market share, trademark, brand history, underlying

product life cycles, operating plans and the macroeconomic

environment of the countries in which the trademarked or

branded products are sold. Our estimates of the useful lives of

determinable-lived intangibles are primarily based on these same

factors. Determinable-lived intangible assets are amortized to

expense over their estimated useful life.

In some of our acquisitions, we acquire in-process research and

development (IPRD) intangible assets. For acquisitions

accounted for as business combinations, IPRD is considered to

be an indefinite-lived intangible asset until the research is

completed (then it becomes a determinable-lived intangible

asset) or determined to have no future use (then it is impaired).

For asset acquisitions, IPRD is expensed immediately unless

there is an alternative future use.

Indefinite-lived intangible assets and goodwill are not amortized

but are tested annually for impairment or whenever events or

circumstances indicate such assets may be impaired. Our annual

impairment testing date is October 31. When it is unlikely that an

indefinite-lived intangible asset or goodwill of a reporting unit is

impaired, we perform a qualitative assessment. For goodwill, that

qualitative assessment may be periodically supplemented with a

corroborative quantitative analysis.

When necessary, we perform a quantitative impairment test and

determine the fair value of the indefinite-lived intangible asset or

reporting unit using an income approach. For the quantitative

impairment test of goodwill, when appropriate, we corroborate

our concluded value under the income approach using a market

approach that utilizes trading multiples derived from a peer set of

similar companies. The income approach calculates the present

value of estimated future cash flows and requires certain

assumptions and estimates be made regarding market conditions

and our future profitability. Considerable management judgment

is necessary to evaluate the impact of operating and

macroeconomic changes and to estimate future cash flows used

to measure fair value. Assumptions used in our impairment

evaluations, such as forecasted growth rates and cost of capital,

are consistent with internal business plans. We believe such

assumptions and estimates are also comparable to those that

would be used by other marketplace participants.

We review our other long-lived assets for indicators of impairment

whenever events or changes in circumstances indicate that the

carrying amount may not be recoverable. The evaluation is

performed at the lowest level of identifiable cash flows, which is

at the individual asset level or the asset group level. The

undiscounted cash flows expected to be generated by the related

assets are estimated over their useful life based on updated

projections. If the evaluation indicates that the carrying amount of

the assets may not be recoverable, any potential impairment is

measured based upon the fair value of the related assets or

asset group as determined by an appropriate market appraisal or

other valuation technique. Assets classified as held for sale, if

any, are recorded at the lower of carrying amount or fair value

less costs to sell.

In our annual impairment test of goodwill as of October 31, 2024

we performed a quantitative assessment of the Spine reporting

unit using a discounted cash flow analysis to estimate the fair

value. The carrying value of the Spine reporting unit exceeded its

fair value and a charge of $273 was recognized in goodwill and

other impairments in our Consolidated Statements of Earnings.

The impairment charge for the Spine reporting unit was driven by

a decrease in future product demand due to the competitive

environment and an increase in the Spine reporting unit's

weighted average cost of capital.

During the fourth quarter 2024 management committed to a plan

to sell certain assets associated with the Spinal Implants

business (disposal group) and such assets were classified as

held for sale beginning November 2024. We tested the net

carrying amounts of other assets, such as working capital

accounts, and determined that there was no impairment as the

fair values of these assets approximated their carrying values.

Goodwill was allocated to the disposal group and the retained

portion of the Spine reporting unit based on the relative fair

values. Goodwill allocated to the disposal group was tested for

impairment which resulted in an impairment charge of $183. As of

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **24** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

December 31, 2024, there was no goodwill remaining attributable

to the Spinal Implants disposal group.

Finally we compared the carrying amount of the disposal group to

the fair value less cost to sell. As a result, we recognized an

estimated loss of $362 to record the disposal group at its fair

value less cost to sell in goodwill and other impairments in our

Consolidated Statements of Earnings.

In April 2025 we completed the sale of the disposal group to the

Viscogliosi Brothers, LLC as further discussed in Note 16. In the

first half of 2025 we recognized immaterial impairment charges to

record the disposal group at its fair value less cost to sell within

goodwill and other impairments in our Consolidated Statements

of Earnings. The fair value of the disposal group and

consideration received was measured using a discounted cash

flow analysis based upon the selling price and unobservable

inputs, such as market conditions and the rate used to discount

the estimated future cash flows to their present value based on

factors including the disposal group's cost of equity and market

yield rates, which are Level 3 inputs. Consideration could

increase by up to $57 or decrease by up to $245 based on the

amount received.

With the acquisition of Inari in February 2025 discussed in Note 6

to our Consolidated Financial Statements, we established a new

Peripheral Vascular reporting unit consisting of the acquired Inari

business. Given the proximity of the impairment testing date to

the date of acquisition, the fair value of this new reporting unit

was not expected to exceed its carrying value by a significant

amount. We performed a quantitative impairment test for our

Peripheral Vascular reporting unit at October 31, 2025 and

determined that its fair value exceeded its carrying amount by

12%. At October 31, 2025, goodwill attributable to this reporting

unit was $3,203. The fair value of this reporting unit was

determined using a discounted cash flow analysis, which is a

form of the income approach. Significant inputs to the analysis

included assumptions for future revenue growth, operating

margin and the rate used to discount the estimated future cash

flows to their present value, based on the reporting unit's

estimated weighted average cost of capital. We believe our

estimates are appropriate based upon current and future market

conditions and the best information available at the impairment

assessment date; however, future impairment charges could be

required if we do not achieve our cash flow, revenue and

profitability projections or if there is an increase in the weighted

average cost of capital.

The assumptions used in the discounted cash flow analysis are

subject to inherent uncertainties and subjectivity. The use of

different assumptions, estimates or judgments with respect to the

estimation of future cash flows and the determination of the

discount rate used to reduce such estimated future cash flows to

their net present value could materially affect the determination of

any impairment charges. Hypothetical changes in our estimates

of the discount rate, long-term revenue growth and long-term

operating margin would result in impairment charges as follows:

---

| | | |
|:---|:---|:---|
| **Change in selected assumption**  | **Percentage** <br>**decline in fair** <br>**value**<br>| **Impairment** <br>**charge**<br>|
| 100 bps increase in discount rate | 14% | $198 |
| 100 bps decrease in long-term revenue growth | 8 |  |
| 100 bps decrease in long-term operating margin | 2 |  |

---

We did not identify any factors in 2025 or 2024 that would lead us

to believe that our other reporting units were at risk of a goodwill

impairment. Accordingly, we performed qualitative assessments

and concluded it was more likely than not that the fair values of

those reporting units exceeded their respective carrying amounts.

In 2025 our qualitative assessment was supplemented with a

corroborative quantitative analysis which indicated that the

implied fair values of our other reporting units exceed their

respective carrying amounts by at least 100%. Future changes in

the judgments, assumptions and estimates that are used in our

impairment testing for goodwill and indefinite-lived intangible

assets, including discount rates and cash flow projections, could

result in different estimates of fair value. A significant reduction in

estimated fair values could result in impairment charges that

could materially affect our results of operations.

**Legal and Other Contingencies**

We are involved in various ongoing proceedings, legal actions

and claims arising in the normal course of business, including

proceedings related to product, labor, tax, intellectual property

and other matters that are more fully described in Notes 7 and 11

to our Consolidated Financial Statements. The outcomes of these

matters will generally not be known for prolonged periods of time.

In certain of the legal proceedings, the claimants seek damages,

as well as other compensatory and equitable relief, that could

result in the payment of significant claims and settlements and/or

the imposition of injunctions or other equitable relief. For legal

matters for which management had sufficient information to

reasonably estimate our future obligations, a liability representing

management's best estimate of the probable loss, or the

minimum of the range of probable losses when a best estimate

within the range is not known, for the resolution of these legal

matters is recorded. The estimates are based on consultation

with legal counsel, previous settlement experience and

settlement strategies. If actual outcomes are less favorable than

those projected by management, additional expense may be

incurred, which could unfavorably affect future operating results.

We are currently self-insured for certain claims and expenses.

The ultimate cost to us with respect to product liability claims

could be materially different than the amount of the current

estimates and accruals and could have a material adverse effect

on our financial position, results of operations and cash flows.

**NEW ACCOUNTING PRONOUNCEMENTS**

Refer to Note 1 to our Consolidated Financial Statements for

further information.

---

| | |
|:---|:---|
| **ITEM 7A.** | **QUANTITATIVE AND QUALITATIVE** <br>**DISCLOSURES ABOUT MARKET RISK.**<br>|

---

We sell our products globally and, as a result, our operations and

financial results could be significantly affected by market risk

exposure from exchange rate risk. Our operating results are

primarily exposed to changes in exchange rates among the

United States Dollar, Australian Dollar, British Pound, Canadian

Dollar, Euro and Japanese Yen. We develop and manufacture

products in the United States, Canada, China, Costa Rica,

France, Germany, India, Ireland, Israel, Mexico, Poland,

Switzerland, Turkey and the United Kingdom and incur costs in

the applicable local currencies. This global deployment of

facilities serves to partially mitigate the impact of currency

exchange rate changes on our cost of sales. Refer to Notes 1, 4

and 5 to our Consolidated Financial Statements for information

regarding our use of derivative instruments to mitigate these

risks. A hypothetical 10% change in foreign currencies relative to

the United States Dollar would change the December 31, 2025

fair value of these instruments by approximately $449.

**25**<br>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

---

| | |
|:---|:---|
| **ITEM 8.** | **FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.** |

---

**Report of Independent Registered Public Accounting Firm**

To the Shareholders and the Board of Directors of Stryker Corporation

**Opinion on the Financial Statements**

We have audited the accompanying consolidated balance sheets of Stryker Corporation and subsidiaries (the Company) as of

December 31, 2025 and 2024, the related consolidated statements of earnings, comprehensive income, shareholders' equity and cash

flows for each of the three years in the period ended December 31, 2025, and the related notes and financial statement schedule listed

in the Index at Item 15(a) (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial

statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results

of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with U.S. generally

accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB),

the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control—

Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our

report dated February 11, 2026 expressed an unqualified opinion thereon.

**Basis for Opinion**

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the

Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be

independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations

of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit

to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to

error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence

regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used

and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe

that our audits provide a reasonable basis for our opinion.

**Critical Audit Matters**

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were

communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to

the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical

audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by

communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or

disclosures to which they relate.

---

| | |
|:---|:---|
|  | **Uncertain Tax Positions** |
| *Description* <br>*of the Matter*<br>| As described in Note 11 to the consolidated financial statements, the Company is involved in various income tax matters<br>for which the ultimate outcomes are uncertain. As of December 31, 2025, the Company had unrecognized tax benefits<br>of $403. The Company received a final audit report and assessments from the German Federal Central Tax Office<br>(FCTO) related to the years 2010 through 2017 of $754 and expect to receive additional assessments of $11 based on<br>the final audit report.<br>Auditing management's evaluation of the uncertain tax positions associated with the FCTO tax assessments was<br>especially challenging due to the level of subjectivity and significant judgment associated with the recognition and<br>measurement of the tax positions.<br>|
| *How We* <br>*Addressed* <br>*the Matter in* <br>*Our Audit*<br>| We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the<br>Company's accounting process for uncertain tax positions. For example, we tested controls over management's<br>identification of uncertain tax positions and its application of the recognition and measurement principles, including<br>management's review of developments related to existing uncertain tax positions.<br>Our audit procedures included, among others, evaluating the assumptions the Company used to assess its uncertain tax<br>positions and related unrecognized tax benefits. We evaluated evidence of management's assessment of the uncertain<br>tax positions related to certain German tax matters. Including inspection of technical memos, inspection of the FCTO tax<br>assessments, and written representations of management. We involved professionals with specialized skill and<br>knowledge to assist in our evaluation of the tax technical merits of the Company's assessments, the amount of the<br>potential benefits to be realized, and the application of relevant tax law. We also assessed the Company's disclosures of<br>uncertain tax positions included in Note 11 related to this tax matter.<br>|

---

**26**<br>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

---

| | |
|:---|:---|
|  | **Acquisitions** |
| *Description* <br>*of the Matter*<br>| As described in Note 6 to the consolidated financial statements, in 2025 the Company completed the acquisition of Inari<br>Medical, Inc. (Inari) for total consideration of $4,810, net of cash acquired. The acquisition was accounted for as a<br>business combination. Auditing the Company's fair value measurement of certain acquired developed technologies was<br>complex and required significant auditor judgment due to the significant estimation uncertainty in determining the fair<br>value of these intangible assets. The Company used an income approach to measure the developed technology<br>intangible assets acquired. The significant assumptions used to estimate the fair value of the intangible assets included<br>discount rates and certain assumptions that form the basis of the forecasted results, including revenue growth rates and<br>profit margins.<br>|
| *How We* <br>*Addressed* <br>*the Matter in* <br>*Our Audit*<br>| We obtained an understanding, evaluated the design and tested the operating effectiveness of the controls over the<br>identification and measurement of developed technologies. For example, we tested controls over the valuation of<br>intangibles, including the valuation models and underlying assumptions used to develop such estimates.<br>To test the fair value measurement of developed technologies, we performed audit procedures that included, among<br>others, evaluating the Company's use of the income approach and testing the significant assumptions used in the<br>model, as described above. We involved our valuation specialists in assisting with the evaluation of methodologies used<br>by the Company and significant assumptions included in the fair value measurements. For example, to evaluate the<br>revenue growth rates and projected profit margins, we compared the amounts to historical results of the Company's<br>business, as well as the acquired business' historical results, and current industry and market trends for those in which<br>the Company operates and performed sensitivity analyses on key assumptions. We also evaluated the adequacy of the<br>Company's disclosures included in Note 6 related to these acquisitions.<br>|

---

/s/&nbsp;&nbsp;&nbsp;&nbsp;Ernst & Young LLP

We have served as the Company's auditor since 1974.

Grand Rapids, Michigan

February 11, 2026

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **27** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

**Stryker Corporation and Subsidiaries**

**CONSOLIDATED STATEMENTS OF EARNINGS**

---

| | | | |
|:---|:---|:---|:---|
|  | **2025** | **2024** | **2023** |
| **Net sales** | **$25116** | **$22595** | **$20498** |
| Cost of sales | 9051 | 8155 | 7440 |
| **Gross profit** | **$16065** | **$14440** | **$13058** |
| Research, development and engineering expenses | 1623 | 1466 | 1388 |
| Selling, general and administrative expenses | 8651 | 7685 | 7111 |
| Amortization of intangible assets | 732 | 623 | 635 |
| Goodwill and other impairments | 170 | 977 | 36 |
| Total operating expenses | $11176 | $10751 | $9170 |
| **Operating income** | **$4889** | **$3689** | **$3888** |
| Interest expense | (607) | (409) | (363) |
| Other income | 232 | 212 | 148 |
| **Earnings before income taxes** | **$4514** | **$3492** | **$3673** |
| Income taxes | 1268 | 499 | 508 |
| **Net earnings** | **$3246** | **$2993** | **$3165** |
| **Net earnings per share of common stock:** |  |  |  |
| Basic | $8.49 | $7.86 | $8.34 |
| Diluted | $8.40 | $7.76 | $8.25 |
| **Weighted-average shares outstanding (in millions):** |  |  |  |
| Basic | 382.2 | 381.0 | 379.6 |
| Effect of dilutive employee stock compensation | 4.3 | 4.6 | 4.1 |
| **Diluted** | **386.5** | **385.6** | **383.7** |

---

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

---

| | | | |
|:---|:---|:---|:---|
|  | **2025** | **2024** | **2023** |
| **Net earnings** | **$3246** | **$2993** | **$3165** |
| **Other comprehensive income (loss), net of tax** |  |  |  |
| Marketable securities |  |  | 1 |
| Pension plans | 66 | 32 | (59) |
| Unrealized gains (losses) on designated hedges | 11 | (8) | (13) |
| Financial statement translation | (471) | 99 | (124) |
| **Total other comprehensive income (loss), net of tax** | **$(394)** | **$123** | **$(195)** |
| **Comprehensive income** | **$2852** | **$3116** | **$2970** |

---

*See accompanying notes to Consolidated Financial Statements.*

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **28** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

**Stryker Corporation and Subsidiaries**

**CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **2025** | **2024** |
| **Assets** |  |  |
| **Current assets** |  |  |
| Cash and cash equivalents | $4011 | $3652 |
| Short-term investments |  | 750 |
| Marketable securities | 89 | 91 |
| Accounts receivable, less allowance of $216 ($213 in 2024) | 4039 | 3987 |
| **Inventories:** |  |  |
| Materials and supplies | 1349 | 1147 |
| Work in process | 415 | 336 |
| Finished goods | 3546 | 3291 |
| **Total inventories** | **$5310** | **$4774** |
| Prepaid expenses and other current assets | 1306 | 1593 |
| **Total current assets** | **$14755** | **$14847** |
| **Property, plant and equipment:** |  |  |
| Land, buildings and improvements | 1793 | 1627 |
| Machinery and equipment | 5744 | 5056 |
| Total property, plant and equipment | 7537 | 6683 |
| Less allowance for depreciation | 3661 | 3235 |
| **Property, plant and equipment, net** | **$3876** | **$3448** |
| Goodwill | 19291 | 15855 |
| Other intangibles, net | 5681 | 4395 |
| Noncurrent deferred income tax assets | 1098 | 1742 |
| Other noncurrent assets | 3143 | 2684 |
| **Total assets** | **$47844** | **$42971** |
| **Liabilities and shareholders' equity** |  |  |
| **Current liabilities** |  |  |
| Accounts payable | $1799 | $1679 |
| Accrued compensation | 1595 | 1403 |
| Income taxes | 418 | 539 |
| Dividend payable | 337 | 320 |
| Accrued expenses and other liabilities | 2645 | 2266 |
| Current maturities of debt | 1000 | 1409 |
| **Total current liabilities** | **$7794** | **$7616** |
| Long-term debt, excluding current maturities | 14859 | 12188 |
| Income taxes | 402 | 349 |
| Other noncurrent liabilities | 2369 | 2184 |
| **Total liabilities** | **$25424** | **$22337** |
| **Shareholders' equity** |  |  |
| Common stock, $0.10 par value | 38 | 38 |
| Additional paid-in capital | 2597 | 2361 |
| Retained earnings | 20472 | 18528 |
| Accumulated other comprehensive loss | (687) | (293) |
| **Total shareholders' equity** | **$22420** | **$20634** |
| **Total liabilities & shareholders' equity** | **$47844** | **$42971** |

---

*See accompanying notes to Consolidated Financial Statements.*

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **29** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

**Stryker Corporation and Subsidiaries**

**CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** |
| **Common stock** |  |  |  |  |  |  |
| Beginning | 381.4 | $38 | 380.1 | $38 | 378.7 | $38 |
| Issuance of common stock under stock compensation <br>and benefit plans<br>| 1.1 |  | 1.3 |  | 1.4 |  |
| **Ending** | **382.5** | **$38** | **381.4** | **$38** | **380.1** | **$38** |
| **Additional paid-in capital** |  |  |  |  |  |  |
| Beginning |  | $2361 |  | $2200 |  | $2034 |
| Issuance of common stock under stock compensation <br>and benefit plans<br>|  | (7) |  | (68) |  | (39) |
| Share-based compensation |  | 243 |  | 229 |  | 205 |
| **Ending** |  | **$2597** |  | **$2361** |  | **$2200** |
| **Retained earnings** |  |  |  |  |  |  |
| Beginning |  | $18528 |  | $16771 |  | $14765 |
| Net earnings |  | 3246 |  | 2993 |  | 3165 |
| Cash dividends declared |  | (1302) |  | (1236) |  | (1159) |
| **Ending** |  | **$20472** |  | **$18528** |  | **$16771** |
| **Accumulated other comprehensive (loss) income** |  |  |  |  |  |  |
| Beginning |  | $(293) |  | $(416) |  | $(221) |
| Other comprehensive income (loss) |  | (394) |  | 123 |  | (195) |
| **Ending** |  | **$(687)** |  | **$(293)** |  | **$(416)** |
| **Total shareholders' equity** |  | **$22420** |  | **$20634** |  | **$18593** |

---

*See accompanying notes to Consolidated Financial Statements.*

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **30** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

**Stryker Corporation and Subsidiaries**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

---

| | | | |
|:---|:---|:---|:---|
|  | **2025** | **2024** | **2023** |
| **Operating activities** |  |  |  |
| **Net earnings** | **$3246** | **$2993** | **$3165** |
| Adjustments to reconcile net earnings to net cash provided by operating activities: |  |  |  |
| Depreciation | 461 | 427 | 393 |
| Amortization of intangible assets | 732 | 623 | 635 |
| Goodwill and other impairments | 170 | 977 | 36 |
| Share-based compensation | 243 | 229 | 205 |
| Sale of inventory stepped up to fair value at acquisition | 173 | 46 |  |
| Deferred income tax (benefit) expense | 392 | (370) | (206) |
| Changes in operating assets and liabilities: |  |  |  |
| Accounts receivable | 127 | (321) | (175) |
| Inventories | (297) | (206) | (797) |
| Accounts payable | 94 | 192 | 77 |
| Accrued expenses and other liabilities | 318 | 74 | 516 |
| Income taxes | (145) | (116) | (4) |
| Other, net | (470) | (306) | (134) |
| **Net cash provided by operating activities** | **$5044** | **$4242** | **$3711** |
| **Investing activities** |  |  |  |
| Acquisitions, net of cash acquired | (4960) | (1628) | (390) |
| Proceeds/(Purchases) of short-term investments | 750 | (750) |  |
| Purchases of property, plant and equipment | (761) | (755) | (575) |
| Proceeds from the sale of the Spinal Implants business | 165 |  |  |
| Other investing, net | (60) | 133 | 3 |
| **Net cash used in investing activities** | **$(4866)** | **$(3000)** | **$(962)** |
| **Financing activities** |  |  |  |
| Proceeds (payments) on short-term borrowings, net |  | (32) | 540 |
| Proceeds from issuance of long-term debt | 2979 | 3011 | 1241 |
| Payments on long-term debt | (1400) | (2039) | (2058) |
| Payments of dividends  | (1284) | (1219) | (1139) |
| Cash paid for taxes from withheld shares | (149) | (195) | (155) |
| Other financing, net | (33) | (51) | (23) |
| **Net cash provided by (used in) financing activities** | **$113** | **$(525)** | **$(1594)** |
| Effect of exchange rate changes on cash and cash equivalents | 68 | (36) | (28) |
| **Change in cash and cash equivalents** | **$359** | **$681** | **$1127** |
| Cash and cash equivalents at beginning of year | 3652 | 2971 | 1844 |
| **Cash and cash equivalents at end of year** | **$4011** | **$3652** | **$2971** |
| **Supplemental cash flow disclosure:** |  |  |  |
| Cash paid for income taxes, net of refunds | $1002 | $989 | $693 |
| Cash paid for interest on debt | $582 | $396 | $356 |

---

*See accompanying notes to Consolidated Financial Statements.*

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **31** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES**

**Nature of Operations:** Stryker (the "Company," "we," "us," or

"our") is a global leader in medical technologies and, together

with our customers, we are driven to make healthcare better. We

offer innovative products and services in MedSurg,

Neurotechnology and Orthopaedics that help improve patient and

healthcare outcomes. Our products include surgical equipment

and surgical navigation systems; endoscopic and

communications systems; patient handling, emergency medical

equipment and intensive care disposable products; clinical

communication and artificial intelligence-assisted virtual care

platform technology; products for traditional brain and open skull-

based surgical procedures; minimally invasive products for the

treatment of acute ischemic and hemorrhagic stroke and venous

thromboembolism; implants used in joint replacement and trauma

surgeries; Mako robotic-arm assisted technology; as well as other

products used in a variety of medical specialties.

**Basis of Presentation and Consolidation:** The Consolidated

Financial Statements include the Company and its subsidiaries.

All significant intercompany accounts and transactions are

eliminated in consolidation. We have no material interests in

variable interest entities. Certain prior year amounts have been

reclassified to conform with current year presentation in our

Consolidated Financial Statements.

**Use of Estimates:**The preparation of financial statements in

conformity with accounting principles generally accepted in the

United States (GAAP) requires management to make estimates

and assumptions that affect the reported amounts of assets and

liabilities and disclosure of contingent assets and liabilities on the

date of the financial statements and the reported amounts of net

sales and expenses in the reporting period. Actual results could

differ from those estimates.

**Revenue Recognition:** Sales are recognized as the

performance obligations to deliver products or services (including

services under extended warranty service contracts) are satisfied

and are recorded based on the amount of consideration we

expect to receive in exchange for satisfying the performance

obligations. Our sales are recognized primarily when we transfer

control to the customer, which can be on the date of shipment,

the date of receipt by the customer or, for most Orthopaedics

products, when we have received a purchase order and

appropriate notification the product has been used or implanted.

Products and services are primarily transferred to customers at a

point in time, with some transfers of services taking place over

time.

Sales represent the amount of consideration we expect to receive

from customers in exchange for transferring products and

services. Net sales exclude sales, value added and other taxes

we collect from customers. Other costs to obtain and fulfill

contracts are generally expensed as incurred due to the short-

term nature of most of our sales. We extend terms of payment to

our customers based on commercially reasonable terms for the

markets of our customers, while also considering their credit

quality.

A provision for estimated sales returns, discounts and rebates is

recognized as a reduction of sales in the same period that the

sales are recognized. Our estimate of the provision for sales

returns has been established based on contract terms with our

customers and historical business practices and current trends.

Shipping and handling costs charged to customers are included

in net sales.

**Cost of Sales:** Cost of sales include direct materials and

supplies consumed in the manufacture of product, as well as

manufacturing labor, depreciation expense and direct overhead

expense necessary to acquire and convert the purchased

materials and supplies into finished product. Cost of sales also

includes the cost to distribute products to customers, inbound

freight costs, warehousing costs and other shipping and handling

activity.

**Research, Development and Engineering Expenses:**

Research, development and engineering costs are charged to

expense as incurred and include research, development and

engineering activities relating to the development of new

products, improvement of existing products, technical support of

products and compliance with governmental regulations for the

protection of customers and patients. Costs primarily include

salaries, wages, consulting and depreciation and maintenance of

research facilities and equipment.

**Selling, General and Administrative Expenses:** Costs include

selling expenses, marketing expenses, administrative and other

indirect overhead costs, amortization of loaner instrumentation,

depreciation and amortization expense of non-manufacturing

assets and other miscellaneous operating items.

**Currency Translation:** Financial statements of subsidiaries

outside the United States generally are measured using the local

currency as the functional currency. Adjustments to translate

those statements into United States Dollars are recorded in other

comprehensive income (OCI). Transactional exchange gains and

losses are included in other income.

**Cash Equivalents:** Highly liquid investments with remaining

stated maturities of three months or less when purchased or

other money market instruments that are redeemable upon

demand are considered cash equivalents and recorded at cost.

**Short-term Investments:** Short-term investments that have a

maturity greater than three months and less than a year from the

date of purchase primarily include time deposits, certificates of

deposit, commercial paper, bonds and notes, substantially all of

which are denominated in United States Dollars and are stated at

cost plus accrued interest, which approximates fair value. We

expect to hold all of our short-term investments to maturity.

**Marketable Securities:** Marketable securities include marketable

debt securities and mutual funds. Mutual funds are acquired to

offset changes in certain liabilities related to deferred

compensation arrangements and are expected to be used to

settle these liabilities. Mutual funds are recognized in other

noncurrent assets. Pursuant to our investment policy, all

individual marketable security investments must have a minimum

credit quality of single A (Standard & Poor's and Fitch) and A2

(Moody's Corporation) at the time of acquisition, while the overall

portfolio of marketable securities must maintain a minimum

average credit quality of double A (Standard & Poor's and Fitch)

or Aa (Moody's Corporation). In the event of a rating downgrade

below the minimum credit quality subsequent to purchase, the

marketable security investment is evaluated to determine the

appropriate action to take to minimize the overall risk to our

marketable security investment portfolio. Our marketable

securities are classified as available-for-sale and trading

securities. Investments in trading securities represent participant-

directed investments of deferred employee compensation.

**Accounts Receivable:** Accounts receivable include trade and

other miscellaneous receivables. An allowance is maintained for

doubtful accounts for estimated losses in the collection of

accounts receivable. Estimates are made regarding the ability of

customers to make required payments based on historical credit

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **32** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

experience, current market conditions and expected credit

losses. Accounts receivable are written off when all reasonable

collection efforts are exhausted.

**Inventories:** Inventories are stated at the lower of cost or net

realizable value, with cost generally determined using the first-in,

first-out (FIFO) cost method. For excess and obsolete inventory

resulting from the potential inability to sell specific products at

prices in excess of current carrying costs, reserves are

maintained to reduce current carrying cost to net realizable value.

**Financial Instruments:**Our financial instruments include cash,

cash equivalents, marketable securities, accounts receivable,

other investments, accounts payable, debt and foreign currency

exchange contracts. The carrying value of our financial

instruments, with the exception of our senior unsecured notes,

approximates fair value on December 31, 2025 and 2024. Refer

to Notes 3 and 10 for further details.

All marketable securities are recognized at fair value.

Adjustments to the fair value of marketable securities that are

classified as available-for-sale are recognized as increases or

decreases, net of income taxes, within accumulated other

comprehensive income (AOCI) in shareholders' equity and

adjustments to the fair value of marketable securities that are

classified as trading are recognized in earnings. The amortized

cost of marketable debt securities is adjusted for amortization of

premiums and discounts to maturity computed under the effective

interest method. Such amortization, interest and realized gains

and losses are included in other income. The cost of securities

sold is determined by the specific identification method.

We review declines in the fair value of our investments classified

as available-for-sale to determine whether the decline in fair

value is a result of credit loss or other factors. Impairments of

available-for-sale marketable debt securities related to credit loss

are included in earnings and impairments related to other factors

are recognized within AOCI.

**Derivatives:**All derivatives are recognized at fair value and

reported on a gross basis. We enter into forward currency

exchange contracts to mitigate the impact of currency fluctuations

on transactions denominated in nonfunctional currencies, thereby

limiting our risk that would otherwise result from changes in

exchange rates. The periods of the forward currency exchange

contracts correspond to the periods of the exposed transactions,

with realized gains and losses included in the measurement and

recording of transactions denominated in the nonfunctional

currencies. All forward currency exchange contracts are recorded

at their fair value each period.

Forward currency exchange contracts designated as cash flow

hedges are designed to hedge the variability of cash flows

associated with forecasted transactions denominated in a foreign

currency that will take place in the future. These nonfunctional

currency exposures principally relate to forecasted intercompany

sales and purchases of manufactured products and generally

have maturities up to eighteen months. Changes in value of

derivatives designated as cash flow hedges are recorded in AOCI

in shareholders' equity until earnings are affected by the

variability of the underlying cash flows. At that time, the

applicable amount of gain or loss from the derivative instrument

that is deferred in shareholders' equity is reclassified into

earnings and is included in cost of goods sold. Cash flows

associated with these hedges are included in cash provided by

operating activities in the same category as the cash flows from

the items being hedged.

Forward currency exchange contracts are used to offset our

exposure to the change in value of specific foreign currency

denominated assets and liabilities, primarily intercompany

payables and receivables. These derivatives are not designated

as hedges and, therefore, changes in the value of these forward

contracts are recognized in earnings, thereby offsetting the

current earnings effect of the related changes in value of foreign

currency denominated assets and liabilities. The estimated fair

value of our forward currency exchange contracts represents the

measurement of the contracts at month-end spot rates as

adjusted by current forward points.

From time to time, we designate derivative and non-derivative

financial instruments as net investment hedges of our

investments in certain international subsidiaries. For derivative

instruments that are designated and qualify as a net investment

hedge, the effective portion of the derivative's gain or loss is

recognized in OCI and reported as a component of AOCI. We

have elected to use the spot method to assess effectiveness for

our derivatives designated as net investment hedges.

Accordingly, the change in fair value attributable to changes in

the spot rate is recorded in AOCI. We exclude the spot-forward

difference from the assessment of hedge effectiveness and

amortize this amount separately on a straight-line basis over the

term of the forward contracts. This amortization is recognized in

other income.

From time to time, we designate forward starting interest rate

derivative instruments as cash flow hedges to manage the

exposure to interest rate volatility with regard to future issuance

and refinancing of debt. Changes in value of derivatives

designated as cash flow hedges are recorded in AOCI until

earnings are affected by the variability of the underlying cash

flows. At that time, the applicable amount of gain or loss from the

derivative instrument that is deferred in shareholders' equity is

reclassified into earnings and is included in interest expense.

Interest rate derivative instruments designated as fair value

hedges have been used in the past to manage the exposure to

interest rate movements and to reduce borrowing costs by

converting fixed-rate debt into floating-rate debt. Under these

agreements, we agree to exchange, at specified intervals, the

difference between fixed and floating interest amounts calculated

by reference to an agreed-upon notional principal amount.

**Property, Plant and Equipment:**Property, plant and equipment

is stated at cost. Depreciation is generally computed by the

straight-line method over the estimated useful lives of three to 30

years for buildings and improvements and three to 15 years for

machinery and equipment.

**Goodwill and Other Intangible Assets:**Goodwill represents the

excess of purchase price over fair value of tangible net assets of

acquired businesses at the acquisition date, after amounts

allocated to other identifiable intangible assets. Factors that

contribute to the recognition of goodwill include synergies that are

specific to our business and not available to other market

participants and are expected to increase net sales and profits;

acquisition of a talented workforce; cost savings opportunities;

the strategic benefit of expanding our presence in core and

adjacent markets; and diversifying our product portfolio.

The fair values of other identifiable intangible assets acquired in a

business combination are primarily determined using the income

approach. Other intangible assets include, but are not limited to,

developed technologies, customer and distributor relationships

(which reflect expected continued customer or distributor

patronage) and trademarks and patents. Intangible assets with

determinable useful lives are amortized on a straight-line basis

over their estimated useful lives of four to 40 years. Certain

acquired trade names are considered to have indefinite lives and

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **33** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

are not amortized, but are assessed annually for potential

impairment as described below.

In some of our acquisitions, we acquire in-process research and

development (IPRD) intangible assets. For acquisitions

accounted for as business combinations IPRD is considered to

be an indefinite-lived intangible asset until the research is

completed (then it becomes a determinable-lived intangible

asset) or determined to have no future use (then it is impaired).

For asset acquisitions IPRD is expensed immediately unless

there is an alternative future use.

**Goodwill, Intangibles and Long-Lived Asset Impairment**

**Tests:**We perform our annual impairment test for goodwill as of

October 31 each year. We consider qualitative indicators of the

fair value of a reporting unit when it is unlikely that a reporting

unit has impaired goodwill and periodically corroborate that

assessment with quantitative information. In certain

circumstances, we may also utilize a discounted cash flow

analysis that requires certain assumptions and estimates be

made regarding market conditions and our future profitability.

Indefinite-lived intangible assets are also tested at least annually

for impairment by comparing the individual carrying values to the

fair value.

We review long-lived assets for indicators of impairment

whenever events or changes in circumstances indicate that the

carrying amount may not be recoverable. The evaluation is

performed at the lowest level of identifiable cash flows.

Undiscounted cash flows expected to be generated by the related

assets are estimated over the asset's useful life based on

updated projections. If the evaluation indicates that the carrying

amount of the asset may not be recoverable, any potential

impairment is measured based upon the fair value of the related

asset or asset group as determined by an appropriate market

appraisal or other valuation technique.

**Assets and Liabilities Held for Sale:** Weclassify assets and

liabilities or disposal groups to be sold as held for sale in the

period in which all of the following criteria are met: management,

having the authority to approve the action, commits to a plan to

sell the disposal group; the disposal group is available for

immediate sale in its present condition subject only to terms that

are usual and customary for sales of such disposal groups; an

active program to locate a buyer and other actions required to

complete the plan to sell the disposal group have been initiated;

the sale of the disposal group is probable, and transfer of the

disposal group is expected to qualify for recognition as a

completed sale within one year, except if events or circumstances

beyond our control extend the period of time required to sell the

disposal group beyond one year; the disposal group is being

actively marketed for sale at a price that is reasonable in relation

to its current fair value; and actions required to complete the plan

indicate that it is unlikely that significant changes to the plan will

be made or that the plan will be withdrawn.

We initially measure a disposal group that is classified as held for

sale at the lower of its carrying value or fair value less any costs

to sell. Any loss resulting from this measurement is recognized in

the period in which the held for sale criteria are met. Conversely,

gains are not recognized on the sale of a disposal group until the

sale is completed. We assess the fair value of a disposal group,

less any costs to sell, each reporting period it remains classified

as held for sale and report any subsequent changes as an

adjustment to the carrying value of the disposal group, as long as

the new carrying value does not exceed the carrying value of the

disposal group at the time it was initially classified as held for

sale.

Upon determining that a disposal group meets the criteria to be

classified as held for sale, we cease depreciation and

amortization of the assets and disclose the major classes of

assets and liabilities of the disposal group in the Notes to the

Consolidated Financial Statements. Refer to Note 16 for further

information.

**Share-Based Compensation:** Share-based compensation is in

the form of stock options, restricted stock units (RSUs) and

performance stock units (PSUs). Stock options are granted under

long-term incentive plans to certain key employees and non-

employee directors at an exercise price not less than the fair

market value of the underlying common stock, which is the

quoted closing price of our common stock on the day prior to the

date of grant. The options are granted for periods of up to 10

years and become exercisable in varying installments.

We grant RSUs to key employees and non-employee directors

and PSUs to certain key employees under our long-term

incentive plans. The fair value of RSUs is determined based on

the number of shares granted and the quoted closing price of our

common stock on the date of grant, adjusted for the fact that

RSUs do not include anticipated dividends. RSUs generally vest

in one-third increments over a three-year period and are settled

in stock. PSUs are earned over a three-year performance cycle

and vest in March of the year following the end of that

performance cycle. The number of PSUs that will ultimately be

earned is based on our performance relative to pre-established

goals in that three-year performance cycle. The fair value of

PSUs is determined based on the quoted closing price of our

common stock on the day of grant.

Compensation expense is recognized in the Consolidated

Statements of Earnings based on the estimated fair value of the

awards on the grant date. Compensation expense recognized

reflects an estimate of the number of awards expected to vest

after taking into consideration an estimate of award forfeitures

based on actual experience and is recognized on a straight-line

basis over the requisite service period, which is generally the

period required to obtain full vesting. Management expectations

related to the achievement of performance goals associated with

PSU grants is assessed regularly and that assessment is used to

determine whether PSU grants are expected to vest. If

performance-based milestones related to PSU grants are not met

or not expected to be met, any compensation expense

recognized associated with such grants will be reversed.

**Income Taxes:**Deferred income tax assets and liabilities are

determined based on differences between financial reporting and

income tax bases of assets and liabilities and are measured

using the enacted income tax rates in effect for the years in which

the differences are expected to reverse. Deferred income tax

benefits generally represent the change in net deferred income

tax assets and liabilities in the year. Other amounts result from

adjustments related to acquisitions and foreign currency as

appropriate.

We operate in multiple income tax jurisdictions both within the

United States and internationally. Accordingly, management must

determine the appropriate allocation of income to each of these

jurisdictions based on current interpretations of complex income

tax regulations. Income tax authorities in these jurisdictions

regularly perform audits of our income tax filings. Income tax

audits associated with the allocation of this income and other

complex issues, including inventory transfer pricing and cost

sharing, product royalty and foreign branch arrangements, may

require an extended period of time to resolve and may result in

significant income tax adjustments if changes to the income

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **34** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

allocation are required between jurisdictions with different income

tax rates.

The Tax Cuts and Jobs Act (the Act) was enacted in 2017 in the

United States. The Act also subjects a United States shareholder

to tax on Global Intangible Low-Taxed Income (GILTI) earned by

certain foreign subsidiaries. We have elected to account for GILTI

tax in the year the tax is incurred.

**New Accounting Pronouncements Not Yet Adopted**

In December 2025 the Financial Accounting Standards Board

(FASB) issued ASU 2025-10 (Topic 832): *Accounting for*

*Government Grants Received by Business Entities*. This update

establishes guidance on the recognition, measurement and

presentation of government grants received by business entities

including grants related to the purchase, construction or

acquisition of an asset and grants related to income. The update

is effective for fiscal years beginning after December 15, 2028

including interim periods within those fiscal years. Early adoption

is permitted. We do not expect this ASU to have a significant

impact on our Consolidated Financial Statements.

In September 2025 the FASB issued ASU 2025-07 (Topics 815

and 606): *Derivatives and Hedging: Derivatives Scope*

*Refinements* and *Revenue from Contracts with Customers:*

*Scope Clarification for Share-Based Noncash Consideration from*

*a Customer in a Revenue Contract*. This update expands the

scope exception in Topic 815 to certain nonexchange-traded

contracts for which settlement is based on operations or activities

specific to one of the parties to the contract. The update is

effective for fiscal years beginning after December 15, 2026

including interim periods within those fiscal years. Early adoption

is permitted. We are evaluating if the ASU will have an impact on

our Consolidated Financial Statements.

In September 2025 the FASB issued ASU 2025-06 (Subtopic

350-40): *Intangibles - Goodwill and Other - Internal-Use*

*Software: Targeted Improvements to the Accounting for Internal-*

*Use Software*. This update clarifies and modernizes the

accounting for costs related to internal-use software by removing

all references to project stages and clarifying that the probable-

to-complete threshold is not met if significant development

uncertainty exists. The update is effective for fiscal years

beginning after December 15, 2027 including interim periods

within those fiscal years. Early adoption is permitted. We do not

expect this ASU to have a significant impact on our Consolidated

Financial Statements.

In July 2025 the FASB issued ASU 2025-05 (Topic 326):

*Financial Instruments - Credit Losses: Measurement of Credit*

*Losses for Accounts Receivable and Contract Assets*. This

update provides a practical expedient allowing entities to assume

that current conditions as of the balance sheet date will remain

unchanged for the remaining life of the asset when estimating

expected credit losses for current accounts receivable and

current contract assets arising from transactions accounting for

under Accounting Standards Codification 606, Revenue from

Contracts with Customers. The update is effective for fiscal years

beginning after December 15, 2025 including interim periods

within those fiscal years. Early adoption is permitted. We are

evaluating if the ASU will have an impact on our Consolidated

Financial Statements.

In November 2024 the FASB issued ASU 2024-03 (Subtopic

220-40): *Income Statement: Reporting Comprehensive Income -*

*Expense Disaggregation Disclosures* which requires

disaggregation of certain expense captions into specified

categories in disclosures within the Notes to the Consolidated

Financial Statements. The new disclosure requirements are

effective for fiscal years beginning after December 15, 2026 and

interim periods within fiscal years beginning after December 15,

2027. Early adoption is permitted. We are evaluating these new

expanded disclosure requirements.

We evaluate all ASUs issued by the FASB for consideration of

their applicability. ASUs not included in our disclosures were

assessed and determined to be either not applicable or are not

expected to have a material impact on our Consolidated Financial

Statements.

**Accounting Pronouncements Recently Adopted**

We adopted ASU 2023-09 (Topic 740): *Income Taxes:*

*Improvements to Income Tax Disclosures* for the annual period

beginning on January 1, 2025. Refer to Note 11 for further

information.

**NOTE 2 - REVENUE RECOGNITION**

We disaggregate our net sales by business and geographic

location for each of our segments as we believe it best depicts

how the nature, amount, timing and certainty of our net sales and

cash flows are affected by economic factors.

Products and services are primarily transferred to customers at a

point in time, with some transfers of services taking place over

time. In 2025 less than 10% of our sales were recognized as

services transferred over time. Refer to Note 1 for further

discussion on our revenue recognition policies.

---

| | | | |
|:---|:---|:---|:---|
| ***Segment Net Sales*** |  |  |  |
| **MedSurg and Neurotechnology:** | **2025** | **2024** | **2023** |
| Instruments | $3183 | $2834 | $2534 |
| Endoscopy | 3807 | 3389 | 3068 |
| Medical | 4204 | 3852 | 3459 |
| Vascular | 1968 | 1307 | 1226 |
| Neuro Cranial | 2485 | 2136 | 1876 |
|  | **$15647** | **$13518** | **$12163** |
| **Orthopaedics:** |  |  |  |
| Knees | $2656 | $2447 | $2273 |
| Hips | 1865 | 1704 | 1544 |
| Trauma and Extremities | 3948 | 3507 | 3147 |
| Spinal Implants | 185 | 707 | 713 |
| Other | 815 | 712 | 658 |
|  | **$9469** | **$9077** | **$8335** |
| **Total** | **$25116** | **$22595** | **$20498** |

---

---

| | | | |
|:---|:---|:---|:---|
| ***United States Net Sales*** |  |  |  |
| **MedSurg and Neurotechnology:** | **2025** | **2024** | **2023** |
| Instruments | $2562 | $2267 | $2016 |
| Endoscopy | 3133 | 2792 | 2513 |
| Medical | 3510 | 3191 | 2785 |
| Vascular | 1048 | 506 | 483 |
| Neuro Cranial | 2052 | 1761 | 1531 |
|  | **$12305** | **$10517** | **$9328** |
| **Orthopaedics:** |  |  |  |
| Knees | $1924 | $1788 | $1676 |
| Hips | 1137 | 1059 | 988 |
| Trauma and Extremities | 2926 | 2586 | 2297 |
| Spinal Implants | 118 | 489 | 500 |
| Other | 596 | 504 | 468 |
|  | **$6701** | **$6426** | **$5929** |
| **Total** | **$19006** | **$16943** | **$15257** |

---

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **35** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

---

| | | | |
|:---|:---|:---|:---|
| ***International Net Sales*** |  |  |  |
| **MedSurg and Neurotechnology:** | **2025** | **2024** | **2023** |
| Instruments | $621 | $567 | $518 |
| Endoscopy | 674 | 597 | 555 |
| Medical | 694 | 661 | 674 |
| Vascular | 920 | 801 | 743 |
| Neuro Cranial | 433 | 375 | 345 |
|  | **$3342** | **$3001** | **$2835** |
| **Orthopaedics:** |  |  |  |
| Knees | $732 | $659 | $597 |
| Hips | 728 | 645 | 556 |
| Trauma and Extremities | 1022 | 921 | 850 |
| Spinal Implants | 67 | 218 | 213 |
| Other | 219 | 208 | 190 |
|  | **$2768** | **$2651** | **$2406** |
| **Total** | **$6110** | **$5652** | **$5241** |

---

***MedSurg and Neurotechnology***

MedSurg and Neurotechnology products include surgical

equipment, patient and caregiver safety technologies, and

navigation systems (Instruments), endoscopic and

communications systems (Endoscopy), patient handling,

emergency medical equipment, intensive care disposable

products, clinical communication and artificial intelligence-

assisted virtual care platform technology (Medical), minimally

invasive products for the treatment of acute ischemic and

hemorrhagic stroke and venous thromboembolism (Vascular) and

a comprehensive line of products for traditional brain and open

skull-based surgical procedures, orthobiologic and biosurgery

products, including synthetic bone grafts and vertebral

augmentation products (Neuro Cranial). Substantially all

MedSurg and Neurotechnology sales are recognized when a

purchase order has been received and control has transferred.

For certain Endoscopy, Instruments and Medical services, we

may recognize sales over time as we satisfy performance

obligations that may include an obligation to complete installation,

provide training and perform ongoing services, generally

performed within one year.

***Orthopaedics***

Orthopaedics products primarily include implants used in total

joint replacements, such as hip, knee and shoulder, ankle and

trauma and extremities surgeries. Substantially all Orthopaedics

sales are recognized when we have received a purchase order

and appropriate notification the product has been used or

implanted. For certain Orthopaedic products in the "other"

category, we recognize sales at a point in time, as well as over

time for performance obligations that may include an obligation to

complete installation and provide training and ongoing services.

Performance obligations are generally satisfied within one year.

***Costs to Obtain or Fulfill a Contract***

We typically do not incur costs to fulfill a contract before a

product or service is provided to a customer due to the nature of

our products and services. Our costs to obtain contracts are

typically in the form of sales commissions paid to employees or

third-party agents. Certain sales commissions paid to employees

prior to recognition of sales are recorded as deferred contract

costs. We expense sales commissions associated with obtaining

a contract at the time of the sale or as incurred as the

amortization period is generally less than one year. These costs

have been presented within selling, general and administrative

expenses. On December 31, 2025 and 2024 deferred contract

costs recorded in our Consolidated Balance Sheets were not

significant.

***Contract Assets and Liabilities***

Our contract assets primarily relate to conditional rights to

consideration for work completed but not billed at the reporting

date. On December 31, 2025 and 2024 contract assets recorded

in our Consolidated Balance Sheets were not significant.

Our contract liabilities arise as a result of consideration received

from customers at inception of contracts for certain businesses or

where the timing of billing for services precedes satisfaction of

our performance obligations. This occurs primarily when payment

is received upfront for certain multi-period extended warranty

service contracts. Our contract liabilities of $1,024 and $978 on

December 31, 2025 and 2024are classified within accrued

expenses and other liabilities and other noncurrent liabilities in

our Consolidated Balance Sheets based on the timing of when

we expect to complete our performance obligations. Changes in

contract liabilities during the year were as follows:

---

| | | |
|:---|:---|:---|
|  | **2025** | **2024** |
| **Beginning contract liabilities** | **$978** | **$860** |
| Revenue recognized from beginning of year contract <br>liabilities<br>| (546) | (553) |
| Net advance consideration received during the period | 592 | 671 |
| **Ending contract liabilities** | **$1024** | **$978** |

---

***Transfers and Servicing of Financial Assets***

We sell certain customer lease agreements and the related

leased assets to third-party financial institutions to accelerate our

cash collection cycle. The lease receivables are sold without

recourse and are derecognized from our Consolidated Balance

Sheets at the time of sale. Under the terms of our arrangements,

we collect lease payments on behalf of the financial institutions

but maintain no other form of continuing involvement. Sales of

these lease agreements are classified as operating activities in

our Consolidated Statements of Cash Flows. Fees earned for our

servicing activities are immaterial. Revenue related to customer

lease agreements sold under these arrangements represented

less than 4% of our total revenue for 2025, 2024 and 2023.

**NOTE 3 - FAIR VALUE MEASUREMENTS**

Fair value is defined as the price that would be received to sell an

asset or paid to transfer a liability in an orderly transaction

between market participants at the measurement date. Financial

assets and liabilities carried at fair value are classified in their

entirety based on the lowest level of input and disclosed in one of

the following three categories:

---

| | |
|:---|:---|
| Level 1 | Quoted market prices in active markets for identical assets or <br>liabilities.<br>|
| Level 2 | Observable market-based inputs or unobservable inputs that <br>are corroborated by market data.<br>|
| Level 3 | Unobservable inputs reflecting our assumptions or external <br>inputs from active markets.<br>|

---

Use of observable market data, when available, is required in

making fair value measurements. When inputs used fall within

different levels of the hierarchy, the level within which the fair

value measurement is categorized is based on the lowest level

input that is significant to the fair value measurement. We

determine fair value for Level 1 instruments using exchange-

traded prices for identical instruments. We determine fair value of

Level 2 instruments using exchange-traded prices of similar

instruments, where available, or utilizing other observable inputs

that take into account our credit risk and that of our

counterparties. Foreign currency exchange contracts and interest

rate hedges, when outstanding, are included in Level 2 and are

primarily valued using standard calculations and models that use

readily observable market data as their basis. Our Level 3

liabilities comprise contingent consideration arising from recently

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **36** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

completed acquisitions. We determine fair value of these Level 3

liabilities using a discounted cash flow technique. Significant

unobservable inputs were used in our assessment of fair value,

including assumptions regarding future business results, discount

rates, discount periods and probability assessments based on the

likelihood of reaching various targets. We remeasure the fair

value of our assets and liabilities each reporting period. We

record the changes in fair value within selling, general and

administrative expense.

In 2025 we assumed contingent consideration liabilities with a fair

value of $90 related to previous acquisitions made by Inari

Medical Inc. (Inari). Refer to Note 6 for further information on the

acquisition of Inari.

In 2024 we recorded $208 of contingent consideration related to

various acquisitions described in Note 6.

There were no significant transfers into or out of any level of the

fair value hierarchy in 2025.

---

| | | |
|:---|:---|:---|
| ***Assets Measured at Fair Value*** | ***Assets Measured at Fair Value*** | ***Assets Measured at Fair Value*** |
|  | **2025** | **2024** |
| Cash and cash equivalents | $4011 | $3652 |
| Short-term investments |  | 750 |
| Trading marketable securities | 307 | 259 |
| **Level 1 - Assets** | **$4318** | **$4661** |
| Available-for-sale marketable securities: |  |  |
| Corporate and asset-backed debt securities | $52 | $53 |
| United States agency debt securities |  | 1 |
| United States treasury debt securities | 37 | 34 |
| Certificates of deposit |  | 3 |
| Total available-for-sale marketable securities | $89 | $91 |
| Foreign currency exchange forward contracts | 46 | 225 |
| **Level 2 - Assets** | **$135** | **$316** |
| **Total assets measured at fair value** | **$4453** | **$4977** |

---

---

| | | |
|:---|:---|:---|
| ***Liabilities Measured at Fair Value*** | ***Liabilities Measured at Fair Value*** | ***Liabilities Measured at Fair Value*** |
|  | **2025** | **2024** |
| Deferred compensation arrangements | $307 | $259 |
| **Level 1 - Liabilities** | **$307** | **$259** |
| Foreign currency exchange forward contracts | $170 | $77 |
| **Level 2 - Liabilities** | **$170** | **$77** |
| Contingent consideration: |  |  |
| Beginning | $452 | $289 |
| Additions | 123 | 208 |
| Change in estimate and foreign exchange | 24 | 8 |
| Settlements | (81) | (53) |
| Ending | $518 | $452 |
| **Level 3 - Liabilities** | **$518** | **$452** |
| **Total liabilities measured at fair value** | **$995** | **$788** |

---

---

| | | |
|:---|:---|:---|
| ***Fair Value of Available for Sale Securities by Maturity*** | ***Fair Value of Available for Sale Securities by Maturity*** | ***Fair Value of Available for Sale Securities by Maturity*** |
|  | **2025** | **2024** |
| Due in one year or less | $41 | $47 |
| Due after one year through three years | $48 | $44 |

---

On December 31, 2025the aggregate difference between the

cost and fair value of available-for-sale marketable securities was

nominal. Interest income on cash and cash equivalents, short-

term investments and marketable securities income was $121,

$139 and $75 in 2025, 2024 and 2023, which was recorded in

other income.

Our investments in available-for-sale marketable securities had a

minimum credit quality rating of A2 (Moody's), A (Standard &

Poor's) and A (Fitch). We do not plan to sell the investments, and

it is not more likely than not that we will be required to sell the

investments before recovery of their amortized cost basis, which

may be maturity.

**NOTE 4 - DERIVATIVE INSTRUMENTS**

We use operational and economic hedges, foreign currency

exchange forward contracts, net investment hedges (both

derivative and non-derivative financial instruments) and interest

rate derivative instruments to manage the impact of currency

exchange and interest rate fluctuations on earnings, cash flow

and equity. We do not enter into derivative instruments for

speculative purposes. We are exposed to potential credit loss in

the event of nonperformance by counterparties on our

outstanding derivative instruments but do not anticipate

nonperformance by any of our counterparties. Should a

counterparty default, our maximum loss exposure is the asset

balance of the instrument.

**Foreign Currency Hedges**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **2025** | **Cash Flow** | **Net** <br>**Investment**<br>| **Non-**<br>**Designated**<br>| **Total** |
| **Gross notional amount** | **$1738** | **$2647** | **$4391** | **$8776** |
| Maximum term in years |  |  |  | 8.7 |
| **Fair value:** |  |  |  |  |
| Other current assets | $33 | $— | $11 | $44 |
| Other noncurrent assets | 2 |  |  | 2 |
| Other current liabilities | (10) | (71) | (21) | (102) |
| Other noncurrent <br>liabilities<br>| (2) | (66) |  | (68) |
| **Total fair value** | **$23** | **$(137)** | **$(10)** | **$(124)** |
| **2024** | **Cash Flow** | **Net** <br>**Investment**<br>| **Non-**<br>**Designated**<br>| **Total** |
| **Gross notional amount** | **$1588** | **$2338** | **$5164** | **$9090** |
| Maximum term in years |  |  |  | 9.7 |
| **Fair value:** |  |  |  |  |
| Other current assets | $43 | $24 | $119 | $186 |
| Other noncurrent assets | 4 | 35 |  | 39 |
| Other current liabilities | (29) |  | (41) | (70) |
| Other noncurrent <br>liabilities<br>| (3) | (4) |  | (7) |
| **Total fair value** | **$15** | **$55** | **$78** | **$148** |

---

We had €2.3 billion at December 31, 2025 and 2024 in certain

forward currency contracts designated as net investment hedges,

for which the maximum term is 8.7 years, to hedge a portion of

our investments in certain of our entities with functional

currencies denominated in Euros. In addition to these derivative

financial instruments designated as net investment hedges, we

had €5.0 billion at December 31, 2025 and 2024 of senior

unsecured notes designated as net investment hedges to

selectively hedge portions of our investment in certain

international subsidiaries. The currency effects of our Euro-

denominated senior unsecured notes are reflected in AOCI within

shareholders' equity where they offset gains and losses recorded

on our net investment in international subsidiaries.

The total after-tax gain (loss) recognized in OCI related to

designated net investment hedges was ($715) in 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***Currency Exchange Rate Gains (Losses) Recognized in Net*** <br>***Earnings*** | ***Currency Exchange Rate Gains (Losses) Recognized in Net*** <br>***Earnings*** | ***Currency Exchange Rate Gains (Losses) Recognized in Net*** <br>***Earnings*** | ***Currency Exchange Rate Gains (Losses) Recognized in Net*** <br>***Earnings*** | ***Currency Exchange Rate Gains (Losses) Recognized in Net*** <br>***Earnings*** |
| **Derivative Instrument** | **Recognized in:** | **2025** | **2024** | **2023** |
| Cash Flow | Cost of sales | $25 | $31 | $39 |
| Net Investment | Other income | 44 | 35 | 34 |
| Non-Designated | Other income | 33 | 40 | 25 |
|  | **Total** | **$102** | **$106** | **$98** |

---

Pretax gains (losses) on derivatives designated as cash flow

hedges of $39 and net investment hedges of $38 recorded in

AOCI are expected to be reclassified to cost of sales and other

income in earnings within 12 months of December 31, 2025. This

cash flow hedge reclassification is primarily due to the sale of

inventory that includes previously hedged purchases. A

component of the AOCI amounts related to net investment

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **37** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

hedges is reclassified over the life of the hedge instruments as

we elected to exclude the initial value of the component related to

the spot-forward difference from the effectiveness assessment.

**Interest Rate Hedges**

Pretax gains of $5 recorded in AOCI related to interest rate

hedges closed in conjunction with debt issuances are expected to

be reclassified to interest expense in earnings within 12 months

of December 31, 2025. The cash flow effect of interest rate

hedges is recorded in cash flow from operations.

**NOTE 5 - ACCUMULATED OTHER COMPREHENSIVE (LOSS)**

**INCOME (AOCI)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Pension** <br>**Plans**<br>| **Hedges** | **Financial** <br>**Statement** <br>**Translation**<br>| **Total** |
| **2023** | **$(28)** | **$39** | **$(427)** | **$(416)** |
| OCI | 43 | 26 | 236 | 305 |
| Income taxes | (11) | (7) | (110) | (128) |
| Reclassifications to: |  |  |  |  |
| Cost of sales |  | (31) |  | (31) |
| Interest expense |  | (4) |  | (4) |
| Other income |  |  | (35) | (35) |
| Income taxes |  | 8 | 8 | 16 |
| Net OCI | $32 | $(8) | $99 | $123 |
| **2024** | **$4** | **$31** | **$(328)** | **$(293)** |
| OCI | 93 | 37 | (562) | (432) |
| Income taxes | (27) | (4) | 125 | 94 |
| Reclassifications to: |  |  |  |  |
| Cost of sales |  | (25) |  | (25) |
| Interest expense |  | (3) |  | (3) |
| Other income |  |  | (44) | (44) |
| Income taxes |  | 6 | 10 | 16 |
| Net OCI | $66 | $11 | $(471) | $(394) |
| **2025** | **$70** | **$42** | **$(799)** | **$(687)** |

---

**NOTE 6 - ACQUISITIONS**

We acquire stock in companies and various assets that continue

to support our capital deployment and product development

strategies. Cash paid for acquisitions, net of cash acquired was

$4,960 and $1,628in 2025 and 2024.

In February 2025 we completed the acquisition of Inari for $80

per share, or an aggregate purchase price of $4,810, net of cash

acquired. Inari's product portfolio includes minimally invasive

products for the treatment of venous thromboembolism. Inari is

part of our Peripheral Vascular business within MedSurg and

Neurotechnology. The purchase price allocation for Inari is based

on preliminary valuations, primarily related to developed

technologies and customer relationships. Goodwill attributable to

the acquisition reflects the strategic benefits of expanding our

market presence, diversifying our product portfolio and advancing

innovations. This goodwill is not deductible for tax purposes.

Share-based awards for Inari employees vested upon our

acquisition and a charge of $139 was recorded in selling, general

and administrative expenses in 2025.

In 2024 we completed various acquisitions for total consideration

that includes $1,628 in upfront payments, net of cash acquired,

and $400 contingent upon the achievement of certain commercial

or clinical milestones. The combined acquisition-date fair values

of the contingent milestone payments totaled $208. The acquired

companies expand the product portfolios of our Instruments,

Endoscopy, Medical and Neuro Cranial businesses within

MedSurg and Neurotechnology and our Trauma and Extremities

and Joint Replacement businesses within Orthopaedics. Goodwill

attributable to the acquisitions reflects the strategic benefits of

expanding our market presence, diversifying our product portfolio

and advancing innovations. This goodwill is not deductible for tax

purposes.

The purchase price allocations for Inari and the acquisitions

completed in the full year 2024 are:

---

| | | |
|:---|:---|:---|
| ***Purchase Price Allocation of Acquired Net Assets*** | ***Purchase Price Allocation of Acquired Net Assets*** | ***Purchase Price Allocation of Acquired Net Assets*** |
|  | **2025** | **2024** |
|  | **Inari** | **Total** |
| Tangible assets acquired: |  |  |
| Accounts receivable | $78 | $40 |
| Inventory | 215 | 99 |
| Deferred income tax assets | 59 | 49 |
| Other assets | 84 | 26 |
| Debt |  | (32) |
| Deferred income tax liabilities | (486) | (204) |
| Other liabilities | (191) | (107) |
| Intangible assets: |  |  |
| Developed technologies | 1458 | 596 |
| Customer relationships | 330 | 215 |
| Patents |  | 6 |
| Trademarks |  | 2 |
| Other intangibles | 72 |  |
| Goodwill | 3191 | 1146 |
| **Purchase price, net of cash acquired of** <br>**$64 and $56**<br>| **$4810** | **$1836** |
| Weighted-average amortization period at <br>acquisition (years):<br>|  |  |
| Developed technologies | 13 | 12 |
| Customer relationships | 13 | 14 |
| Patents |  | 12 |
| Trademarks |  | 5 |
| Other intangibles | 9 |  |

---

**NOTE 7 - CONTINGENCIES AND COMMITMENTS**

We are involved in various ongoing proceedings, legal actions

and claims arising in the normal course of business, including

proceedings related to product, labor, tax, intellectual property

and other matters, the most significant of which are more fully

described below. The outcomes of these matters will generally

not be known for prolonged periods of time. In certain of the legal

proceedings the claimants seek damages as well as other

compensatory and equitable relief that could result in the

payment of significant claims and settlements and/or the

imposition of injunctions or other equitable relief. For legal

matters for which management had sufficient information to

reasonably estimate our future obligations, a liability representing

management's best estimate of the probable loss, or the

minimum of the range of probable losses when a best estimate

within the range is not known, is recorded. The estimates are

based on consultation with legal counsel, previous settlement

experience and settlement strategies. If actual outcomes are less

favorable than those estimated by management, additional

expense may be incurred, which could unfavorably affect future

operating results. We are self-insured for certain claims and

expenses. The ultimate cost to us with respect to product liability

claims could be materially different than the amount of the current

estimates and accruals and could have a material adverse effect

on our financial position, results of operations and cash flows.

Previously we were contacted by the United States Securities

and Exchange Commission (SEC), United States Department of

Justice (DOJ) and certain other regulatory authorities regarding

whether certain business activities in certain foreign countries

violated provisions of the FCPA and analogous local laws. We

have completed our investigation into these matters. During 2025

we were informed by the SEC and DOJ that each agency had

closed its inquiry. We are currently responding to inquiries by

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **38** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

certain foreign authorities arising in the normal course of

business. We do not expect these matters to have a material

effect, if any, on our financial statements.

We have conducted voluntary recalls of certain products,

including our Rejuvenate and ABG II Modular-Neck hip stems

and certain lot-specific sizes and offsets of LFIT Anatomic CoCr

V40 Femoral Heads. Additionally, we are responsible for certain

product liability claims, primarily related to certain hip products

sold by Wright prior to its 2014 divestiture of the OrthoRecon

business.

We have incurred, and expect to incur in the future, costs

associated with the defense and settlement of claims and

lawsuits. Based on the information that has been received related

to the matters discussed above, our accrual for these matters

was $144 at December 31, 2025, representing our best estimate

of probable loss. The final outcomes of these matters are

dependent on many factors that are difficult to predict.

Accordingly the ultimate cost related to these matters may be

materially different than the amount of our current estimate and

accruals and could have a material adverse effect on our results

of operations and cash flows.

**Leases**

We lease various manufacturing, warehousing and distribution

facilities, administrative and sales offices as well as equipment

under operating leases. We evaluate our contracts to identify

leases, which is generally if there is an identified asset and we

have the right to direct the use of and obtain substantially all of

the economic benefit from the use of the identified asset. Certain

of our lease agreements contain rent escalation clauses

(including index-based escalations), rent holidays, capital

improvement funding or other lease incentives. We recognize our

minimum rental expense on a straight-line basis over the term of

the lease beginning with the date of initial control of the asset.

Right-of-use assets are recorded in other noncurrent assets on

our Consolidated Balance Sheets. Current and noncurrent lease

liabilities are recorded in accrued expenses and other liabilities

and other noncurrent liabilities, respectively.

We have made certain significant assumptions and judgments

when recording leases. For all asset classes, we do not

recognize a right-of-use asset and lease liability for short-term

leases. We also do not separate non-lease components from

lease components to which they relate and account for the

combined lease and non-lease components as a single lease

component. The determination of the discount rate used in a

lease is our incremental borrowing rate which is based on what

we would normally pay to borrow on a collateralized basis over a

similar term an amount equal to the lease payments.

---

| | | |
|:---|:---|:---|
|  | **2025** | **2024** |
| Right-of-use assets  | $519 | $516 |
| Lease liabilities, current  | $153 | $144 |
| Lease liabilities, noncurrent  | $348 | $379 |
| **Other information:** |  |  |
| Weighted-average remaining lease term (years) | 5.0 | 5.1 |
| Weighted-average discount rate | 3.77% | 3.87% |

---

Operating lease expense totaled $205, $190 and $172 in 2025,

2024 and 2023.

**Future Obligations**

We lease various manufacturing, warehousing and distribution

facilities, administrative and sales offices as well as equipment

under operating leases. Refer to Note 10 for more information on

the debt obligations.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **2026** | **2027** | **2028** | **2029** | **2030** | **Thereafter** |
| Debt repayments | $1000 | $1382 | $2606 | $1691 | $2565 | $6729 |
| Minimum lease payments | $164 | $125 | $87 | $55 | $38 | $55 |

---

**Other Contractual Obligations and Commitments**

We participate in a supplier financing program that enables our

suppliers, at their sole discretion, to sell their Stryker receivables

to a financial institution on a non-recourse basis in order to be

paid earlier than our payment terms provide. Under this program,

we agree to pay participating banks the stated amount of

confirmed invoices from its designated suppliers on the original

maturity dates of the invoices, generally within 90 days of the

invoice date. We or the banks may agree to terminate the

agreements with advance notice. Separately, the banks may

have arrangements with the suppliers that provide them the

option to request early payment from the bank for invoices

confirmed by us. Our outstanding balances of confirmed invoices

in the programs were $75 and $71 on December 31, 2025 and

2024 and are included within accounts payable on our

Consolidated Balance Sheets.

---

| | | |
|:---|:---|:---|
|  | **2025** | **2024** |
| **Beginning confirmed obligations** | **$71** | **$51** |
| Additions | 420 | 392 |
| Settlements | (416) | (372) |
| **Ending confirmed obligations** | **$75** | **$71** |

---

**NOTE 8 - GOODWILL AND OTHER INTANGIBLE ASSETS**

In our annual impairment test of goodwill as of October 31, 2024

we performed a quantitative assessment of the Spine reporting

unit using a discounted cash flow analysis to estimate the fair

value. The carrying value of the Spine reporting unit exceeded its

fair value and a charge of $273 was recognized in goodwill and

other impairments in the Consolidated Statements of Earnings.

The impairment charge for the Spine reporting unit was driven by

a decrease in future product demand due to the competitive

environment and an increase in the Spine reporting unit's

weighted average cost of capital. Subsequent to the annual

goodwill impairment test management committed to a plan to sell

certain assets associated with the Spinal Implants business

(disposal group). Goodwill was allocated to the disposal group

based on the relative fair values of the disposal group and the

portion of the Spine reporting unit that will be retained. Goodwill

allocated to the disposal group was tested for impairment which

resulted in an impairment charge of $183 recognized in goodwill

and other impairments in the Consolidated Statements of

Earnings. Refer to Note 16 for additional information on the sale

of the Spinal Implants business.

In our annual impairment test as of October 31, 2025 we

performed a quantitative impairment test for our Peripheral

Vascular reporting unit and determined that its fair value

exceeded its carrying amount by 12%. At October 31, 2025,

goodwill attributable to the Peripheral Vascular reporting unit was

$3,203. The fair value of this reporting unit was determined using

a discounted cash flow analysis, which is a form of the income

approach. Significant inputs to the analysis included assumptions

for future revenue growth, operating margin and the rate used to

discount the estimated future cash flows to their present value,

based on the reporting unit's estimated weighted average cost of

capital.

For our other reporting units, we considered qualitative indicators

of impairment as it was considered more likely than not that the

fair values of those reporting units exceeded their respective

carrying values. No impairment was identified for those reporting

units in 2025 or 2024.

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **39** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

Future changes in the judgments, assumptions and estimates

that are used in our impairment testing for goodwill, including

discount and tax rates and future cash flow projections, could

result in different estimates of the fair values. A significant

reduction in the estimated fair values could result in impairment

charges that could materially affect our results of operations.

In 2024 goodwill of $117 previously reported within Orthopaedics

was reclassified to MedSurg and Neurotechnology to reflect the

reclassification of the Interventional Spine reporting unit from

Orthopaedics to MedSurg and Neurotechnology to align with

certain updates in our internal reporting structure.

---

| | | | |
|:---|:---|:---|:---|
| ***Changes in the Net Carrying Value of Goodwill by Segment*** | ***Changes in the Net Carrying Value of Goodwill by Segment*** | ***Changes in the Net Carrying Value of Goodwill by Segment*** | ***Changes in the Net Carrying Value of Goodwill by Segment*** |
|  | **MedSurg and** <br>**Neurotechnology**<br>| **Orthopaedics** | **Total** |
| **2023** | **$8270** | **$6973** | **$15243** |
| Goodwill impairment |  | (456) | (456) |
| Additions and adjustments | 852 | 300 | 1152 |
| Foreign exchange and other | 86 | (170) | (84) |
| **2024** | **$9208** | **$6647** | **$15855** |
| Additions and adjustments | 3275 | (1) | 3274 |
| Foreign exchange and other | 73 | 89 | 162 |
| **2025** | **$12556** | **$6735** | **$19291** |

---

---

| | | | |
|:---|:---|:---|:---|
| ***Summary of Other Intangible Assets*** | ***Summary of Other Intangible Assets*** | ***Summary of Other Intangible Assets*** | ***Summary of Other Intangible Assets*** |
|  | **Gross**<br>**Carrying**<br>**Amount**<br>| **Less**<br>**Accumulated**<br>**Amortization**<br>| **Net**<br>**Carrying**<br>**Amount**<br>|
| **Developed technologies** | **Developed technologies** | **Developed technologies** | **Developed technologies** |
| 2025 | $7273 | $3430 | $3843 |
| 2024 | 5698 | 2931 | 2767 |
| **Customer relationships** | **Customer relationships** | **Customer relationships** | **Customer relationships** |
| 2025 | $3425 | $1844 | $1581 |
| 2024 | 3055 | 1636 | 1419 |
| **Patents** | **Patents** | **Patents** | **Patents** |
| 2025 | $157 | $144 | $13 |
| 2024 | 153 | 136 | 17 |
| **Trademarks** | **Trademarks** | **Trademarks** | **Trademarks** |
| 2025 | $420 | $281 | $139 |
| 2024 | 413 | 256 | 157 |
| **In-process research and development** | **In-process research and development** | **In-process research and development** | **In-process research and development** |
| 2025 | $34 | $— | $34 |
| 2024 | 34 |  | 34 |
| **Other** | **Other** | **Other** | **Other** |
| 2025 | $132 | $61 | $71 |
| 2024 | 63 | 62 | 1 |
| **Total** | **Total** | **Total** | **Total** |
| **2025** | **$11441** | **$5760** | **$5681** |
| **2024** | **9416** | **5021** | **4395** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***Estimated Amortization Expense*** | ***Estimated Amortization Expense*** | ***Estimated Amortization Expense*** | ***Estimated Amortization Expense*** | ***Estimated Amortization Expense*** |
| **2026** | **2027** | **2028** | **2029** | **2030** |
| $699 | $711 | $631 | $616 | $597 |

---

**NOTE 9 - CAPITAL STOCK**

The aggregate number of shares of all classes of stock which we

are authorized to issue is up to 1,000,500,000, divided into two

classes consisting of 500,000 shares of $1 par value preferred

stock and 1,000,000,000 shares of common stock with a par

value of $0.10. No shares of preferred stock were outstanding on

December 31, 2025.

We made no repurchases of shares in 2025. The manner, timing

and amount of repurchases are determined by management

based on an evaluation of market conditions, stock price and

other factors and are subject to regulatory considerations.

Purchases are made from time-to-time in the open market, in

privately negotiated transactions or otherwise. On December 31,

2025 the total dollar value of shares of our common stock that

could be purchased under our authorized repurchase program

was $1,033.

Shares reserved for future compensation grants of our common

stock were 31 million and 18 million on December 31, 2025 and

2024. **Stock Options**

We measure the cost of employee stock options based on the

grant-date fair value and recognize that cost using the straight-

line method over the period in which a recipient is required to

provide services in exchange for the options, typically the vesting

period. The weighted-average fair value per share of options is

estimated on the date of grant using the Black-Scholes option

pricing model.

---

| | | | |
|:---|:---|:---|:---|
| ***Option Value and Assumptions*** | ***Option Value and Assumptions*** | ***Option Value and Assumptions*** | ***Option Value and Assumptions*** |
|  | **2025** | **2024** | **2023** |
| Weighted-average fair value per share | $141.40 | $118.22 | $83.59 |
| **Assumptions:** |  |  |  |
| Risk-free interest rate | 4.4% | 4.3% | 4.0% |
| Expected dividend yield | 0.9% | 1.1% | 1.2% |
| Expected stock price volatility | 29.1% | 29.9% | 29.0% |
| Expected option life (years) | 6.4 | 6.3 | 6.2 |

---

The risk-free interest rate for periods within the expected life of

options granted is based on the United States Treasury yield

curve in effect at the time of grant. Expected stock price volatility

is based on the historical volatility of our stock. The expected

option life, representing the period of time that options granted

are expected to be outstanding, is based on historical option

exercise and employee termination data.

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***2025 Stock Option Activity*** | ***2025 Stock Option Activity*** | ***2025 Stock Option Activity*** | ***2025 Stock Option Activity*** | ***2025 Stock Option Activity*** |
|  | **Shares** <br>**(in millions)**<br>| **Weighted-**<br>**Average**<br>**Exercise** <br>**Price**<br>| **Weighted-**<br>**Average**<br>**Remaining**<br>**Term (in years)**<br>| **Aggregate**<br>**Intrinsic**<br> **Value**<br>|
| **Outstanding** <br>**January 1**<br>| **10.8** | **$214.87** |  |  |
| Granted | 1.0 | 392.36 |  |  |
| Exercised | (1.2) | 158.83 |  |  |
| Canceled or <br>forfeited<br>| (0.2) | 313.05 |  |  |
| **Outstanding** <br>**December 31**<br>| **10.4** | **$234.56** | **5.0** | **$1246.1** |
| Exercisable <br>December 31<br>| 6.9 | $195.53 | 3.7 | $1073.4 |
| Options expected <br>to vest<br>| 3.3 | $309.91 | 7.5 | $166.7 |

---

The aggregate intrinsic value of options, which represents the

cumulative difference between the fair market value of the

underlying common stock and the option exercise prices,

exercised was $260, $362 and $318 in 2025, 2024 and 2023.

Exercise prices for options outstanding ranged from $96.64 to

$392.39 on December 31, 2025. On December 31, 2025 there

was $160 of unrecognized compensation cost related to

nonvested stock options granted under the long-term incentive

plans. That cost is expected to be recognized as expense over

the weighted-average period of approximately 1.5 years.

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***Restricted Stock Units (RSUs) and Performance Stock Units*** <br>***(PSUs) Activity*** | ***Restricted Stock Units (RSUs) and Performance Stock Units*** <br>***(PSUs) Activity*** | ***Restricted Stock Units (RSUs) and Performance Stock Units*** <br>***(PSUs) Activity*** | ***Restricted Stock Units (RSUs) and Performance Stock Units*** <br>***(PSUs) Activity*** | ***Restricted Stock Units (RSUs) and Performance Stock Units*** <br>***(PSUs) Activity*** |
|  | **Shares**<br>**(in millions)** | **Shares**<br>**(in millions)** | **Weighted-Average**<br>**Grant Date Fair Value** | **Weighted-Average**<br>**Grant Date Fair Value** |
|  | **RSUs** | **PSUs** | **RSUs** | **PSUs** |
| **Nonvested on January 1** | **0.7** | **0.2** | **$290.58** | **$287.51** |
| Granted | 0.3 | 0.1 | 385.68 | 334.24 |
| Vested | (0.3) | (0.1) | 277.40 | 254.47 |
| Canceled or forfeited | (0.1) |  | 337.17 |  |
| **Nonvested on December 31** | **0.6** | **0.2** | **$344.25** | **$333.06** |

---

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **40** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

On December 31, 2025 there was $100 of unrecognized

compensation cost related to nonvested RSUs. That cost is

expected to be recognized as expense over the weighted-

average period of approximately one year. The weighted-average

grant date fair value per share of RSUs granted was $385.68 and

$332.64 in 2025 and 2024. The fair value of RSUs and PSUs

vested in 2025 was $91 and $26. On December 31, 2025 there

was $26 of unrecognized compensation cost related to

nonvested PSUs. That cost is expected to be recognized as

expense over the weighted-average period of approximately one

year.

**Employee Stock Purchase Plans (ESPP)**

Employees may participate in our ESPP provided they meet

certain eligibility requirements. The purchase price for our

common stock under the terms of the ESPP is defined as 95% of

the closing stock price on the last trading day of a purchase

period. We issued 178,090 and 173,708 shares under the ESPP

in 2025 and 2024.

**NOTE 10 - DEBT AND CREDIT FACILITIES**

We have lines of credit issued by various financial institutions that

are available to fund our day-to-day operating needs. Certain of

our credit facilities require us to comply with financial and other

covenants. We were in compliance with all covenants on

December 31, 2025.

In February 2025 we entered into a new revolving credit

agreement that replaces our previous agreement dated October

2021. The primary changes included increasing the aggregate

principal amount of the facility by $750 to $3,000 and extending

the maturity date to February 25, 2030. On December 31, 2025

there were no borrowings outstanding under our revolving credit

facility or our commercial paper program which allows for

maturities up to 397 days from the date of issuance. The

maximum amount of our commercial paper that can be

outstanding at any time is $3,000.

In February 2025 we issued $500 of 4.550% senior unsecured

notes due February 10, 2027, $700 of 4.700% senior unsecured

notes due February 10, 2028, $800 of 4.850% senior unsecured

notes due February 10, 2030 and $1,000 of 5.200% senior

unsecured notes due February 10, 2035. In June 2025 we repaid

$650 of 1.150% senior unsecured notes. In November 2025 we

repaid $750 of 3.375% senior unsecured notes. The following

table summarizes our total debt at December 31:

---

| | | | |
|:---|:---|:---|:---|
| ***Summary of Total Debt*** | ***Summary of Total Debt*** |  |  |
| **Rate** | **Due** | **2025** | **2024** |
| Senior unsecured notes: | Senior unsecured notes: |  |  |
| 1.150% | June 15, 2025 | $— | $649 |
| 3.375% | November 1, 2025 |  | 750 |
| 3.500% | March 15, 2026 | 1000 | 998 |
| 4.550% | February 10, 2027 | 498 |  |
| 2.125% | November 30, 2027 | 881 | 777 |
| 4.700% | February 10, 2028 | 697 |  |
| 3.650% | March 7, 2028 | 599 | 598 |
| 4.850% | December 8, 2028 | 597 | 596 |
| 3.375% | December 11, 2028 | 704 | 621 |
| 0.750% | March 1, 2029 | 939 | 828 |
| 4.250% | September 11, 2029 | 744 | 743 |
| 4.850% | February 10, 2030 | 794 |  |
| 1.950% | June 15, 2030 | 995 | 993 |
| 2.625% | November 30, 2030 | 759 | 669 |
| 1.000% | December 3, 2031 | 876 | 772 |
| 3.375% | September 11, 2032 | 934 | 824 |
| 4.625% | September 11, 2034 | 741 | 740 |
| 5.200% | February 10, 2035 | 990 |  |
| 3.625% | September 11, 2036 | 695 | 613 |
| 4.100% | April 1, 2043 | 393 | 393 |
| 4.375% | May 15, 2044 | 396 | 396 |
| 4.625% | March 15, 2046 | 984 | 984 |
| 2.900% | June 15, 2050 | 643 | 643 |
| Other | Other |  | 10 |
| **Total debt** | **Total debt** | **$15859** | **$13597** |
| Less current maturities | Less current maturities | 1000 | 1409 |
| **Total long-term debt** | **Total long-term debt** | **$14859** | **$12188** |
| Unamortized debt issuance costs | Unamortized debt issuance costs | $70 | $63 |
| Borrowing capacity on existing facilities | Borrowing capacity on existing facilities | $2911 | $2160 |
| Fair value of senior unsecured notes | Fair value of senior unsecured notes | $15344 | $12780 |

---

The fair value of the senior unsecured notes was estimated using

quoted interest rates, maturities and amounts of borrowings

based on quoted active market prices and yields that took into

account the underlying terms of the debt instruments.

Substantially all of our debt is classified within Level 2 of the fair

value hierarchy.

Interest expense on outstanding debt and credit facilities,

including required fees incurred totaled $582, $396 and $356 in

2025, 2024 and 2023.

**NOTE 11 - INCOME TAXES**

On January 1, 2025 we prospectively adopted ASU 2023-09

(Topic 740): *Income Taxes: Improvements to Income Tax*

*Disclosures* which expands the existing rules on income tax

disclosures. This update requires entities to disclose specific

categories in the tax rate reconciliation, provide additional

information for reconciling items that meet a quantitative

threshold and disclose additional information about income taxes

paid on an annual basis. In determining the reconciling items we

considered the effect of tax rulings as part of the statutory tax

rate.

Our effective tax rate was 28.1%, 14.3% and 13.8% for 2025,

2024 and 2023. The effective income tax rate for 2025 increased

from 2024 due to the 2025 tax effect of transfers of intellectual

property between tax jurisdictions and the 2024 tax effect of the

sale of the Spinal Implants business. The effective income tax

rate for 2024 increased from 2023 due to the 2023 tax effect of

transfers of intellectual property between tax jurisdictions offset

by the 2024 tax effect of the sale of the Spinal Implants business.

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **41** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

---

| | | |
|:---|:---|:---|
| ***Effective Income Tax Rate Reconciliation*** | ***Effective Income Tax Rate Reconciliation*** | ***Effective Income Tax Rate Reconciliation*** |
|  | **2025** | **2025** |
|  | **Amount** | **Percent** |
| **United States federal statutory rate** | $948 | 21.0% |
| **State and Local Income Taxes, Net of Federal Income Tax** <br>**Effect**<sup>(1)</sup><br>| 173 | 3.8 |
| **Foreign Tax Effects** |  |  |
| Ireland |  |  |
| Statutory tax rate difference | (177) | (3.9) |
| Other | 17 | 0.4 |
| Puerto Rico |  |  |
| Statutory tax rate difference | (49) | (1.1) |
| Withholding Tax | 60 | 1.3 |
| Expiration of credits carryforward | 78 | 1.7 |
| Change in valuation allowance | (78) | (1.7) |
| Other | (4) | (0.1) |
| Other foreign jurisdictions | 20 | 0.4 |
| **Effect of changes in tax laws or rates enacted in the current** <br>**period**<br>|  |  |
| **Effect of Cross-Border Tax Laws** |  |  |
| Direct foreign tax credits | (90) | (2.0) |
| Global intangible low-taxed income | 70 | 1.6 |
| **Tax Credits** |  |  |
| Research and development tax credits | (53) | (1.2) |
| **Changes in Valuation Allowances** |  |  |
| **Nontaxable or Nondeductible Items** |  |  |
| Spinal Implants divestiture | (51) | (1.1) |
| Transfers of intellectual property | 405 | 9.0 |
| **Changes in unrecognized Tax Benefits** | 17 | 0.4 |
| **Other Adjustments** | (18) | (0.4) |
| **Effective Tax Rate** | **$1268** | **28.1%** |

---

<sup>(1)</sup> State taxes in Pennsylvania, New York, Illinois, Florida, California, Michigan,

Indiana, and Tennessee accounted for the majority (greater than 50%) of the tax

effect in this category.

---

| | | |
|:---|:---|:---|
| ***Effective Income Tax Rate Reconciliation*** | ***Effective Income Tax Rate Reconciliation*** | ***Effective Income Tax Rate Reconciliation*** |
|  | **2024** | **2023** |
| **United States federal statutory rate** | **21.0%** | **21.0%** |
| United States state and local income taxes, less federal <br>deduction<br>| 1.1 | 1.1 |
| Foreign income tax at rates other than 21% | (4.1) | (6.8) |
| Tax related to repatriation of foreign earnings | 0.3 | 1.2 |
| United States research and development credits | (1.4) | (1.2) |
| Intellectual property transfers |  | (3.3) |
| Goodwill impairment | 2.8 |  |
| Outside basis difference related to the anticipated sale of <br>the Spinal Implants business<br>| (4.9) |  |
| Other | (0.5) | 1.8 |
| **Effective income tax rate** | **14.3%** | **13.8%** |

---

---

| | |
|:---|:---|
| ***Cash paid for income taxes (net of refunds received)*** | ***Cash paid for income taxes (net of refunds received)*** |
|  | **2025** |
| **United States - Federal** | 533 |
| **United States - State** | 71 |
| **Foreign** |  |
| Ireland | 175 |
| Other | 223 |
| Subtotal | 398 |
| **Total** | **$1002** |

---

---

| | | | |
|:---|:---|:---|:---|
| ***Earnings Before Income Taxes***  | ***Earnings Before Income Taxes***  | ***Earnings Before Income Taxes***  | ***Earnings Before Income Taxes***  |
|  | **2025** | **2024** | **2023** |
| United States | $1434 | $523 | $701 |
| International | 3080 | 2969 | 2972 |
| **Total** | **$4514** | **$3492** | **$3673** |

---

---

| | | | |
|:---|:---|:---|:---|
| ***Components of Income Tax Expense (Benefit)*** | ***Components of Income Tax Expense (Benefit)*** | ***Components of Income Tax Expense (Benefit)*** | ***Components of Income Tax Expense (Benefit)*** |
| **Current income tax expense (benefit):** | **2025** | **2024** | **2023** |
| United States federal | $414 | $490 | $236 |
| United States state and local | 149 | 90 | 48 |
| International | 313 | 289 | 430 |
| **Total current income tax expense** | **$876** | **$869** | **$714** |
| **Deferred income tax expense (benefit):** |  |  |  |
| United States federal | $186 | $(462) | $(212) |
| United States state and local | 78 | (76) | (20) |
| International | 128 | 168 | 26 |
| **Total deferred income tax expense (benefit)** | **$392** | **$(370)** | **$(206)** |
| **Total income tax expense** | **$1268** | **$499** | **$508** |

---

Interest included in interest expense was $18, $13, and $1 in

2025, 2024 and 2023. The United States federal deferred income

tax expense (benefit) includes the utilization of net operating loss

carryforwards of $32, $9 and $189 in 2025, 2024 and 2023.

---

| | | |
|:---|:---|:---|
| ***Deferred Income Tax Assets and Liabilities*** | ***Deferred Income Tax Assets and Liabilities*** | ***Deferred Income Tax Assets and Liabilities*** |
| **Deferred income tax assets:** | **2025** | **2024** |
| Inventories | $553 | $551 |
| Other accrued expenses | 401 | 207 |
| Depreciation and amortization | 546 | 715 |
| State income taxes | 90 | 167 |
| Share-based compensation | 117 | 100 |
| Research and development capitalization | 40 | 408 |
| International interest expense carryforwards | 56 | 52 |
| Net operating loss and credit carryforwards | 315 | 410 |
| Outside basis difference related to the anticipated sale of <br>the Spinal Implants business<br>|  | 170 |
| Other | 352 | 310 |
| **Total deferred income tax assets** | **$2470** | **$3090** |
| Less valuation allowances | (148) | (228) |
| **Net deferred income tax assets** | **$2322** | **$2862** |
| **Deferred income tax liabilities:** |  |  |
| Depreciation and amortization | $(1222) | $(1141) |
| Undistributed earnings | (139) | (61) |
| **Total deferred income tax liabilities** | **$(1361)** | **$(1202)** |
| **Net deferred income tax assets** | **$961** | **$1660** |
| **Reported as:** |  |  |
| Noncurrent deferred income tax assets | $1098 | $1742 |
| Noncurrent liabilities—Other liabilities | (137) | (82) |
| **Total** | **$961** | **$1660** |

---

Accrued interest was $96 and $71 on December 31, 2025 and

2024 which was reported in accrued expenses and other

liabilities and other noncurrent liabilities.

United States federal loss carryforwards of $271, with $57 of

associated deferred tax asset and with $2 being subject to a

valuation allowance, begin to expire in 2026. United States state

loss carryforwards of $1,606, with $64 associated deferred tax

asset and with $33 being subject to a valuation allowance, begin

to expire in 2026. International loss carryforwards of $309, with

$67 of associated deferred tax asset and with $61 being subject

to a valuation allowance, begin to expire in 2026; however, some

have no expiration. We also have tax credit carryforwards of

$141 with $4 being subject to a full valuation allowance. The

credits with a full valuation allowance begin to expire in 2026.

We recorded deferred income tax on undistributed earnings of

foreign subsidiaries not determined to be indefinitely reinvested.

The amount of undistributed earnings of foreign subsidiaries

determined to be indefinitely reinvested at December 31, 2025

was approximately $11.7 billion. Determination of the total

amount of unrecognized deferred income tax on undistributed

earnings of foreign subsidiaries is not practicable.

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **42** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

---

| | | |
|:---|:---|:---|
| ***Uncertain Income Tax Positions*** | ***Uncertain Income Tax Positions*** | ***Uncertain Income Tax Positions*** |
|  | **2025** | **2024** |
| **Beginning uncertain tax positions** | **$349** | **$371** |
| Increases related to current year income tax positions | 19 | 18 |
| Increases related to prior year income tax positions | 12 |  |
| Decreases related to prior year income tax positions |  | (4) |
| Settlements of income tax audits |  | (21) |
| Statute of limitations expirations and other | (4) | (3) |
| Foreign currency translation | 27 | (12) |
| **Ending uncertain tax positions** | **$403** | **$349** |
| **Reported as:** |  |  |
| Noncurrent liabilities—Income taxes | $403 | $349 |

---

Our income tax expense would have been reduced by $279 and

$224 in 2025 and 2024 had our uncertain income tax positions

been favorably resolved. It is reasonably possible that the

amount of unrecognized tax benefits will significantly change due

to one or more of the following events in the next 12 months:

expiring statutes, audit activity, tax payments, competent

authority proceedings related to transfer pricing or final decisions

in matters that are the subject of controversy in various taxing

jurisdictions in which we operate, including inventory transfer

pricing, cost sharing, product royalty and foreign branch

arrangements. We are not able to reasonably estimate the

amount or the future periods in which changes in unrecognized

tax benefits may be resolved. Interest incurred associated with

uncertain tax positions is included in interest expense.

Income tax authorities in various jurisdictions globally conduct

routine audits of our income tax returns to determine if they agree

with our interpretations of income tax regulations. Any audit

assessment, draft audit assessment, or final audit report received

is reviewed for new information and evaluated for proper financial

statement treatment. We received a final audit report and

assessments from the German Federal Central Tax Office

(FCTO) related to the years 2010 through 2017 of $754 and

expect to receive additional assessments of $11 based on the

final audit report. We intend to defend our filing positions through

the FCTO independent appeals process and/or litigation as

necessary. If the resolution of this matter results in additional

German income taxes, we expect to pursue a claim for

associated foreign tax credits. Our unrecognized tax benefits

associated with this matter remain unchanged from 2024.

Income tax years are open from 2019 through 2025 for the

United States federal jurisdiction and are open for other major

jurisdictions from 2010 through 2025.

**NOTE 12 - RETIREMENT PLANS**

**Defined Contribution Plans**

We provide certain employees with defined contribution plans

and other types of retirement plans. A portion of our retirement

plan expense under the defined contribution plans is funded with

Stryker common stock. The use of Stryker common stock

represents a non-cash operating activity that is not reflected in

our Consolidated Statements of Cash Flows.

---

| | | | |
|:---|:---|:---|:---|
|  | **2025** | **2024** | **2023** |
| Plan expense | $399 | $376 | $327 |
| Expense funded with Stryker common stock | 72 | 62 | 57 |
| **Stryker common stock held by plan:** |  |  |  |
| Dollar amount | $763 | $781 | $649 |
| Shares (in millions) | 2.2 | 2.2 | 2.2 |
| Value as a percentage of total plan assets | 8% | 10% | 10% |

---

**Defined Benefit Plans**

Certain of our subsidiaries have both funded and unfunded

defined benefit pension plans covering some or all of their

employees. The majority of our defined benefit pension plans

have projected benefit obligations in excess of plan assets.

**Discount Rate**

The discount rates were selected using a hypothetical portfolio of

high quality bonds on December 31 that would provide the

necessary cash flows to match our projected benefit payments.

**Expected Return on Plan Assets**

The expected return on plan assets is determined by applying the

target allocation in each asset category of plan investments to the

anticipated return for each asset category based on historical and

projected returns.

---

| | | | |
|:---|:---|:---|:---|
| ***Components of Net Periodic Pension Cost*** | ***Components of Net Periodic Pension Cost*** | ***Components of Net Periodic Pension Cost*** | ***Components of Net Periodic Pension Cost*** |
| **Net periodic benefit cost:** | **2025** | **2024** | **2023** |
| Service cost | $(42) | $(39) | $(32) |
| Interest cost | (24) | (21) | (23) |
| Expected return on plan assets | 22 | 19 | 18 |
| Amortization of prior service credit | 2 | 1 | 1 |
| Recognized actuarial gain (loss) | (2) | (1) | 4 |
| **Net periodic benefit cost** | **$(44)** | **$(41)** | **$(32)** |
| **Changes in assets and benefit obligations** <br>**recognized in OCI:**<br>|  |  |  |
| Net actuarial gain (loss) | $93 | $43 | $(67) |
| Recognized net actuarial (gain) loss | 2 | 1 | (4) |
| Prior service credit and transition amount | (2) | (1) | (1) |
| **Total recognized in other comprehensive** <br>**income (loss)**<br>| **$93** | **$43** | **$(72)** |
| **Total recognized in net periodic benefit cost** <br>**and OCI**<br>| **$49** | **$2** | **$(104)** |
| **Weighted-average rates used to determine net** <br>**periodic benefit cost:**<br>|  |  |  |
| Discount rate | 2.9% | 2.8% | 3.3% |
| Expected return on plan assets | 4.1% | 4.3% | 4.2% |
| Rate of compensation increase | 2.9% | 3.0% | 3.0% |
| Weighted-average discount rate used to <br>determine projected benefit obligations<br>| 3.6% | 2.9% | 2.8% |

---

The actuarial gain (loss) for all pension plans was primarily

related to a change in the discount rate used to measure the

benefit obligations of those plans.

**Investment Strategy**

The investment strategy for our defined benefit pension plans is

to meet the liabilities of the plans as they fall due and to

maximize the return on invested assets within appropriate risk

tolerances.

---

| | | |
|:---|:---|:---|
|  | **2025** | **2024** |
| Fair value of plan assets | $560 | $492 |
| Benefit obligations | (829) | (782) |
| **Funded status** | **$(269)** | **$(290)** |
| **Reported as:** |  |  |
| Noncurrent assets—other assets | $72 | $48 |
| Current liabilities—accrued compensation | (5) | (3) |
| Noncurrent liabilities—other liabilities | (336) | (335) |
| **Pre-tax amounts recognized in AOCI:** |  |  |
| Unrecognized net actuarial gain (loss) | 101 | 6 |
| Unrecognized prior service credit | 8 | 8 |
| **Total** | **$109** | **$14** |

---

---

| | | |
|:---|:---|:---|
| ***Change in Benefit Obligations*** |  |  |
|  | **2025** | **2024** |
| **Beginning projected benefit obligations** | **$782** | **$826** |
| Service cost | 42 | 39 |
| Interest cost | 24 | 21 |
| Foreign exchange impact and other | 114 | (52) |
| Employee contributions | 9 | 7 |
| Actuarial (gains) losses | (116) | (40) |
| Benefits paid | (26) | (19) |
| **Ending projected benefit obligations** | **$829** | **$782** |
| **Ending accumulated benefit obligations** | **$786** | **$748** |

---

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **43** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

---

| | | |
|:---|:---|:---|
| ***Change in Plan Assets*** |  |  |
|  | **2025** | **2024** |
| **Beginning fair value of plan assets** | **$492** | **$485** |
| Actual return | (3) | 22 |
| Employer contributions | 23 | 23 |
| Employee contributions | 9 | 7 |
| Foreign exchange impact | 60 | (31) |
| Benefits paid | (21) | (14) |
| **Ending fair value of plan assets** | **$560** | **$492** |

---

---

| | | | |
|:---|:---|:---|:---|
| ***Allocation of Plan Assets*** | ***Allocation of Plan Assets*** | ***Allocation of Plan Assets*** | ***Allocation of Plan Assets*** |
|  | **2026 Target** | **2025 Actual** | **2024 Actual** |
| Equity securities | 26% | 32% | 28% |
| Debt securities | 41 | 39 | 40 |
| Other | 33 | 29 | 32 |
| **Total** | **100%** | **100%** | **100%** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***Valuation of Plan Assets***  | ***Valuation of Plan Assets***  | ***Valuation of Plan Assets***  | ***Valuation of Plan Assets***  | ***Valuation of Plan Assets***  |
| **2025** | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Cash and cash equivalents | $16 | $— | $— | $16 |
| Equity securities | 9 | 162 |  | 171 |
| Debt securities | 2 | 230 |  | 232 |
| Other | 4 | 83 | 54 | 141 |
| **Total** | **$31** | **$475** | **$54** | **$560** |
| **2024** | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Cash and cash equivalents | $17 | $— | $— | $17 |
| Equity securities | 8 | 125 |  | 133 |
| Debt securities | 2 | 203 |  | 205 |
| Other | 4 | 76 | 57 | 137 |
| **Total** | **$31** | **$404** | **$57** | **$492** |

---

Our Level 3 pension plan assets primarily include guaranteed

investment contracts with insurance companies. The insurance

contracts guarantee us principal repayment and a fixed rate of

return. The $3 decrease in Level 3 pension plan assets is

primarily driven by the change in the corresponding pension

liability. We expect to contribute $24 to our defined benefit

pension plans in 2026.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| ***Estimated Future Benefit Payments*** | ***Estimated Future Benefit Payments*** | ***Estimated Future Benefit Payments*** | ***Estimated Future Benefit Payments*** | ***Estimated Future Benefit Payments*** | ***Estimated Future Benefit Payments*** |
| **2026** | **2027** | **2028** | **2029** | **2030** | **2031-2035** |
| $29 | $32 | $33 | $34 | $38 | $223 |

---

**NOTE 13 - SUMMARY OF QUARTERLY DATA (UNAUDITED)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **2025 Quarters** | **Mar 31** | **Jun 30** | **Sep 30** | **Dec 31** |
| **Net sales** | **$5866** | **$6022** | **$6057** | **$7171** |
| Gross profit | 3744 | 3841 | 3852 | 4628 |
| Earnings before income taxes | 764 | 1016 | 1029 | 1705 |
| **Net earnings** | **654** | **884** | **859** | **849** |
| **Net earnings per share of common stock:** | **Net earnings per share of common stock:** | **Net earnings per share of common stock:** |  |  |
| Basic | $1.71 | $2.32 | $2.25 | $2.21 |
| Diluted | $1.69 | $2.29 | $2.22 | $2.20 |
| Dividends declared per share of <br>common stock<br>| $0.84 | $0.84 | $0.84 | $0.88 |
| **2024 Quarters** | **Mar 31** | **Jun 30** | **Sep 30** | **Dec 31** |
| **Net sales** | **$5243** | **$5422** | **$5494** | **$6436** |
| Gross profit | 3333 | 3416 | 3517 | 4174 |
| Earnings before income taxes | 923 | 998 | 1043 | 528 |
| **Net earnings** | **788** | **825** | **834** | **546** |
| **Net earnings per share of common stock:** | **Net earnings per share of common stock:** | **Net earnings per share of common stock:** |  |  |
| Basic | $2.07 | $2.17 | $2.18 | $1.43 |
| Diluted | $2.05 | $2.14 | $2.16 | $1.41 |
| Dividends declared per share of <br>common stock<br>| $0.80 | $0.80 | $0.80 | $0.84 |

---

**NOTE 14 - SEGMENT AND GEOGRAPHIC DATA**

We segregate our operations into two reportable business

segments: (i) MedSurg and Neurotechnology and (ii)

Orthopaedics which aligns to our internal reporting structure and

how our Chief Operating Decision Maker (CODM) assesses

performance and allocates resources. The CODM is the Chief

Executive Officer. The CODM makes decisions on resource

allocation, assesses performance of the business, and monitors

budget versus actual results using segment operating income.

The Corporate and Other category shown in the table below

includes corporate and administration, corporate initiatives and

share-based compensation, which includes compensation related

to employee stock options, restricted stock units and

performance stock unit grants and director stock options and

restricted stock unit grants.

---

| | | | |
|:---|:---|:---|:---|
| ***Segment Results*** | **2025** | **2024** | **2023** |
| MedSurg and Neurotechnology | $15647 | $13518 | $12163 |
| Orthopaedics | $9469 | 9077 | 8335 |
| **Net sales** | **$25116** | **$22595** | **$20498** |
| MedSurg and Neurotechnology | $5859 | $5320 | $4876 |
| Orthopaedics | $2570 | 2400 | 2254 |
| **Cost of sales**  | **$8429** | **$7720** | **$7130** |
| MedSurg and Neurotechnology | $948 | $784 | $702 |
| Orthopaedics | $524 | 540 | 508 |
| **Segment research, development and** <br>**engineering expenses**<br>| **$1472** | **$1324** | **$1210** |
| MedSurg and Neurotechnology | $3931 | $3203 | $2934 |
| Orthopaedics | $3132 | 3111 | 2922 |
| **Segment selling, general and administrative** <br>**expenses** <br>| **$7063** | **$6314** | **$5856** |
| MedSurg and Neurotechnology | $237 | $208 | $181 |
| Orthopaedics | 423 | 433 | 386 |
| **Segment depreciation and amortization**  | **$660** | **$641** | **$567** |
| Corporate and Other | 178 | 162 | 139 |
| Amortization of intangible assets | 732 | 623 | 635 |
| **Total depreciation and amortization** | **$1570** | **$1426** | **$1341** |
| MedSurg and Neurotechnology | $4672 | $4004 | $3470 |
| Orthopaedics | 2820 | 2591 | 2265 |
| **Segment operating income** | **$7492** | **$6595** | **$5735** |
| **Items not allocated to segments:** |  |  |  |
| Corporate and Other | $(889) | $(880) | $(780) |
| Inventory stepped up to fair value | (173) | (46) |  |
| Acquisition and integration-related charges | (335) | (108) | (20) |
| Amortization of intangible assets | (732) | (623) | (635) |
| Structural optimization and other special <br>charges<br>| (191) | (138) | (170) |
| Goodwill and other impairments | (170) | (977) | (36) |
| Medical device regulation | (38) | (58) | (96) |
| Recall-related matters | (58) | (40) | (18) |
| Regulatory and legal matters | (17) | (36) | (92) |
| **Consolidated operating income** | **$4889** | **$3689** | **$3888** |

---

---

| | | | |
|:---|:---|:---|:---|
| ***Segment Assets and Capital Spending*** | ***Segment Assets and Capital Spending*** | ***Segment Assets and Capital Spending*** | ***Segment Assets and Capital Spending*** |
| **Assets:** | **2025** | **2024** |  |
| MedSurg and Neurotechnology | $27647 | $23115 |  |
| Orthopaedics | 18641 | 18507 |  |
| **Total segment assets** | **$46288** | **$41622** |  |
| Corporate and Other | 1556 | 1349 |  |
| **Total assets** | **$47844** | **$42971** |  |
| **Purchases of property, plant and** <br>**equipment:**<br>| **2025** | **2024** | **2023** |
| Orthopaedics | $296 | $230 | $179 |
| MedSurg and Neurotechnology | 220 | 276 | 183 |
| **Total segment purchases of property,** <br>**plant and equipment**<br>| **$516** | **$506** | **$362** |
| Corporate and Other | 245 | 249 | 213 |
| **Total purchases of property, plant and** <br>**equipment**<br>| **$761** | **$755** | **$575** |

---

We measure the financial results of our reportable segments

using an internal performance measure that excludes acquisition

and integration-related charges, structural optimization and other

special charges, goodwill and other impairments, reserves for

certain product recall matters and reserves for certain legal and

regulatory matters. Identifiable assets are those assets used

exclusively in the operations of each business segment or

allocated when used jointly. Corporate assets are principally

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **44** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

property, plant and equipment and noncurrent assets.

The countries in which we have local revenue generating

operations have been combined into the following geographic

areas: the United States; Europe, Middle East, Africa; Asia

Pacific; and other foreign countries, which include Canada and

countries in the Latin American region. Net sales are reported

based on the geographic area of the Stryker location where the

sales to the customer originated.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| ***Geographic Information*** | ***Geographic Information*** | ***Geographic Information*** | ***Geographic Information*** | ***Geographic Information*** | ***Geographic Information*** |
|  | **Net Sales** | **Net Sales** | **Net Sales** | **Net Property, Plant** <br>**and Equipment** | **Net Property, Plant** <br>**and Equipment** |
|  | **2025** | **2024** | **2023** | **2025** | **2024** |
| United States | $19006 | $16943 | $15257 | $2084 | $1997 |
| Europe, Middle <br>East, Africa<br>| 3181 | 2897 | 2618 | 1562 | 1260 |
| Asia Pacific | 2164 | 2020 | 1946 | 97 | 75 |
| Other countries | 765 | 735 | 677 | 133 | 116 |
| Total | **$25116** | **$22595** | **$20498** | **$3876** | **$3448** |

---

**NOTE 15 - ASSET IMPAIRMENTS**

During 2025, 2024 and 2023 we recorded impairment charges of

$109, $159 and $36 to write off long-lived and intangible assets

excluding long-lived assets held for sale which included charges

related to certain product line exits.

**NOTE 16 - SALE OF SPINAL IMPLANTS BUSINESS**

During the fourth quarter 2024 management committed to a plan

to sell certain assets associated with the Spinal Implants

business (disposal group) and such assets were classified as

held for sale beginning November 2024. As a result we recorded

a valuation allowance of $362 to record the disposal group at its

fair value less cost to sell within goodwill and other impairments

in our Consolidated Statements of Earnings.

In April 2025 we completed the sale of the disposal group to the

Viscogliosi Brothers, LLC. In the first half of 2025 we recognized

immaterial impairment charges to record the disposal group at its

fair value less cost to sell within goodwill and other impairments

in our Consolidated Statements of Earnings. The fair value of the

disposal group and consideration received was measured using a

discounted cash flow analysis based upon the selling price and

unobservable inputs, such as market conditions and the rate

used to discount the estimated future cash flows to their present

value based on factors including the disposal group's cost of

equity and market yield rates, which are Level 3 inputs.

Consideration could increase by up to $57 or decrease by up to

$245 based on the amount received.

The assets associated with the disposal group are reported in our

Orthopaedics segment at December 31, 2024. The assets and

liabilities held for sale at December 31, 2024 are classified within

prepaid expenses and other current assets and accrued

expenses and other liabilities in our Consolidated Balance

Sheets. The assets and liabilities of the disposal group at the

date of sale and at December 31, 2024 were as follows:

---

| | | |
|:---|:---|:---|
|  | <br>**Date of Sale**<br>**2025** | **Held for Sale**<br>**December 31**<br>**2024** |
| Accounts receivable, net | $56 | $62 |
| Total inventories  | 195 | 183 |
| Prepaid expenses and other current assets  | 27 | 10 |
| Property, plant and equipment, net  | 53 | 51 |
| Other intangibles, net  | 323 | 326 |
| Noncurrent deferred income tax assets  | 9 | 9 |
| Other noncurrent assets  | 179 | 171 |
| Valuation allowance  | (395) | (362) |
| **Total assets** | **$447** | **$450** |
| Accounts payable  | $41 | $28 |
| Accrued compensation  | 20 | 26 |
| Accrued expenses and other liabilities  | 24 | 29 |
| Other noncurrent liabilities  | 27 | 21 |
| **Total liabilities** | **$112** | **$104** |

---

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **45** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

---

| | |
|:---|:---|
| **ITEM 9.** | **CHANGES IN AND DISAGREEMENTS WITH** <br>**ACCOUNTANTS ON ACCOUNTING AND** <br>**FINANCIAL DISCLOSURE.**<br>|

---

Not applicable.

---

| | |
|:---|:---|
| **ITEM 9A.** | **CONTROLS AND PROCEDURES.** |

---

**Evaluation of Disclosure Controls and Procedures**

The Company's management, with the participation of the Chief

Executive Officer and Chief Financial Officer (the Certifying

Officers), evaluated the effectiveness of the Company's

disclosure controls and procedures (as defined in Rules

13a-15(e) or 15d-15(e) promulgated under the Securities

Exchange Act of 1934, as amended) (Exchange Act) as of

December 31, 2025. Based on that evaluation, the Certifying

Officers concluded that the Company's disclosure controls and

procedures were effective as of December 31, 2025.

**Changes in Internal Control over Financial Reporting**

There was no change in our internal control over financial

reporting during the fourth quarter of 2025 that materially

affected, or is reasonably likely to materially affect, our internal

control over financial reporting.

**Management's Report on Internal Control Over Financial**

**Reporting**

The Company's management is responsible for establishing and

maintaining adequate internal control over financial reporting, as

such term is defined in Exchange Act Rule 13a-15(f). The

Company's internal control over financial reporting was designed

to provide reasonable assurance to the Company's management

and Board of Directors regarding the reliability of financial

reporting and the preparation of financial statements for external

purposes in accordance with generally accepted accounting

principles and includes those policies and procedures that: (i)

pertain to the maintenance of records that in reasonable detail

accurately and fairly reflect the transactions and dispositions of

the assets of the Company; (ii) provide reasonable assurance

that transactions are recorded as necessary to permit preparation

of financial statements in accordance with generally accepted

accounting principles, and that receipts and expenditures of the

Company are being made only in accordance with authorizations

of management and directors of the Company; and (iii) provide

reasonable assurance regarding prevention or timely detection of

unauthorized acquisition, use or disposition of the Company's

assets that could have a material effect on the financial

statements.

The Company's management assessed the effectiveness of our

internal control over financial reporting on December 31, 2025. In

making this assessment, we used the criteria set forth by the

Committee of Sponsoring Organizations of the Treadway

Commission in *Internal Control—Integrated Framework (2013)*.

We have excluded from our assessment the operations and

related assets of Inari, which we acquired in February 2025. As of

December 31, 2025 Inari represented approximately 10% of our

total assets, including the goodwill and intangible assets recorded

as part of the purchase price allocation, and approximately 2.3%

of our net sales for the year ended December 31, 2025. Based

on its assessment, management concluded that our internal

control over financial reporting was effective as of December 31,

2025. Stryker's independent registered public accounting firm has

issued an audit report on their assessment of the effectiveness of

the Company's internal control over financial reporting.

**Report of Independent Registered Public Accounting Firm**

To the Shareholders and the Board of Directors of Stryker

Corporation

**Opinion on Internal Control Over Financial Reporting**

We have audited Stryker Corporation and subsidiaries' internal

control over financial reporting as of December 31, 2025, based

on criteria established in Internal Control—Integrated Framework

issued by the Committee of Sponsoring Organizations of the

Treadway Commission (2013 framework) (the COSO criteria). In

our opinion, Stryker Corporation and subsidiaries (the Company)

maintained, in all material respects, effective internal control over

financial reporting as of December 31, 2025, based on the COSO

criteria.

As indicated in the accompanying Management's Annual Report

on Internal Control Over Financial Reporting, management's

assessment of and conclusion on the effectiveness of internal

control over financial reporting did not include the internal

controls of Inari Medical, Inc. (Inari), which is included in the 2025

consolidated financial statements of the Company and

constituted 10% of total assets as of December 31, 2025 and

2.3% of net sales for the year then ended. Our audit of internal

control over financial reporting of the Company also did not

include an evaluation of the internal control over financial

reporting of Inari.

We also have audited, in accordance with the standards of the

Public Company Accounting Oversight Board (United States)

(PCAOB), the 2025 consolidated financial statements of the

Company and our report dated February 11, 2026 expressed an

unqualified opinion thereon.

**Basis for Opinion**

The Company's management is responsible for maintaining

effective internal control over financial reporting and for its

assessment of the effectiveness of internal control over financial

reporting included in the accompanying Management's Report on

Internal Control Over Financial Reporting. Our responsibility is to

express an opinion on the Company's internal control over

financial reporting based on our audit. We are a public

accounting firm registered with the PCAOB and are required to

be independent with respect to the Company in accordance with

the U.S. federal securities laws and the applicable rules and

regulations of the Securities and Exchange Commission and the

PCAOB.

We conducted our audit in accordance with the standards of the

PCAOB. Those standards require that we plan and perform the

audit to obtain reasonable assurance about whether effective

internal control over financial reporting was maintained in all

material respects.

Our audit included obtaining an understanding of internal control

over financial reporting, assessing the risk that a material

weakness exists, testing and evaluating the design and operating

effectiveness of internal control based on the assessed risk, and

performing such other procedures as we considered necessary in

the circumstances. We believe that our audit provides a

reasonable basis for our opinion.

**Definition and Limitations of Internal Control Over Financial**

**Reporting**

A company's internal control over financial reporting is a process

designed to provide reasonable assurance regarding the

reliability of financial reporting and the preparation of financial

statements for external purposes in accordance with generally

accepted accounting principles. A company's internal control over

financial reporting includes those policies and procedures that (1)

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **46** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

pertain to the maintenance of records that, in reasonable detail,

accurately and fairly reflect the transactions and dispositions of

the assets of the company; (2) provide reasonable assurance

that transactions are recorded as necessary to permit preparation

of financial statements in accordance with generally accepted

accounting principles, and that receipts and expenditures of the

company are being made only in accordance with authorizations

of management and directors of the company; and (3) provide

reasonable assurance regarding prevention or timely detection of

unauthorized acquisition, use, or disposition of the company's

assets that could have a material effect on the financial

statements.

Because of its inherent limitations, internal control over financial

reporting may not prevent or detect misstatements. Also,

projections of any evaluation of effectiveness to future periods

are subject to the risk that controls may become inadequate

because of changes in conditions, or that the degree of

compliance with the policies or procedures may deteriorate.

/s/&nbsp;&nbsp;&nbsp;&nbsp;Ernst & Young LLP

Grand Rapids, Michigan

February 11, 2026

---

| | |
|:---|:---|
| **ITEM 9B.** | **OTHER INFORMATION.** |

---

**Trading Plan Arrangements**

Certain of our officers or directors have made elections to

participate in and are participating in, our employee stock

purchase plan and 401(k) plan and have made and may from

time to time make elections to have shares withheld to cover

withholding taxes due or pay the exercise price of stock options,

restricted stock units and performance stock units which may

constitute non-Rule 10b5–1 trading arrangements (as defined in

Item 408(c) of Regulation S-K).

---

| | |
|:---|:---|
| **ITEM 9C.** | **DISCLOSURE REGARDING FOREIGN** <br>**JURISDICTIONS THAT PREVENT** <br>**INSPECTIONS.**<br>|

---

Not applicable.

**PART III**<br>

---

| | |
|:---|:---|
| **ITEM 10.** | **DIRECTORS, EXECUTIVE OFFICERS AND** <br>**CORPORATE GOVERNANCE.**<br>|

---

Information regarding our executive officers appears under the

caption "Information about our Executive Officers" in Part I, Item

1 of this report.

Information regarding our directors and certain corporate

governance and other matters appearing under the captions

"Proposal 1—Election of Directors," "Corporate Governance,"

and "Additional Information—Delinquent Section 16(a) Reports"

in the 2026 proxy statement is incorporated herein by reference.

We have adopted Corporate Policy 6 (Trading in Securities by

Company Personnel) and Insider Trading Guidelines (collectively,

Insider Trading Policies) which govern the purchase, sale and/or

other disposition of our securities by our directors, officers and

employees, as well as by the Company itself, that we believe are

reasonably designed to promote compliance with insider trading

laws, rules and regulations and New York Stock Exchange listing

standards. Copies of the Insider Trading Policies are filed as

Exhibits 19(i) and 19(ii) to this report.

The Corporate Governance Guidelines adopted by our Board of

Directors, as well as the charters of each of the Audit Committee,

the Governance and Nominating Committee and the

Compensation Committee and the Code of Conduct applicable to

the principal executive officer, president, principal financial officer

and principal accounting officer or controller or persons

performing similar functions are posted on the "Corporate

Governance" section of our website at *www.stryker.com*.

---

| | |
|:---|:---|
| **ITEM 11.** | **EXECUTIVE COMPENSATION.** |

---

Information regarding the compensation of our management

appearing under the captions "Compensation Discussion and

Analysis," "Compensation and Human Capital Committee

Report," "Executive Compensation" and "Compensation of

Directors" in the 2026 proxy statement is incorporated herein by

reference.

---

| | |
|:---|:---|
| **ITEM 12.** | **SECURITY OWNERSHIP OF CERTAIN** <br>**BENEFICIAL OWNERS AND MANAGEMENT** <br>**AND RELATED STOCKHOLDER MATTERS.**<br>|

---

The information under the caption "Stock Ownership" in the 2026

proxy statement is incorporated herein by reference.

On December 31, 2025 we had an equity compensation plan

under which options were granted at a price not less than fair

market value at the date of grant and under which awards of

restricted stock units (RSUs) and performance stock units (PSUs)

were made. Options and RSUs were also awarded under a

previous plan. Additional information regarding our equity

compensation plans appears in Note 1 and Note 9 to our

Consolidated Financial Statements. On December 31, 2025 we

also had a stock performance incentive award program pursuant

to which shares of our common stock were and may be issued to

certain employees with respect to performance. The status of

these plans, each of which were previously submitted to and

approved by our shareholders, on December 31, 2025 is as

follows:

---

| | | | |
|:---|:---|:---|:---|
| **Plan** | **Number of** <br>**securities to** <br>**be issued** <br>**upon** <br>**exercise of** <br>**outstanding** <br>**options,** <br>**warrants and** <br>**rights**<br>| **Weighted-**<br>**average** <br>**exercise price** <br>**of outstanding** <br>**options,** <br>**warrants and** <br>**rights**<br>| **Number of securities** <br>**remaining available for** <br>**future issuance under** <br>**equity compensation** <br>**plans (excluding** <br>**shares reflected in** <br>**the first column)**<br>|
| 2008 Employee <br>Stock Purchase <br>Plan<br>| N/A | N/A | 4925529 |
| 2011 Long-Term <br>Incentive Plan<sup>(1)</sup><br>| 11165209 | $234.56 | 31297061 |
| 2011 Performance <br>Incentive Award <br>Plan<br>| N/A | N/A | 335395 |
| **Total**  |  |  | **36557985** |

---

<sup>(1)</sup> The 2011 Long-Term Incentive Plan securities to be issued

upon exercise include 627,908 RSUs and 174,228 PSUs. The

weighted-average exercise price does not take these awards into

account.

---

| | |
|:---|:---|
| **ITEM 13.** | **CERTAIN RELATIONSHIPS AND RELATED** <br>**TRANSACTIONS, AND DIRECTOR** <br>**INDEPENDENCE.**<br>|

---

The information under the caption "Corporate Governance" and

"Corporate Governance—Certain Relationships and Related

Party Transactions" in the 2026 proxy statement is incorporated

herein by reference.

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **47** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

---

| | |
|:---|:---|
| **ITEM 14.** | **PRINCIPAL ACCOUNTANT FEES AND** <br>**SERVICES.**<br>|

---

The information under the caption "Proposal 2—Ratification of

Appointment of our Independent Registered Public Accounting

Firm" in the 2026 proxy statement is incorporated herein by

reference.

---

| | |
|:---|:---|
| **Dollar amounts in millions except per share amounts or as otherwise specified.** | **48** |

---

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

**PART IV**<br>

---

| | |
|:---|:---|
| **ITEM 15.** | **EXHIBITS, FINANCIAL STATEMENT SCHEDULES.** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| (a) 1. | Financial Statements |  |  |  |  |  |
|  | The following Consolidated Financial Statements are set forth in Part II, Item 8 of this report. | The following Consolidated Financial Statements are set forth in Part II, Item 8 of this report. | The following Consolidated Financial Statements are set forth in Part II, Item 8 of this report. | The following Consolidated Financial Statements are set forth in Part II, Item 8 of this report. | The following Consolidated Financial Statements are set forth in Part II, Item 8 of this report. |  |
|  | Report of Independent Registered Public Accounting Firm | Report of Independent Registered Public Accounting Firm | Report of Independent Registered Public Accounting Firm | Report of Independent Registered Public Accounting Firm | Report of Independent Registered Public Accounting Firm | <u>[25](#i59ca9e85af6d416eb58f77ff50c4c1c5_79)</u> |
|  | Consolidated Statements of Earnings for 2025, 2024 and 2023 | Consolidated Statements of Earnings for 2025, 2024 and 2023 | Consolidated Statements of Earnings for 2025, 2024 and 2023 | Consolidated Statements of Earnings for 2025, 2024 and 2023 | Consolidated Statements of Earnings for 2025, 2024 and 2023 | <u>[27](#i59ca9e85af6d416eb58f77ff50c4c1c5_82)</u> |
|  | Consolidated Statements of Comprehensive Income for 2025, 2024 and 2023 | Consolidated Statements of Comprehensive Income for 2025, 2024 and 2023 | Consolidated Statements of Comprehensive Income for 2025, 2024 and 2023 | Consolidated Statements of Comprehensive Income for 2025, 2024 and 2023 | Consolidated Statements of Comprehensive Income for 2025, 2024 and 2023 | <u>[27](#i59ca9e85af6d416eb58f77ff50c4c1c5_88)</u> |
|  | Consolidated Balance Sheets on 2025 and 2024 | Consolidated Balance Sheets on 2025 and 2024 | Consolidated Balance Sheets on 2025 and 2024 | Consolidated Balance Sheets on 2025 and 2024 | Consolidated Balance Sheets on 2025 and 2024 | <u>[28](#i59ca9e85af6d416eb58f77ff50c4c1c5_91)</u> |
|  | Consolidated Statements of Shareholders' Equity for 2025, 2024 and 2023 | Consolidated Statements of Shareholders' Equity for 2025, 2024 and 2023 | Consolidated Statements of Shareholders' Equity for 2025, 2024 and 2023 | Consolidated Statements of Shareholders' Equity for 2025, 2024 and 2023 | Consolidated Statements of Shareholders' Equity for 2025, 2024 and 2023 | <u>[29](#i59ca9e85af6d416eb58f77ff50c4c1c5_94)</u> |
|  | Consolidated Statements of Cash Flows for 2025, 2024 and 2023 | Consolidated Statements of Cash Flows for 2025, 2024 and 2023 | Consolidated Statements of Cash Flows for 2025, 2024 and 2023 | Consolidated Statements of Cash Flows for 2025, 2024 and 2023 | Consolidated Statements of Cash Flows for 2025, 2024 and 2023 | <u>[30](#i59ca9e85af6d416eb58f77ff50c4c1c5_97)</u> |
|  | Notes to Consolidated Financial Statements | Notes to Consolidated Financial Statements | Notes to Consolidated Financial Statements | Notes to Consolidated Financial Statements | Notes to Consolidated Financial Statements | <u>[31](#i59ca9e85af6d416eb58f77ff50c4c1c5_100)</u> |
| (a) 2. | Financial Statement Schedules | Financial Statement Schedules | Financial Statement Schedules | Financial Statement Schedules | Financial Statement Schedules | Financial Statement Schedules |
|  | The Consolidated Financial Statement schedule of Stryker Corporation and its subsidiaries is: | The Consolidated Financial Statement schedule of Stryker Corporation and its subsidiaries is: | The Consolidated Financial Statement schedule of Stryker Corporation and its subsidiaries is: | The Consolidated Financial Statement schedule of Stryker Corporation and its subsidiaries is: | The Consolidated Financial Statement schedule of Stryker Corporation and its subsidiaries is: | The Consolidated Financial Statement schedule of Stryker Corporation and its subsidiaries is: |
|  | **SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS** | **SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS** | **SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS** | **SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS** | **SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS** | **SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS** |
|  |  |  | **Additions** | **Deductions** | **Deductions** |  |
|  | **Description** | **Balance at**<br>**Beginning**<br>**of Period**<br>| **Charged to**<br>**Costs &**<br>**Expenses**<br>| **Uncollectible** <br>**Amounts** <br>**Written Off,** <br>**Net of** <br>**Recoveries**<br>| **Effect of** <br>**Changes in** <br>**Foreign** <br>**Currency** <br>**Exchange** <br>**Rates**<br>| **Balance**<br>**at End**<br>**of Period**<br>|
|  | DEDUCTED FROM ASSET ACCOUNTS |  |  |  |  |  |
|  | Allowance for Doubtful Accounts: |  |  |  |  |  |
|  | Year ended December 31, 2025 | $213 | $95 | $91 | $1 | $216 |
|  | Year ended December 31, 2024 | $182 | $69 | $36 | $2 | $213 |
|  | Year ended December 31, 2023 | $154 | $69 | $40 | $1 | $182 |
|  | All other schedules for which provision is made in the applicable accounting regulation of the United States Securities and <br>Exchange Commission are not required under the related instructions or are inapplicable and, therefore, have been omitted. | All other schedules for which provision is made in the applicable accounting regulation of the United States Securities and <br>Exchange Commission are not required under the related instructions or are inapplicable and, therefore, have been omitted. | All other schedules for which provision is made in the applicable accounting regulation of the United States Securities and <br>Exchange Commission are not required under the related instructions or are inapplicable and, therefore, have been omitted. | All other schedules for which provision is made in the applicable accounting regulation of the United States Securities and <br>Exchange Commission are not required under the related instructions or are inapplicable and, therefore, have been omitted. | All other schedules for which provision is made in the applicable accounting regulation of the United States Securities and <br>Exchange Commission are not required under the related instructions or are inapplicable and, therefore, have been omitted. | All other schedules for which provision is made in the applicable accounting regulation of the United States Securities and <br>Exchange Commission are not required under the related instructions or are inapplicable and, therefore, have been omitted. |
| (a) 3. | Exhibits |  |  |  |  |  |

---

**FORM 10-K—ITEM 15(a) 3. AND ITEM 15(c)**

**STRYKER CORPORATION AND SUBSIDIARIES**

**EXHIBIT INDEX**

---

| | | |
|:---|:---|:---|
| Exhibit 2— |  | Plan of Acquisition, Reorganization, Arrangement, Liquidation or Succession |
| (i) |  | <u>[Purchase Agreement, dated as of November 4, 2019, among Stryker Corporation, Stryker B.V. and Wright Medical Group N.V. —](https://www.sec.gov/Archives/edgar/data/310764/000119312519285387/d818709dex21.htm)</u><br><u>[Incorporated by reference to Exhibit 2.1 to the Company's Form 8-K dated November 6, 2019 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312519285387/d818709dex21.htm)</u><br>|
| (ii) | 🟂 | <u>[Agreement and Plan of Merger, dated as of January 6, 2022, by and among Stryker Corporation, Voice Merger Sub Corp., and](https://www.sec.gov/Archives/edgar/data/310764/000119312522006816/d105293dex21.htm)</u><br><u>[Vocera Communications, Inc. — Incorporated by reference to Exhibit 2.1 to the Company's Form 8-K dated January 11, 2022](https://www.sec.gov/Archives/edgar/data/310764/000119312522006816/d105293dex21.htm)</u><br><u>[(Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312522006816/d105293dex21.htm)</u><br>|
| (iii) |  | <u>[Agreement and Plan of Merger, dated January 6, 2025, by and between Stryker Corporation and Inari Medical, Inc. — Incorporated](https://www.sec.gov/Archives/edgar/data/310764/000119312525002537/d899660dex21.htm)</u><br><u>[by reference to Exhibit 2.1 to the Company's Form 8-K dated January 7, 2025 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312525002537/d899660dex21.htm)</u><br>|
| Exhibit 3— |  | Articles of Incorporation and By-Laws |
| (i) |  | <u>[Restated Articles of Incorporation — Incorporated by reference to Exhibit 3(i) to the Company's Form 10-Q for the quarterly period](https://www.sec.gov/Archives/edgar/data/310764/000031076418000205/ex3i10qq32018.htm)</u><br><u>[ended September 30, 2018 (Commission File No. 00-09165).](https://www.sec.gov/Archives/edgar/data/310764/000031076418000205/ex3i10qq32018.htm)</u><br>|
| (ii) |  | <u>[Amended and Restated Bylaws - Incorporated by reference to Exhibit 3(ii) to the Company's Form 10-K for the year ended](https://www.sec.gov/Archives/edgar/data/310764/000031076423000017/ex3iiamendedbylaws-nov 2022.htm)</u><br><u>[December 31, 2022 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076423000017/ex3iiamendedbylaws-nov 2022.htm)</u><br>|
| Exhibit 4— |  | Instruments defining the rights of security holders, including indentures—We agree to furnish to the Commission upon request a <br>copy of each instrument pursuant to which long-term debt of Stryker Corporation and its subsidiaries not exceeding 10% of the <br>total assets of Stryker Corporation and its consolidated subsidiaries is authorized.<br>|
| (i) |  | <u>[Indenture, dated January 15, 2010, between Stryker Corporation and U.S. Bank National Association.— Incorporated by reference](https://www.sec.gov/Archives/edgar/data/310764/000119312510007135/dex41.htm)</u><br><u>[to Exhibit 4.1 to the Company's Form 8-K dated January 15, 2010 (Commission File No. 000-09165).](https://www.sec.gov/Archives/edgar/data/310764/000119312510007135/dex41.htm)</u><br>|

---

**49**<br>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

---

| | | |
|:---|:---|:---|
| (ii) |  | <u>[Fifth Supplemental Indenture (including the form of 2043 note) dated March 25, 2013, between Stryker Corporation and U.S. Bank](https://www.sec.gov/Archives/edgar/data/310764/000119312513123574/d508904dex43.htm)</u><br><u>[National Association.— Incorporated by reference to Exhibit 4.3 to the Company's Form 8-K dated March 25, 2013 (Commission](https://www.sec.gov/Archives/edgar/data/310764/000119312513123574/d508904dex43.htm)</u><br><u>[File No. 000-09165).](https://www.sec.gov/Archives/edgar/data/310764/000119312513123574/d508904dex43.htm)</u><br>|
| (iii) |  | <u>[Seventh Supplemental Indenture (including the form of 2044 note), dated May 1, 2014, between Stryker Corporation and U.S.](https://www.sec.gov/Archives/edgar/data/310764/000119312514175095/d720177dex43.htm)</u><br><u>[Bank National Association.— Incorporated by reference to Exhibit 4.3 to the Company's Form 8-K dated May 1, 2014 (Commission](https://www.sec.gov/Archives/edgar/data/310764/000119312514175095/d720177dex43.htm)</u><br><u>[File No. 000-09165).](https://www.sec.gov/Archives/edgar/data/310764/000119312514175095/d720177dex43.htm)</u><br>|
| (iv) |  | <u>[Eighth Supplemental Indenture (including the form of 2025 note), dated October 29, 2015, between Stryker Corporation and U.S.](https://www.sec.gov/Archives/edgar/data/310764/000119312515358209/d46878dex42.htm)</u><br><u>[Bank National association.— Incorporated by reference to Exhibit 4.2 to the Company's Form 8-K dated October 29, 2015](https://www.sec.gov/Archives/edgar/data/310764/000119312515358209/d46878dex42.htm)</u><br><u>[(Commission File No. 000-09165).](https://www.sec.gov/Archives/edgar/data/310764/000119312515358209/d46878dex42.htm)</u><br>|
| (v) |  | <u>[Eleventh Supplemental Indenture (including the form of the 2026 note), dated March 10, 2016, between Stryker Corporation and](https://www.sec.gov/Archives/edgar/data/310764/000119312516499457/d159431dex44.htm)</u><br><u>[U.S. Bank National Association.— Incorporated by reference to Exhibit 4.4 to the Company's Form 8-K dated March 10, 2016](https://www.sec.gov/Archives/edgar/data/310764/000119312516499457/d159431dex44.htm)</u><br><u>[(Commission File No. 000-09615).](https://www.sec.gov/Archives/edgar/data/310764/000119312516499457/d159431dex44.htm)</u><br>|
| (vi) |  | <u>[Twelfth Supplemental Indenture (including the form of the 2046 note), dated March 10, 2016, between Stryker Corporation and](https://www.sec.gov/Archives/edgar/data/310764/000119312516499457/d159431dex45.htm)</u><br><u>[U.S. Bank National Association. — Incorporated by reference to Exhibit 4.5 to the Company's Form 8-K dated March 10, 2016](https://www.sec.gov/Archives/edgar/data/310764/000119312516499457/d159431dex45.htm)</u><br><u>[(Commission File No. 000-09615).](https://www.sec.gov/Archives/edgar/data/310764/000119312516499457/d159431dex45.htm)</u><br>|
| (vii) |  | <u>[Fourteenth Supplemental Indenture (including the form of the 2028 note), dated March 7, 2018, between Stryker Corporation and](https://www.sec.gov/Archives/edgar/data/310764/000119312518073610/d518544dex42.htm)</u><br><u>[U.S. Bank National Association. — Incorporated by reference to Exhibit 4.2 to the Company's Form 8-K dated March 7, 2018](https://www.sec.gov/Archives/edgar/data/310764/000119312518073610/d518544dex42.htm)</u><br><u>[(Commission File No. 000-09615).](https://www.sec.gov/Archives/edgar/data/310764/000119312518073610/d518544dex42.htm)</u><br>|
| (viii) |  | <u>[Sixteenth Supplemental Indenture (including the form of the 2027 note), dated November 30, 2018, between Stryker Corporation](https://www.sec.gov/Archives/edgar/data/310764/000119312518339720/d661644dex43.htm)</u><br><u>[and U.S. Bank National Association. — Incorporated by reference to Exhibit 4.3 to the Company's Form 8-K dated November 30,](https://www.sec.gov/Archives/edgar/data/310764/000119312518339720/d661644dex43.htm)</u><br><u>[2018 (Commission File No. 000-09615).](https://www.sec.gov/Archives/edgar/data/310764/000119312518339720/d661644dex43.htm)</u><br>|
| (ix) |  | <u>[Seventeenth Supplemental Indenture (including the form of the 2030 note), dated November 30, 2018, between Stryker](https://www.sec.gov/Archives/edgar/data/310764/000119312518339720/d661644dex44.htm)</u><br><u>[Corporation and U.S. Bank National Association. — Incorporated by reference to Exhibit 4.4 to the Company's Form 8-K dated](https://www.sec.gov/Archives/edgar/data/310764/000119312518339720/d661644dex44.htm)</u><br><u>[November 30, 2018 (Commission File No. 000-09615).](https://www.sec.gov/Archives/edgar/data/310764/000119312518339720/d661644dex44.htm)</u><br>|
| (x) |  | <u>[Twentieth Supplemental Indenture (including the form of the 2029 note), dated December 3, 2019, between Stryker Corporation](https://www.sec.gov/Archives/edgar/data/310764/000119312519305266/d103227dex43.htm)</u><br><u>[and U.S. Bank National Association. — Incorporated by reference to Exhibit 4.3 to the Company's Form 8-K dated December 3,](https://www.sec.gov/Archives/edgar/data/310764/000119312519305266/d103227dex43.htm)</u><br><u>[2019 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312519305266/d103227dex43.htm)</u><br>|
| (xi) |  | <u>[Twenty-First Supplemental Indenture (including the form of the 2031 note), dated December 3, 2019, between Stryker Corporation](https://www.sec.gov/Archives/edgar/data/310764/000119312519305266/d103227dex44.htm)</u><br><u>[and U.S. Bank National Association. — Incorporated by reference to Exhibit 4.4 to the Company's Form 8-K dated December 3,](https://www.sec.gov/Archives/edgar/data/310764/000119312519305266/d103227dex44.htm)</u><br><u>[2019 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312519305266/d103227dex44.htm)</u><br>|
| (xii) |  | <u>[Twenty-Second Supplemental Indenture (including the form of the 2025 note), dated June 4, 2020, between Stryker Corporation](https://www.sec.gov/Archives/edgar/data/310764/000119312520160734/d927297dex42.htm)</u><br><u>[and U.S. Bank National Association, as trustee - Incorporated by reference to Exhibit 4.2 to the Company's Form 8-K dated June 4,](https://www.sec.gov/Archives/edgar/data/310764/000119312520160734/d927297dex42.htm)</u><br><u>[2020 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312520160734/d927297dex42.htm)</u><br>|
| (xiii) |  | <u>[Twenty-Third Supplemental Indenture (including the form of the 2030 note), dated June 4, 2020, between Stryker Corporation and](https://www.sec.gov/Archives/edgar/data/310764/000119312520160734/d927297dex43.htm)</u><br><u>[U.S. Bank National Association — Incorporated by reference to Exhibit 4.3 to the Company's Form 8-K dated June 4, 2020](https://www.sec.gov/Archives/edgar/data/310764/000119312520160734/d927297dex43.htm)</u><br><u>[(Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312520160734/d927297dex43.htm)</u><br>|
| (xiv) |  | <u>[Twenty-Fourth Supplemental Indenture (including the form of the 2050 note), dated June 4, 2020, between Stryker Corporation and](https://www.sec.gov/Archives/edgar/data/310764/000119312520160734/d927297dex44.htm)</u><br><u>[U.S. Bank National Association — Incorporated by reference to Exhibit 4.4 to the Company's Form 8-K dated June 4, 2020](https://www.sec.gov/Archives/edgar/data/310764/000119312520160734/d927297dex44.htm)</u><br><u>[(Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312520160734/d927297dex44.htm)</u><br>|
| (xv) |  | <u>[Twenty-Sixth Supplemental Indenture (including the form of the 2028 note), dated December 8, 2023, between Stryker Corporation](https://www.sec.gov/Archives/edgar/data/310764/000119312523291773/d54031dex42.htm)</u><br><u>[and U.S. Bank Trust Company, National Association, as trustee — Incorporated by reference to Exhibit 4.2 to the Company's Form](https://www.sec.gov/Archives/edgar/data/310764/000119312523291773/d54031dex42.htm)</u><br><u>[8-K dated December 8, 2023 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312523291773/d54031dex42.htm)</u><br>|
| (xvi) |  | <u>[Twenty-Seventh Supplemental Indenture (including the form of the 2028 note), dated December 11, 2023, between Stryker](https://www.sec.gov/Archives/edgar/data/310764/000119312523292590/d18061dex42.htm)</u><br><u>[Corporation and U.S. Bank Trust Company, National Association, as trustee — Incorporated by reference to Exhibit 4.2 to the](https://www.sec.gov/Archives/edgar/data/310764/000119312523292590/d18061dex42.htm)</u><br><u>[Company's Form 8-K dated December 11, 2023 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312523292590/d18061dex42.htm)</u><br>|
| (xvii) |  | <u>[Twenty-Eighth Supplemental Indenture (including the form of 2032 note), dated September 11, 2024, between Stryker Corporation](https://www.sec.gov/Archives/edgar/data/310764/000119312524217275/d894557dex42.htm)</u><br><u>[and U.S. Bank Trust Company, National Association, as trustee — Incorporated by reference to Exhibit 4.2 to the Company's Form](https://www.sec.gov/Archives/edgar/data/310764/000119312524217275/d894557dex42.htm)</u><br><u>[8-K dated September 11, 2024 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312524217275/d894557dex42.htm)</u><br>|
| (xviii) |  | <u>[Twenty-Ninth Supplemental Indenture (including the form of 2036 note), dated September 11, 2024, between Stryker Corporation](https://www.sec.gov/Archives/edgar/data/310764/000119312524217275/d894557dex43.htm)</u><br><u>[and U.S. Bank Trust Company, National Association, as trustee — Incorporated by reference to Exhibit 4.3 to the Company's Form](https://www.sec.gov/Archives/edgar/data/310764/000119312524217275/d894557dex43.htm)</u><br><u>[8-K dated September 11, 2024 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312524217275/d894557dex43.htm)</u><br>|
| (xix) |  | <u>[Thirtieth Supplemental Indenture (including the form of 2029 note), dated September 11, 2024, between Stryker Corporation and](https://www.sec.gov/Archives/edgar/data/310764/000119312524217275/d894557dex44.htm)</u><br><u>[U.S. Bank Trust Company, National Association, as trustee — Incorporated by reference to Exhibit 4.4 to the Company's Form 8-K](https://www.sec.gov/Archives/edgar/data/310764/000119312524217275/d894557dex44.htm)</u><br><u>[dated September 11, 2024 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312524217275/d894557dex44.htm)</u><br>|
| (xx) |  | <u>[Thirty-First Supplemental Indenture (including the form of 2034 note), dated September 11, 2024, between Stryker Corporation and](https://www.sec.gov/Archives/edgar/data/310764/000119312524217275/d894557dex45.htm)</u><br><u>[U.S. Bank Trust Company, National Association, as trustee — Incorporated by reference to Exhibit 4.5 to the Company's Form 8-K](https://www.sec.gov/Archives/edgar/data/310764/000119312524217275/d894557dex45.htm)</u><br><u>[dated September 11, 2024 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312524217275/d894557dex45.htm)</u><br>|
| (xxi) |  | <u>[Thirty-Second Supplemental Indenture (including the form of 2027 note), dated February 10, 2025, between Stryker Corporation](https://www.sec.gov/Archives/edgar/data/310764/000119312525023587/d907608dex42.htm)</u><br><u>[and U.S. Bank Trust Company, National Association, as trustee — Incorporated by reference to Exhibit 4.2 to the Company's Form](https://www.sec.gov/Archives/edgar/data/310764/000119312525023587/d907608dex42.htm)</u><br><u>[8-K dated February 10, 2025 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312525023587/d907608dex42.htm)</u><br>|
| (xxii) |  | <u>[Thirty-Third Supplemental Indenture (including the form of 2028 note), dated February 10, 2025, between Stryker Corporation and](https://www.sec.gov/Archives/edgar/data/310764/000119312525023587/d907608dex43.htm)</u><br><u>[U.S. Bank Trust Company, National Association, as trustee — Incorporated by reference to Exhibit 4.3 to the Company's Form 8-K](https://www.sec.gov/Archives/edgar/data/310764/000119312525023587/d907608dex43.htm)</u><br><u>[dated February 10, 2025 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312525023587/d907608dex43.htm)</u><br>|
| (xxiii) |  | <u>[Thirty-Fourth Supplemental Indenture (including the form of 2030 note), dated February 10, 2025, between Stryker Corporation and](https://www.sec.gov/Archives/edgar/data/310764/000119312525023587/d907608dex44.htm)</u><br><u>[U.S. Bank Trust Company, National Association, as trustee — Incorporated by reference to Exhibit 4.4 to the Company's Form 8-K](https://www.sec.gov/Archives/edgar/data/310764/000119312525023587/d907608dex44.htm)</u><br><u>[dated February 10, 2025 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312525023587/d907608dex44.htm)</u><br>|
| (xxiv) |  | <u>[Thirty-Fifth Supplemental Indenture (including the form of 2035 note), dated February 10, 2025, between Stryker Corporation and](https://www.sec.gov/Archives/edgar/data/310764/000119312525023587/d907608dex45.htm)</u><br><u>[U.S. Bank Trust Company, National Association, as trustee — Incorporated by reference to Exhibit 4.5 to the Company's Form 8-K](https://www.sec.gov/Archives/edgar/data/310764/000119312525023587/d907608dex45.htm)</u><br><u>[dated February 10, 2025 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312525023587/d907608dex45.htm)</u><br>|
| (xxv) | † | <u>[Description of Securities](ex4xxv1231202510k.htm)</u> |

---

**50**<br>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

---

| | | |
|:---|:---|:---|
| Exhibit 10— |  | Material contracts |
| (i)\* | † | <u>[Form of grant notice and terms and conditions for stock options granted in 2026 under the 2011 Long-Term Incentive Plan](ex10i2026stockoptionawardl.htm)</u>. |
| (ii)\* | † | <u>[Form of grant notice and terms and conditions for restricted stock units granted in 2026 under the 2011 Long-Term Incentive Plan](ex10ii2026rsuawardletteran.htm)</u>. |
| (iii)\* | † | <u>[Form of grant notice and terms and conditions for performance stock units granted in 2026 under the 2011 Long-Term Incentive](ex10iii2026psuawardlettera.htm)</u><br><u>[Plan](ex10iii2026psuawardlettera.htm)</u>.<br>|
| (iv)\* | † | <u>[Form of grant notice and terms and conditions for restricted stock units with no retirement provisions granted in 2026 under the](ex10iv2026norersuawardlett.htm)</u><br><u>[2011 Long-Term Incentive Plan](ex10iv2026norersuawardlett.htm)</u>.<br>|
| (v)\* |  | <u>[Form of grant notice and terms and conditions for stock options granted in 2025 under the 2011 Long-Term Incentive Plan —](https://www.sec.gov/Archives/edgar/data/310764/000031076425000023/ex10i2025stockoptionawardl.htm)</u><br><u>[Incorporated by reference to Exhibit 10(i) to the Company's Form 10-K for the year ended December 31, 2024 (Commission File](https://www.sec.gov/Archives/edgar/data/310764/000031076425000023/ex10i2025stockoptionawardl.htm)</u><br><u>[No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076425000023/ex10i2025stockoptionawardl.htm)</u><br>|
| (vi)\* |  | <u>[Form of grant notice and terms and conditions for restricted stock units granted in 2025 under the 2011 Long-Term Incentive Plan](https://www.sec.gov/Archives/edgar/data/310764/000031076425000023/ex10ii2025rsuawardletteran.htm)</u><br><u>[— Incorporated by reference to Exhibit 10(ii) to the Company's Form 10-K for the year ended December 31, 2024 (Commission](https://www.sec.gov/Archives/edgar/data/310764/000031076425000023/ex10ii2025rsuawardletteran.htm)</u><br><u>[File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076425000023/ex10ii2025rsuawardletteran.htm)</u><br>|
| (vii)\* |  | <u>[Form of grant notice and terms and conditions for performance stock units granted in 2025 under the 2011 Long-Term Incentive](https://www.sec.gov/Archives/edgar/data/310764/000031076425000023/ex10iii2025psuawardlettera.htm)</u><br><u>[Plan — Incorporated by reference to Exhibit 10(iii) to the Company's Form 10-K for the year ended December 31, 2024](https://www.sec.gov/Archives/edgar/data/310764/000031076425000023/ex10iii2025psuawardlettera.htm)</u><br><u>[(Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076425000023/ex10iii2025psuawardlettera.htm)</u><br>|
| (viii)\* |  | <u>[Form of grant notice and terms and conditions for restricted stock units with no retirement provisions granted in 2025 under the](https://www.sec.gov/Archives/edgar/data/310764/000031076425000023/ex10iv2025norersuawardlett.htm)</u><br><u>[2011 Long-Term Incentive Plan — Incorporated by reference to Exhibit 10(iv) to the Company's Form 10-K for the year ended](https://www.sec.gov/Archives/edgar/data/310764/000031076425000023/ex10iv2025norersuawardlett.htm)</u><br><u>[December 31, 2024 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076425000023/ex10iv2025norersuawardlett.htm)</u><br>|
| (ix)\* |  | <u>[Form of grant notice and terms and conditions for restricted stock units granted in 2025 under the 2011 Long-Term Incentive Plan](https://www.sec.gov/Archives/edgar/data/310764/000031076424000098/ex10i2024non-employeedirec.htm)</u><br><u>[to non-employee directors — Incorporated by reference to Exhibit 10.1(i) to the Company's Form 10-Q for the quarterly period](https://www.sec.gov/Archives/edgar/data/310764/000031076424000098/ex10i2024non-employeedirec.htm)</u><br><u>[ended June 30, 2025 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076424000098/ex10i2024non-employeedirec.htm)</u><br>|
| (x)\* |  | <u>[Form of grant notice and terms and conditions for restricted stock units granted in 2024 under the 2011 Long-Term Incentive Plan](https://www.sec.gov/Archives/edgar/data/310764/000031076424000098/ex10i2024non-employeedirec.htm)</u><br><u>[to non-employee directors — Incorporated by reference to Exhibit 10.1 to the Company's Form 10-Q for the quarterly period ended](https://www.sec.gov/Archives/edgar/data/310764/000031076424000098/ex10i2024non-employeedirec.htm)</u><br><u>[June 30, 2024 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076424000098/ex10i2024non-employeedirec.htm)</u><br>|
| (xi)\* |  | <u>[Form of grant notice and terms and conditions for stock options granted in 2024 under the 2011 Long-Term Incentive Plan —](https://www.sec.gov/Archives/edgar/data/310764/000031076424000024/ex10i2024nqstockoptionawar.htm)</u><br><u>[Incorporated by reference to Exhibit 10(i) to the Company's Form 10-K for the year ended December 31, 2023 (Commission File](https://www.sec.gov/Archives/edgar/data/310764/000031076424000024/ex10i2024nqstockoptionawar.htm)</u><br><u>[No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076424000024/ex10i2024nqstockoptionawar.htm)</u><br>|
| (xii)\* |  | <u>[Form of grant notice and terms and conditions for restricted stock units granted in 2024 under the 2011 Long-Term Incentive Plan](https://www.sec.gov/Archives/edgar/data/310764/000031076424000024/ex10ii2024rsuawardletteran.htm)</u><br><u>[— Incorporated by reference to Exhibit 10(ii) to the Company's Form 10-K for the year ended December 31, 2023 (Commission](https://www.sec.gov/Archives/edgar/data/310764/000031076424000024/ex10ii2024rsuawardletteran.htm)</u><br><u>[File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076424000024/ex10ii2024rsuawardletteran.htm)</u><br>|
| (xiii)\* |  | <u>[Form of grant notice and terms and conditions for performance stock units granted in 2024 under the 2011 Long-Term Incentive](https://www.sec.gov/Archives/edgar/data/310764/000031076424000024/ex10iii2024psuawardlettera.htm)</u><br><u>[Plan — Incorporated by reference to Exhibit 10(iii) to the Company's Form 10-K for the year ended December 31, 2023](https://www.sec.gov/Archives/edgar/data/310764/000031076424000024/ex10iii2024psuawardlettera.htm)</u><br><u>[(Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076424000024/ex10iii2024psuawardlettera.htm)</u><br>|
| (xiv)\* |  | <u>[Form of grant notice and terms and conditions for restricted stock units granted in 2023 under the 2011 Long-Term Incentive Plan](https://www.sec.gov/Archives/edgar/data/310764/000031076423000106/ex10i630202310q.htm)</u><br><u>[to non-employee directors — Incorporated by reference to Exhibit 10(i) to the Company's Form 10-Q for the quarterly period](https://www.sec.gov/Archives/edgar/data/310764/000031076423000106/ex10i630202310q.htm)</u><br><u>[ended June 30, 2023 (Commission File No. 000-09165).](https://www.sec.gov/Archives/edgar/data/310764/000031076423000106/ex10i630202310q.htm)</u><br>|
| (xv)\* |  | <u>[Form of grant notice and terms and conditions for stock options granted in 2023 under the 2011 Long-Term Incentive Plan -](https://www.sec.gov/Archives/edgar/data/310764/000031076423000017/ex10i2023nqstockoptionawar.htm)</u><br><u>[Incorporated by reference to Exhibit 10(i) to the Company's Form 10-K for the year ended December 31, 2022 (Commission File](https://www.sec.gov/Archives/edgar/data/310764/000031076423000017/ex10i2023nqstockoptionawar.htm)</u><br><u>[No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076423000017/ex10i2023nqstockoptionawar.htm)</u><br>|
| (xvi)\* |  | <u>[Form of grant notice and terms and conditions for restricted stock units granted in 2023 under the 2011 Long-Term Incentive Plan -](https://www.sec.gov/Archives/edgar/data/310764/000031076423000017/ex10ii2023rsuawardletteran.htm)</u><br><u>[Incorporated by reference to Exhibit 10(ii) to the Company's Form 10-K for the year ended December 31, 2022 (Commission File](https://www.sec.gov/Archives/edgar/data/310764/000031076423000017/ex10ii2023rsuawardletteran.htm)</u><br><u>[No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076423000017/ex10ii2023rsuawardletteran.htm)</u><br>|
| (xvii)\* |  | <u>[Form of grant notice and terms and conditions for performance stock units granted in 2023 under the 2011 Long-Term Incentive](https://www.sec.gov/Archives/edgar/data/310764/000031076423000017/ex10iii2023psuawardlettera.htm)</u><br><u>[Plan - Incorporated by reference to Exhibit 10(iii) to the Company's Form 10-K for the year ended December 31, 2022](https://www.sec.gov/Archives/edgar/data/310764/000031076423000017/ex10iii2023psuawardlettera.htm)</u><br><u>[(Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076423000017/ex10iii2023psuawardlettera.htm)</u><br>|
| (xviii)\* |  | <u>[Form of grant notice and terms and conditions for restricted stock units granted in 2022 under the 2011 Long-Term Incentive Plan](https://www.sec.gov/Archives/edgar/data/310764/000031076422000092/ex10i630202210q.htm)</u><br><u>[to non-employee directors — Incorporated by reference to Exhibit 10(i) to the Company's Form 10-Q for the quarterly period ended](https://www.sec.gov/Archives/edgar/data/310764/000031076422000092/ex10i630202210q.htm)</u><br><u>[June 30, 2022 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076422000092/ex10i630202210q.htm)</u><br>|
| (xix)\* |  | <u>[Form of grant notice and terms and conditions for stock options granted in 2022 under the 2011 Long-Term Incentive Plan —](https://www.sec.gov/Archives/edgar/data/310764/000031076422000028/ex10i2022nqstockoptionawar.htm)</u><br><u>[Incorporated by reference to Exhibit 10(i) to the Company's Form 10-K for the year ended December 31, 2021 (Commission File](https://www.sec.gov/Archives/edgar/data/310764/000031076422000028/ex10i2022nqstockoptionawar.htm)</u><br><u>[No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076422000028/ex10i2022nqstockoptionawar.htm)</u><br>|
| (xx)\* |  | <u>[Form of grant notice and terms and conditions for stock options granted in 2021 under the 2011 Long-Term Incentive Plan —](https://www.sec.gov/Archives/edgar/data/310764/000031076421000027/ex10i2021nqstockoptionawar.htm)</u><br><u>[Incorporated by reference to Exhibit 10(i) to the Company's Form 10-K for the year ended December 31, 2020 (Commission File](https://www.sec.gov/Archives/edgar/data/310764/000031076421000027/ex10i2021nqstockoptionawar.htm)</u><br><u>[No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076421000027/ex10i2021nqstockoptionawar.htm)</u><br>|
| (xxi)\* |  | <u>[2011 Long-Term Incentive Plan (as amended and restated effective May 8, 2025) — Incorporated by reference to Appendix B to](https://www.sec.gov/Archives/edgar/data/310764/000031076420000014/ex10i1231201910k.htm)</u><br><u>[the Proxy Statement for the Company's 2025 Annual Meeting of Shareholders (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076420000014/ex10i1231201910k.htm)</u><br>|
| (xxii)\* |  | <u>[Form of grant notice and terms and conditions for stock options granted in 2020 under the 2011 Long-Term Incentive Plan —](https://www.sec.gov/Archives/edgar/data/310764/000031076420000014/ex10ii1231201910k.htm)</u><br><u>[Incorporated by reference to Exhibit 10(ii) to the Company's Form 10-K for the year ended December 31, 2019 (Commission File](https://www.sec.gov/Archives/edgar/data/310764/000031076420000014/ex10ii1231201910k.htm)</u><br><u>[No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076420000014/ex10ii1231201910k.htm)</u><br>|
| (xxiii)\* |  | <u>[Supplemental Savings and Retirement Plan (as amended effective January 1, 2008 and January 1, 2019) — Incorporated by](https://www.sec.gov/Archives/edgar/data/310764/000031076420000014/ex10vi1231201910k.htm)</u><br><u>[reference to Exhibit 10(vi) to the Company's Form 10-K for the year ended December 31, 2019 (Commission File No. 001-13149)](https://www.sec.gov/Archives/edgar/data/310764/000031076420000014/ex10vi1231201910k.htm)</u><br>|
| (xxiv)\* |  | <u>[Form of grant notice and terms and conditions for stock options granted in 2019 under the 2011 Long-Term Incentive Plan —](https://www.sec.gov/Archives/edgar/data/310764/000031076419000014/ex10ii12311810k.htm)</u><br><u>[Incorporated by reference to Exhibit 10(ii) to the Company's Form 10-K for the year ended December 31, 2018 (Commission File](https://www.sec.gov/Archives/edgar/data/310764/000031076419000014/ex10ii12311810k.htm)</u><br><u>[No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076419000014/ex10ii12311810k.htm)</u><br>|
| (xxv)\* |  | <u>[Form of grant notice and terms and conditions for stock options granted in 2018 under the 2011 Long-Term Incentive Plan —](https://www.sec.gov/Archives/edgar/data/310764/000031076418000031/ex10ii12311710k.htm)</u><br><u>[Incorporated by reference to Exhibit 10(ii) to the Company's Form 10-K for the year ended December 31, 2017 (Commission File](https://www.sec.gov/Archives/edgar/data/310764/000031076418000031/ex10ii12311710k.htm)</u><br>|

---

**51**<br>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

---

| | | |
|:---|:---|:---|
| (xxvi)\* |  | <u>[Stryker Corporation Executive Bonus Plan — Incorporated by reference to Exhibit 10.1 to the Company's Form 8-K dated February](https://www.sec.gov/Archives/edgar/data/310764/000031076407000052/sykex101.htm)</u><br><u>[21, 2007 (Commission File No. 000-09165).](https://www.sec.gov/Archives/edgar/data/310764/000031076407000052/sykex101.htm)</u><br>|
| (xxvii)\* |  | <u>[Letter Agreement between Stryker Corporation and Glenn Boehnlein — Incorporated by reference to Exhibit 10.2 to the Company's](https://www.sec.gov/Archives/edgar/data/310764/000031076416000206/syk8kex10212616.htm)</u><br><u>[Form 8-K dated January 26, 2016 (Commission File No. 000-09165)](https://www.sec.gov/Archives/edgar/data/310764/000031076416000206/syk8kex10212616.htm)</u><br>|
| (xxviii) |  | <u>[Form of Indemnification Agreement for Directors — Incorporated by reference to Exhibit 10 (xiv) to the Company's Form 10-K for](https://www.sec.gov/Archives/edgar/data/310764/000031076409000035/sykex10xiv.htm)</u><br><u>[the year ended December 31, 2008 (Commission File No. 000-09165).](https://www.sec.gov/Archives/edgar/data/310764/000031076409000035/sykex10xiv.htm)</u><br>|
| (xxix) |  | <u>[Form of Indemnification Agreement for Certain Officers—Incorporated by reference to Exhibit 10 (xv) to the Company's Form 10-K](https://www.sec.gov/Archives/edgar/data/310764/000031076409000035/sykex10xv.htm)</u><br><u>[for the year ended December 31, 2008 (Commission File No. 000-09165).](https://www.sec.gov/Archives/edgar/data/310764/000031076409000035/sykex10xv.htm)</u>.<br>|
| (xxx) |  | <u>[Settlement Agreement between Howmedica Osteonics Corp. and the counsel listed on the signature pages thereto, dated as of](https://www.sec.gov/Archives/edgar/data/310764/000031076415000022/ex10xxiii10k2014.htm)</u><br><u>[November 3, 2014 (Rejuvenate and ABF II Hip Implant Products Liability Litigation) — Incorporated by reference to Exhibit 10xxiii](https://www.sec.gov/Archives/edgar/data/310764/000031076415000022/ex10xxiii10k2014.htm)</u><br>|
| (xxxi)\* |  | <u>[Letter Agreement, dated January 27, 2025, between Stryker Corporation and Preston Wells — Incorporated by reference to Exhibit](https://www.sec.gov/Archives/edgar/data/310764/000119312525014415/d919971dex102.htm)</u><br><u>[10.2 to the Company's Form 8-K dated January 28, 2025 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312525014415/d919971dex102.htm)</u><br>|
| (xxxii) |  | <u>[Credit Agreement, dated February 25, 2025, between Stryker Corporation, certain subsidiaries as borrowers, Wells Fargo Bank,](https://www.sec.gov/Archives/edgar/data/310764/000119312525039302/d904508dex101.htm)</u><br><u>[National Association as Administrative Agent, Swing Line Lender and L/C Issuer, Bank of America, N.A. and Citibank, N.A. as](https://www.sec.gov/Archives/edgar/data/310764/000119312525039302/d904508dex101.htm)</u><br><u>[Syndication Agents, the Co-Documentation Agents and Other Lenders party thereto — Incorporated by reference to Exhibit 10.1 to](https://www.sec.gov/Archives/edgar/data/310764/000119312525039302/d904508dex101.htm)</u><br><u>[the Company's Form 8-K dated February 25, 2025 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312525039302/d904508dex101.htm)</u><br>|
| (xxxiii)\* |  | <u>[Letter Agreement, dated December 2, 2025, between Stryker Corporation and Spencer Stiles — Incorporated by reference to](https://www.sec.gov/Archives/edgar/data/310764/000119312525308097/d78127dex101.htm)</u><br><u>[Exhibit 10.1 to the Company's Form 8-K dated December 4, 2025 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312525308097/d78127dex101.htm)</u><br>|
| (xxxiv)\* |  | <u>[Letter Agreement, dated December 2, 2025, between Stryker Corporation and Dylan Crotty — Incorporated by reference to Exhibit](https://www.sec.gov/Archives/edgar/data/310764/000119312525308097/d78127dex102.htm)</u><br><u>[10.2 to the Company's Form 8-K dated December 4, 2025 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000119312525308097/d78127dex102.htm)</u><br>|
| Exhibit 19— |  | Insider Trading Policy |
| (i) | † | <u>[Corporate Policy No. 6](ex19icorporatepolicy6_as.htm)</u> |
| (ii) | † | <u>[Insider Trading Guidelines](ex19iiinsidertradingguid.htm)</u> |
| Exhibit 21— |  | Subsidiaries of the registrant |
| (i) | † | <u>[List of Subsidiaries.](ex21i1231202510k.htm)</u> |
| Exhibit 23— |  | Consent of experts and counsel |
| (i) | † | <u>[Consent of Independent Registered Public Accounting Firm.](ex23i1231202510k.htm)</u> |

---

---

| | | |
|:---|:---|:---|
| Exhibit 31— |  | Rule 13a-14(a) Certifications |
| (i) | † | <u>[Certification by Principal Executive Officer of Stryker Corporation.](ex31i1231202510k.htm)</u> |
| (ii) | † | <u>[Certification by Principal Financial Officer of Stryker Corporation.](ex31ii1231202510k.htm)</u> |
| Exhibit 32— |  | 18 U.S.C. Section 1350 Certifications |
| (i) | †† | <u>[Certification by Principal Executive Officer of Stryker Corporation.](ex32i1231202510k.htm)</u> |
| (ii) | †† | <u>[Certification by Principal Financial Officer of Stryker Corporation.](ex32ii1231202510k.htm)</u> |
| Exhibit 97— |  | Policy Relating to Recovery of Erroneously Awarded Compensation |
| (i) |  | <u>[Stryker Corporation Mandatory Clawback Policy — Incorporated by reference to Exhibit 97(i) to the Company's Form 10-K for the](https://www.sec.gov/Archives/edgar/data/310764/000031076424000024/ex97istrykercorporationman.htm)</u><br><u>[year ended December 31, 2023 (Commission File No. 001-13149).](https://www.sec.gov/Archives/edgar/data/310764/000031076424000024/ex97istrykercorporationman.htm)</u><br>|
| Exhibit 101— |  | iXBRL (Inline Extensible Business Reporting Language) Documents |
| 101.INS |  | iXBRL Instance Document |
| 101.SCH |  | iXBRL Schema Document |
| 101.CAL |  | iXBRL Calculation Linkbase Document |
| 101.DEF |  | iXBRL Definition Linkbase Document |
| 101.LAB |  | iXBRL Label Linkbase Document |
| 101.PRE |  | iXBRL Presentation Linkbase Document |
| 104 |  | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document) |

---

\* Compensation arrangement

---

| | |
|:---|:---|
| † | Filed with this Form 10-K |

---

---

| | |
|:---|:---|
| †† | Furnished with this Form 10-K |

---

---

| | |
|:---|:---|
| 🟂 | Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Stryker hereby agrees to furnish supplementally a copy of any omitted <br>schedule upon request by the U.S. Securities and Exchange Commission.<br>|

---

---

| | |
|:---|:---|
| **ITEM 16.** | **FORM 10-K SUMMARY.** |

---

None.

**52**<br>

---

| | |
|:---|:---|
| **STRYKER CORPORATION** | **2025 FORM 10-K** |

---

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to

be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | STRYKER CORPORATION |
| Date: | February 11, 2026 | /s/ PRESTON W. WELLS |
|  |  | Preston W. Wells |
|  |  | Vice President, Chief Financial Officer |

---

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on the

date indicated above on behalf of the registrant and in the capacities indicated.

---

| | |
|:---|:---|
| /s/ KEVIN A. LOBO | /s/ PRESTON W. WELLS |
| Kevin A. Lobo | Preston W. Wells |
| Chair and Chief Executive Officer | Vice President, Chief Financial Officer |
| (Principal Executive Officer) | (Principal Financial Officer) |
| /s/ WILLIAM E. BERRY JR. |  |
| William E. Berry, Jr. |  |
| Vice President, Chief Accounting Officer |  |
| (Principal Accounting Officer) |  |
| /s/ SHERILYN S. MCCOY | /s/ ANDREW K. SILVERNAIL |
| Sherilyn S. McCoy | Andrew K. Silvernail |
| Lead Independent Director | Director |
| /s/ MARY K. BRAINERD | /s/ LISA M. SKEETE TATUM |
| Mary K. Brainerd | Lisa M. Skeete Tatum |
| Director | Director |
| /s/ GIOVANNI CAFORIO | /s/ RONDA E. STRYKER |
| Giovanni Caforio, M.D. | Ronda E. Stryker |
| Director | Director |
| /s/ RACHEL M. RUGGERI | /s/ RAJEEV SURI |
| Rachel M. Ruggeri | Rajeev Suri |
| Director | Director |
| /s/ EMMANUEL P. MACEDA |  |
| Emmanuel P. Maceda |  |
| Director |  |

---

## Exhibit 19.1

![](ex19icorporatepolicy6_as001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate Policy 6 Trading in Securities by Company Personnel Purpose To outline the company's policy concerning trading in securities by company personnel. Scope This Policy applies to all employees and directors of Stryker. Basic policies 1. Confidential and proprietary information: Stryker's employees and directors have access to corporate information, some of which is highly confidential and of considerable value to Stryker and those with whom we do business. Employees and directors who possess confidential information hold a special position of trust and confidence with regard to it and have an important responsibility to keep such information within the company until it is made public. We also have a legal obligation in this regard. It is both illegal and against Stryker policy for any individual to profit from undisclosed information relating to the company. 2. No trading on material, nonpublic information 2.1. If an employee or director has material, non-public information relating to Stryker, it is the company's policy that neither that person, nor any person with whom he or she may have a business or family relationship, may buy or sell shares of Stryker common stock or engage in any other action to take advantage of that information or pass it on to others. This Policy applies as well to information obtained in the course of employment relating to Stryker's customers, suppliers, and other companies with which we do business and the purchase or sale of securities of those companies. 2.2. Information is material if a reasonable investor would consider it important in making a decision to buy or sell securities. Both positive and negative information can be material. Examples of information generally regarded as material are significant new contracts or the termination of existing contracts, potential acquisitions, mergers, changes in estimates of earnings, increases or decreases in dividend payments, the introduction of important new product lines, significant technological breakthroughs, commencement or settlement of major litigation, and changes in key management personnel. You may not trade in securities while in possession of non-public information, or communicate such information to others who might trade. 2.3. Information remains non-public until it has been effectively disclosed in a manner sufficient to insure its general availability to the investing public. In order to afford Stryker's stockholders and the investing public time to receive and act upon information, you should not engage in transactions until the second business day after a public announcement of the information has been made (the day of the announcement is not counted). 2.4. As a simple rule-of-thumb, you should treat all corporate information with discretion, discuss confidential information only with those who have a right and need to know, and refrain from trading in securities until any inside information you possess is made public. 2.5. The restrictions on trading set forth in this Policy do not apply to sales of Stryker common stock pursuant to a written plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934. Further information about 10b5-1 trading plans may be obtained from your broker and the corporate secretary. 3. Compliance: Stryker expects nothing short of full compliance with the letter and spirit of this statement of policy. The consequences of illegal insider trading and tipping of others can be severe and include civil penalties and liability for both the individuals involved and the company, criminal prosecution, with exposure to prison terms and additional fines if convicted, and company-imposed sanctions, including dismissal. If you have questions about specific transactions or doubts as to your responsibilities under this statement of policy, please contact Stryker's chief legal officer or corporate secretary. The ultimate responsibility for compliance, however, is yours. www.stryker.com CP-006 Rev 8.0 Trading in Securities by Company Personnel \| 1

------

## Exhibit 19.2

![](ex19iiinsidertradingguid001.jpg)

1 Effective Date: August 1, 20231 Insider Trading Guidelines In the course of performing their duties, employees and directors of Stryker Corporation and its subsidiaries (collectively, "Stryker" or the "Company") may learn material, non-public information about Stryker or another company. This information may be valuable to those who trade in Stryker's securities, including common stock or public debt securities (collectively, "Stryker Securities"), or the securities of other companies. It is the law, as well as the policy of the Company, that this information may not be disclosed to anyone outside Stryker and that no one may trade while in possession of material information not available to the general public. Stryker is committed to protecting its confidential information. The Company's policy in this regard, which is applicable to all employees and directors, is set forth in Corporate Policy Number Six, "Trading in Securities by Company Personnel" (the "Policy"). The Policy serves the mutual interest of the Company and its employees and directors in limiting the potential for an insider trading investigation or even the appearance that Stryker, its employees or its directors may have violated the law. The Policy is available from the Human Resources Department, or at http://www.stryker.com/corporatepolicies. Insider trading is a serious legal matter. The law provides for significant civil and criminal penalties for insider trading violations. Those penalties may be imposed upon individuals who purchase or sell securities while in possession of material, non-public information about the issuer or the securities. Civil and criminal liability could also extend to an employee or director who "tips" another person about material, non-public information where that person, in turn, buys or sells securities. The Policy is simple. No trading is permitted while you have material, non-public information. The Company is also prohibited from trading at any time in Stryker Securities on the basis of material non-public information, consistent with applicable law. In all cases, information should be considered "material" if it would be considered important by investors in making decisions whether to purchase, sell or hold securities. Materiality will be construed broadly and with the benefit of hindsight, and it is possible that a group of facts that are immaterial on a stand-alone basis would be deemed material when pieced together. The materiality of earnings information cannot be disputed. Other examples of types of information that could be deemed material include a significant new contract or the termination of an existing contract; mergers, acquisitions, joint ventures or dispositions or terminations thereof; internal financial projections or changes in estimates of earnings; increases or decreases in dividend payments; a change in control of the Company; new product developments; significant technological breakthroughs; the status of regulatory approvals, cybersecurity incidents; ratings changes; changes in senior management; and initiation or resolution of significant litigation or government investigations or proceedings. This list is provided only for illustrative purposes and 1 These Insider Trading Guidelines supersede any previous Insider Trading Guidelines of the Company. In the event of any conflict or inconsistency between these Guidelines and any other materials previously distributed by the Company, these Guidelines shall govern.

------

![](ex19iiinsidertradingguid002.jpg)

2 is not exhaustive; other types of information may be material at any particular time depending upon the circumstances. Our Corporate Secretary and Chief Legal Officer may always be contacted for advice as to whether a particular fact pattern constitutes material non-public information. Non-public information, whether or not material, is information that has not been made available to the general public. Information should also be treated as being non-public unless a reasonable period of time has passed since it has been distributed by Stryker by means likely to result in a general public awareness, for example, by publication of the information in a press release or filing with the U.S. Securities and Exchange Commission. Information does not cease to be "non-public" as a result of being the subject of rumors or other unofficial statements in the marketplace and can be "non-public" even if the information was obtained by a Company employee from a source outside of the Company. In addition to the Policy, the Board of Directors has adopted the following guidelines (these "Guidelines") applicable to transactions in Stryker Securities by directors and certain employees ("Covered Persons" as defined in Attachment A hereto). These Guidelines restrict trading in Stryker Securities by any Covered Person to a limited "trading window" following the release of annual or quarterly earnings provided he or she does not actually possess material non-public information at that time. If you are a Covered Person, then this policy also applies to your spouse and minor children, other family members who reside with you, anyone else who lives with you and any other person or entity whose transactions in Stryker Securities are directed by you or are subject to your influence or control (collectively, "Family Members") and, as a general matter, references in these Guidelines to Covered Persons also includes Family Members. You are responsible for making sure that Family Members comply with these Guidelines. Set forth below is a discussion of the trading window and blackout periods and their application to various stock-related events: Trading Window Periods Subject to the important qualifications set forth below, a Covered Person may engage in purchases or sales of Stryker Securities only during the period beginning at 12:01 a.m., Eastern time, on the second (2nd) trading day after the public release of the Company's annual or quarterly earnings (the day of the release is not counted) and ending at 11:59 p.m., Eastern time, on the fifth (5th) business day of the third month of each reporting period (i.e., March, June, September and December). A "trading day" is a day when the New York Stock Exchange is open for transactions. It is imperative that Covered Persons not trade in Stryker Securities even during a trading window if they are in possession of material non-public information. Blackout Periods Conversely, a Covered Person may not engage in transactions in Stryker Securities during the period beginning at 12:01 a.m., Eastern time, on the sixth (6th) business day of the last month

------

![](ex19iiinsidertradingguid003.jpg)

3 of each quarter (March, June, September, and December) and ending at 11:59 p.m., Eastern time, on the first (1st) trading day after Stryker issues a press release disclosing its most recent quarterly earnings (again, the day of the release is not counted). Additional Blackout Periods; Early Closing of Trading Windows There may be times during what would otherwise be a trading window when the Company will advise certain persons, including certain Covered Persons, that trading must be suspended or that a blackout period must be extended. It is important to note in that regard that the facts giving rise to such a suspension or extension of a blackout period could be either positive or negative. In addition, the fact of a suspension of trading privileges or that a blackout is being extended is itself information that could be misinterpreted by the trading market and, therefore, should not be disclosed to anyone, including other Stryker employees. At those times, if you are affected, you will receive a separate communication from the Corporate Secretary or Legal team advising of this situation. Gifts Gifts and donations of Stryker Securities by a Covered Person during a blackout period require prior approval by the Corporate Secretary. Gifts and donations may not be made if a Stryker employee or director is aware of material non-public information about Stryker or Stryker Securities and has reason to believe, or is reckless in not knowing, that the recipient is likely to sell the shares prior to the disclosure of the information. Prohibition of Short Sales and Standardized Options Trading Selling Stryker Securities short creates the appearance of an inherent conflict of interest for Stryker employees and directors. A short sale is a bet that a security will decline in value. Writing (selling) or buying standardized exchange-traded put and call options on Stryker Securities may create a similar appearance or an appearance that a Covered Person has non- public information suggesting a significant upcoming price movement. Accordingly, Covered Persons are prohibited from short sales of and option trading on Stryker Securities at all times. Prohibition of Pledging and Hedging Margin Accounts and Pledges. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of material non-public information or otherwise is not permitted to trade in Stryker Securities, Covered Persons may not hold Stryker Securities in a margin account or otherwise pledge Stryker Securities as collateral for a loan, except for Stryker Securities that had been pledged as of the effective date of these Guidelines or that already have been pledged at the time an individual becomes a Covered Person. Hedging Transactions. Covered Persons may not engage in hedging transactions such as (but not limited to) zero-cost collars, equity swaps and forward sale contracts. Hedging transactions may allow a director, officer or other employee to continue to own Stryker Securities, but without the full risks and rewards of ownership. This may lead to the director, officer or other employee no longer having the same objectives as the Company's other

------

![](ex19iiinsidertradingguid004.jpg)

4 shareholders. Pre-Clearance of Trades by Directors and Section 16 Officers All trades in Stryker Securities by directors and officers subject to reporting under Section 16 of the Securities Exchange Act of 1934 ("Section 16 officers") and their Family Members must be pre-cleared in advance by any two of the Corporate Secretary, Assistant Secretary, Chief Legal Officer, Chief Financial Officer, Chief Accounting Officer or Corporate Controller. One of the approvers must be the Corporate Secretary, Assistant Secretary or Chief Legal Officer. The Company's pre-clearance procedures are set forth in the memorandum entitled "Section 16 Reporting and Other Responsibilities Related to Stryker Stock" provided to directors and Section 16 officers during their onboarding process. Exceptions to the Prohibitions on Trading Exercise of Stock Options Stock options may be exercised at any time without regard to possession of material non-public information or a blackout period, provided the shares received upon exercise are held, not traded. This includes a related election to withhold a portion of the Stryker stock that would otherwise be issued upon exercise to pay the exercise price or satisfy withholding tax obligations or to use already owned shares for those purposes. The rationale is that the transaction is with the Company rather than the general public and, accordingly, that concerns about the use of non-public inside information are not present. It is important to note, however, that the public sale of shares of Stryker Securities to finance the exercise of an option or the public sale of shares acquired upon exercise of an option may only be made if the seller is not in possession of material non- public information, and, with respect to Covered Persons, only during a trading window. Employee Stock Purchase Plan A participant in the Employee Stock Purchase Plan may only change the dollar amount that is deducted from his or her paycheck, including starting or discontinuing such deductions, if such participant is not in possession of material non-public information at that time, and with respect to participants that are Covered Persons, only during a trading window. Based on the current ESPP open enrollment periods and trading windows, changes may only be made by a Covered Person during the first fifteen (15) days of February, May, August and November of each year, and the first five (5) business days of March, June, September and December of each year. In addition, note that Stryker stock acquired for the account of a Covered Person pursuant to the Plan may only be sold during a trading window and, again, only if the Covered Person is not in possession of material non-public information at that time. 401(k) Plan The trading restrictions in these Guidelines do not apply to purchases of Stryker stock in the 401(k) Plan resulting from periodic contributions of money to the Plan

------

![](ex19iiinsidertradingguid005.jpg)

5 pursuant to payroll deduction elections. The trading restrictions do apply, however, to elections made under the 401(k) Plan to: (a) increase or decrease the percentage of periodic contributions that will be allocated to the Stryker stock fund, (b) transfer amounts into or out of the Stryker stock fund, (c) borrow money against a 401(k) Plan account if the loan will result in a liquidation of some or all of a Stryker stock fund balance and (d) pre-pay a Plan loan if the pre-payment will result in allocation of loan proceeds to the Stryker stock fund. It is important to note that the foregoing may only be done by employees or directors who are not in possession of material non-public information, and, with respect to Covered Persons, only during a trading window. 10b5-1 Trading Plans—An Exception to the Restrictions on Trading The restrictions on trading set forth in these Guidelines do not apply to sales of Stryker Securities that are made pursuant to a written plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934 that has been approved by our Corporate Secretary. Directors and Section 16 officers are also required to preclear any other written trading arrangements (such as arrangements that are not intended to qualify for the affirmative defense under Rule 10b5-1) with the Corporate Secretary. Any amendment to, or termination of, a trading plan or arrangement must also be pre-cleared with the Corporate Secretary. Any person with a 10b5-1 plan must be in compliance with any stock ownership guidelines (if applicable to that person) after full implementation of the 10b5-1 plan. Questions Any questions regarding these matters should be directed to our Corporate Secretary or Chief Legal Officer.

------

![](ex19iiinsidertradingguid006.jpg)

6 Guidelines for Trading in Stryker Securities Attachment A "Covered Person" is defined as: Members of the Board of Directors Corporate Officers (including Section 16 officers) and their administrative assistants Anyone involved in the preparation of or who receives or has regular access to consolidated financial information, including consolidated financial statements or summaries of consolidated financial statements, and their administrative assistants Anyone involved in the preparation of or who receives or has regular access to consolidated daily sales information and their administrative assistants Members of the Legal function and other persons, in each case as deemed appropriate by the Chief Legal Officer and Corporate Secretary

------

## Exhibit 21.1

Exhibit 21(i)

STRYKER CORPORATION LIST OF SUBSIDIARIES

As of December 31, 2025

---

| | |
|:---|:---|
| <u>Name of Subsidiary</u> | <u>State or Country of Incorporation</u> |
| 2Hip Holdings  | France |
| Advanced Medical Balloons GmbH | Germany |
| Advanced Medical Balloons, Inc. | USA - Delaware |
| Alcott Indemnity Company | USA - Vermont |
| Arrinex, Inc. | USA - Delaware |
| Artelon, Inc. | USA - Delaware |
| Berchtold + Fritz GmbH | Germany |
| Berchtold Corporation | USA - Delaware |
| Berchtold GmbH & Co. KG | Germany |
| BioMimetic Therapeutics USA, Inc. | USA - Delaware |
| BioMimetic Therapeutics, LLC | USA - Delaware |
| Cerus Endovascular, Inc. | USA - Delaware |
| Cerus Endovascular Limited | United Kingdom |
| Changzhou Orthmed Medical Instrument Co., Ltd. | China |
| EnMovi Ltd | United Kingdom |
| Entellus Medical, Inc. | USA - Delaware |
| Gongping (Shanghai) Medical Devices Trading Co. Ltd. | China |
| Guard Medical Inc. | USA - Delaware |
| Guard Medical  | France |
| HeartSine Technologies Limited | United Kingdom |
| Howmedica International S. de R.L. | Panama |
| Howmedica Osteonics Corp. | USA - New Jersey |
| HyperBranch Medical Technology, Inc. | USA - Delaware |
| Imascap  | France |
| Imorphics Limited | United Kingdom |
| Inari Medical Asia PTE. LTD. | Singapore |
| Inari Medical Australia Pty. Ltd. | Australia |
| Inari Medical Canada, Inc. | Canada |
| Inari Medical Chile SpA | Chile |
| Inari Medical Costa Rica, Srl | Costa Rica |
| Inari Medical Distribuição de Dispositivos Médicos Ltda. | Brazil |
| Inari Medical EU Limited | Ireland |
| Inari Medical Europe GmbH | Switzerland |
| Inari Medical International, Inc. | USA - Delaware |
| Inari Medical Japan G.K. | Japan |
| Inari Medical Latin America, Inc. | USA - Delaware |
| Inari Medical UK Limited | United Kingdom |
| Inari Medical, Inc. | USA - Delaware |
| International Life Sciences, LLC | USA - Delaware |
| Invuity, Inc. | USA - Delaware |
| Jolife AB | Sweden |
| LimFlow Inc. | USA - Delaware |
| LimFlow | France |
| LimFlow, GmbH | Germany |
| MAKO Surgical Corp. | USA - Delaware |
| Mobius Imaging, LLC | USA - Delaware |
| MOLLI Surgical Inc. | Canada |
| Muka Metal Ticaret ve Sanayi Anonim Sirketi  | Turkey |
| Nettrick Limited | Ireland |
| NICO Corporation | USA - Indiana |
| North Georgia Industrial Supply, LLC | USA - Delaware |
| Novadaq Corp. | USA - Delaware |
| Novadaq Technologies ULC | Canada |
| N.V. Stryker S.A. | Belgium |
| OOO Stryker (Stryker Ltd.) | Russia |
| Orneo Özel Sağlık Hizmetleri Medikal Ticaret Anonim Şirketi | Turkey |

---

Exhibit 21(i)

---

| | |
|:---|:---|
| <u>Name of Subsidiary</u> | <u>State or Country of Incorporation</u> |
| Orthmed (Hong Kong) Medical Instrument Company Limited | Hong Kong |
| OrthoSensor, Inc. | USA - Delaware |
| Ortho-Space Ltd. | Israel |
| Physio-Control Manufacturing, Inc. | USA - Washington |
| Physio-Control Operations Netherlands B.V. | Netherlands |
| Physio-Control, Inc. | USA - Washington |
| POMedical L.L.C. | USA - Nevada |
| Protheos | France |
| REV Neuro, LLC | USA - Delaware |
| Sage Products Holdings II, LLC | USA - Delaware |
| Sage Products Holdings III, LLC | USA - Delaware |
| Sage Products, LLC | USA - Delaware |
| SCI Calyx | France |
| SERF Technologies  | France |
| Société d'Etudes de Recherches et de Fabrication | France |
| Spirox, Inc. | USA - Delaware |
| SSI Divestiture, Inc. | USA - Massachusetts |
| Stryker (Barbados) Foreign Sales Corporation | Barbados |
| Stryker (Beijing) Healthcare Products Co., Ltd. | China |
| Stryker (Shanghai) Healthcare Products Co., Ltd. | China |
| Stryker (Suzhou) Medical Technology Co Ltd | China |
| Stryker (Thailand) Limited | Thailand |
| Stryker AB | Sweden |
| Stryker Acquisitions B.V. | Netherlands |
| Stryker Australia LLC | USA - Delaware |
| Stryker Australia Pty Ltd | Australia |
| Stryker Austria GmbH | Austria |
| Stryker B.V. | Netherlands |
| Stryker Berchtold B.V. | Netherlands |
| Stryker Berlin GmbH | Germany |
| Stryker Beteiligungs GmbH | Germany |
| Stryker Canada ULC | Canada |
| Stryker Canadian Technologies ULC | Canada |
| Stryker Capital B.V. | Netherlands |
| Stryker China Limited | Hong Kong  |
| Stryker Colombia SAS | Colombia |
| Stryker Communications, Inc. | USA - Delaware |
| Stryker Corporation (Chile) y Compania Limitada | Chile |
| Stryker Corporation (Malaysia) Sdn. Bhd. | Malaysia |
| Stryker Customs Brokers, LLC | USA - Delaware |
| Stryker Deutschland Services GmbH | Germany |
| Stryker do Brasil Ltda. | Brazil |
| Stryker EMEA Supply Chain Services B.V. | Netherlands |
| Stryker Employment Company, LLC | USA - Michigan |
| Stryker European Operations B.V. | Netherlands |
| Stryker European Operations Holdings I B.V. | Netherlands |
| Stryker European Operations Holdings I Ltd. | Ireland |
| Stryker European Operations Holdings II B.V. | Netherlands |
| Stryker European Operations Holdings II Limited | Ireland |
| Stryker European Operations Holdings III B.V. | Netherlands |
| Stryker European Operations Holdings LLC | USA - Delaware |
| Stryker European Operations Limited | Ireland |
| Stryker Far East, Inc. | USA - Michigan |
| Stryker Foreign Acquisitions, Inc. | USA - Delaware |
| Stryker France  | France |
| Stryker Funding B.V. | Netherlands |

---

Exhibit 21(i)

---

| | |
|:---|:---|
| <u>Name of Subsidiary</u> | <u>State or Country of Incorporation</u> |
| Stryker Global Technology Center Private Limited | India |
| Stryker GmbH | Switzerland |
| Stryker GmbH & Co. KG | Germany |
| Stryker Grundstücks GmbH & Co KG | Germany |
| Stryker Grundstücks Verwaltungs GmbH | Germany |
| Stryker Holdings B.V. | Netherlands |
| Stryker Iberia, S.L. | Spain |
| Stryker IFSC Designated Activity Company | Ireland |
| Stryker India Private Limited | India |
| Stryker International Acquisitions B.V. | Netherlands |
| Stryker International Holdings B.V. | Netherlands |
| Stryker Ireland Global Unlimited Company | Ireland |
| Stryker Ireland Limited | Ireland |
| Stryker Ireland Technology Limited | Ireland |
| Stryker Irish Holdings Unlimited Company | Ireland |
| Stryker Italia S.r.l. | Italy |
| Stryker Japan K.K. | Japan |
| Stryker Korea Limited | South Korea |
| Stryker Lebanon (Offshore) S.A.L. | Lebanon |
| Stryker Leibinger GmbH & Co. KG | Germany |
| Stryker Luxembourg S.à.r.l. | Luxembourg |
| Stryker Malta Holdings Limited | Malta |
| Stryker Malta International Limited | Malta |
| Stryker Manufacturing Holding Company B.V. | Netherlands |
| Stryker Manufacturing S. de R.L. de C.V. | Mexico |
| Stryker Mauritius Holding Ltd | Mauritius |
| Stryker Mexico Holdings B.V. | Netherlands |
| Stryker Mexico, S.A. de C.V. | Mexico |
| Stryker Nederland B.V. | Netherlands |
| Stryker New Zealand Limited | New Zealand |
| Stryker NV Operations Limited | Ireland |
| Stryker-Osteonics AG | Switzerland |
| Stryker Pacific Limited | Hong Kong  |
| Stryker Performance Solutions, LLC | USA - New Jersey |
| Stryker Poland Manufacturing sp. z. o. o. | Poland |
| Stryker Poland Services sp. z o.o. | Poland |
| Stryker Polska Sp.z.o.o. | Poland |
| Stryker Portugal - Produtos Medicos, Unipessoal, Lda. | Portugal |
| Stryker Professional Latin America S. de R.L. de C.V. | Mexico |
| Stryker Puerto Rico Holdings B.V. | Netherlands |
| Stryker Puerto Rico Sales, LLC | Puerto Rico |
| Stryker Puerto Rico, LLC | Puerto Rico |
| Stryker Renovation Services, LLC | USA - Delaware |
| Stryker Romania SRL | Romania |
| Stryker Sales, LLC | USA - Michigan |
| Stryker Saudi Healthcare Services | Saudi Arabia |
| Stryker Singapore Private Limited | Singapore |
| Stryker South Africa (Proprietary) Limited | South Africa |
| Stryker Spain Medtech Holdings, S.L.U. | Spain |
| Stryker Spine  | France |
| Stryker Sterilization Tijuana, S. de R.L. de C.V. | Mexico |
| Stryker Sustainability Solutions, Inc. | USA - Delaware |
| Stryker Tıbbi Cihazları Sanayi ve Ticaret Limited Şirketi | Turkey |
| Stryker Tijuana Operations, S. de R.L. de C.V. | Mexico |
| Stryker Trauma GmbH | Germany |
| Stryker Turkish Holdings B.V. | Netherlands |

---

Exhibit 21(i)

---

| | |
|:---|:---|
| <u>Name of Subsidiary</u> | <u>State or Country of Incorporation</u> |
| Stryker UK Limited | United Kingdom |
| Stryker U.S. Investments, Inc. | USA - Delaware |
| Stryker Verwaltungs GmbH | Germany |
| SYK Costa Rica Services Sociedad De Responsabilidad Limitada | Costa Rica |
| Thermedx, LLC | USA - Ohio |
| TMG France  | France |
| TMJ Solutions, LLC | USA - Florida |
| Tornier Orthopedics Ireland Limited | Ireland |
| Tornier  | France |
| Tornier, Inc. | USA - Delaware |
| Trauson (China) Medical Instrument Company Limited | China |
| Trauson (Hong Kong) Company Limited | Hong Kong |
| Trauson Holdings (BVI) Company Limited | British Virgin Islands |
| Trauson Holdings (Hong Kong) Company Limited | Hong Kong |
| Trauson Holdings Company Limited | Cayman Islands |
| Vertos Medical, Inc. | USA - Delaware |
| Vocera Communications Australia Pty Limited | Australia |
| Vocera Communications India Private Limited | India |
| Vocera Communications, Inc. | USA - Delaware |
| Vuaant, Inc. | USA - Delaware |
| Wright Medical Costa Rica, S.A. | Costa Rica |
| Wright Medical Group, Inc. | USA - Delaware |
| Wright Medical Technology, Inc. | USA - Delaware |

---

Stryker Corporation directly or indirectly owns 100% of the outstanding voting securities of each of the above-named

subsidiaries, with the exception of any designated by an asterisk (\*), which Stryker Corporation directly or indirectly owns a

majority of the outstanding voting securities.

## Exhibit 23.1

Exhibit 23(i)

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

1. Registration Statement (Form S-3ASR No. 333-275853) of Stryker Corporation, and

2. Registration Statement (Form S-8 No. 333-140961) pertaining to the 2006 Long-Term Incentive Plan of

Stryker Corporation, and

3. Registration Statements (Form S-8 No. 333-150396, Form S-8 333-221959 and Form S-8 No. 333-287683)

pertaining to the 2008 Employee Stock Purchase Plan of Stryker Corporation, and

4. Registration Statements (Form S-8 No. 333-179142, Form S-8 333-221958 and Form S-8 No. 333-287683)

pertaining to the 2011 Long-Term Incentive Plan of Stryker Corporation;

of our reports dated February 11, 2026, with respect to the consolidated financial statements and schedule of Stryker

Corporation and subsidiaries and the effectiveness of internal control over financial reporting of Stryker Corporation

and subsidiaries included in this Annual Report (Form 10-K) for the year ended December 31, 2025.

/s/ Ernst & Young LLP

Grand Rapids, Michigan

February 11, 2026

## Exhibit 31.1

Exhibit 31(i)

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

**PURSUANT TO SECTION 302**

**OF THE SARBANES-OXLEY ACT OF 2002**

I, Kevin A. Lobo, certify that:

1. I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2025 of Stryker Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a

material fact necessary to make the statements made, in light of the circumstances under which such statements

were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly

present in all material respects the financial condition, results of operations and cash flows of the registrant as of,

and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure

controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over

financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures

to be designed under our supervision, to ensure that material information relating to the registrant, including

its consolidated subsidiaries, is made known to us by others within those entities, particularly during the

period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial

reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of

financial reporting and the preparation of financial statements for external purposes in accordance with

generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this

report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of

the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that

occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of

an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's

internal control over financial reporting.

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal

control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of

directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over

financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process,

summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a

significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: | February 11, 2026 | /s/ KEVIN A. LOBO |
|  |  | Kevin A. Lobo |
|  |  | Chair and Chief Executive Officer |

---

## Exhibit 31.2

Exhibit 31(ii)

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO SECTION 302**

**OF THE SARBANES-OXLEY ACT OF 2002**

I, Preston W. Wells, certify that:

1. I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2025 of Stryker Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a

material fact necessary to make the statements made, in light of the circumstances under which such statements

were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly

present in all material respects the financial condition, results of operations and cash flows of the registrant as of,

and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure

controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over

financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures

to be designed under our supervision, to ensure that material information relating to the registrant, including

its consolidated subsidiaries, is made known to us by others within those entities, particularly during the

period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial

reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of

financial reporting and the preparation of financial statements for external purposes in accordance with

generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this

report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of

the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that

occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of

an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's

internal control over financial reporting.

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal

control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of

directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over

financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process,

summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a

significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: | February 11, 2026 | /s/ PRESTON W. WELLS |
|  |  | Preston W. Wells |
|  |  | Vice President, Chief Financial Officer |

---

## Exhibit 32.1

Exhibit 32(i)

**CERTIFICATION PURSUANT TO** 

**18 U.S.C. SECTION 1350,** 

**AS ADOPTED PURSUANT TO** 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002** 

In connection with the Annual Report on Form 10-K of Stryker Corporation (the "Company") for the year ended

December 31, 2025 (the "Report"), I, Kevin A. Lobo, Chair, Chief Executive Officer and President of the Company,

certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of

1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and

results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: | February 11, 2026 | /s/ KEVIN A. LOBO |
|  |  | Kevin A. Lobo |
|  |  | Chair and Chief Executive Officer |

---

## Exhibit 32.2

Exhibit 32(ii)

**CERTIFICATION PURSUANT TO** 

**18 U.S.C. SECTION 1350,** 

**AS ADOPTED PURSUANT TO** 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002** 

In connection with the Annual Report on Form 10-K of Stryker Corporation (the "Company") for the year ended

December 31, 2025 (the "Report"), I, Preston W. Wells, Vice President, Chief Financial Officer of the Company,

certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of

1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and

results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: | February 11, 2026 | /s/ PRESTON W. WELLS |
|  |  | Preston W. Wells |
|  |  | Vice President, Chief Financial Officer |

---